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1. Abstract 
Stimulation of the B cell antigen receptor (BCR) triggers an intracellular signaling cascade 
through its integral signaling components Igα and Igβ. This signaling cascade involves several 
protein classes like kinases, lipases and adaptor molecules and ultimately leads to nuclear 
translocation of transcription factors such as NF-κB and NFAT, promotes proliferation and 
metabolism via the PI3K/Akt kinase pathway, induces actin remodeling and activates MAPK 
like JNK, Erk and p38. The signaling cascade downstream of the BCR plays a crucial role in 
the life of B cells, starting from maturation of the cells in the bone marrow to activation and 
differentiation in peripheral lymphoid organs. Any dysregulation of this pathway can cause 
severe diseases such as immunodeficiencies, autoimmune diseases or malignancies. Hence, 
it is important to understand the biochemical mechanisms by which this signaling pathway is 
controlled. However, the exact function of some of the involved players, such as the Vav family 
of guanine nucleotide exchange factors, still remains only partially understood. Using a cellular 
model system based on a Vav1-deficient subline of a human B cell line, our group revealed a 
critical role of Vav family members for BCR-proximal signaling reactions including mobilization 
of the second messenger Ca2+. This work unraveled several other signaling axes within the 
BCR signaling cascade, such as induction of actin remodeling, activation of MAPK p38 and 
Erk and phosphorylation of Akt, that depend on the expression of Vav family members. 
Strikingly, all of those signaling axes were significantly impeded upon loss of the catalytic 
guanine-nucleotide exchange factor (GEF) activity of Vav family members. Interestingly, Vav2 
was able to mediate BCR-induced actin remodeling and phosphorylation of Akt even though it 
does not support BCR-induced Ca2+-mobilization. In vitro GEF-activity assays revealed Vav 
family isoform-specific activation of the Rho family. Whereas Vav1 mediated activation of Rac1 
and RhoA, Vav2 selectively activated Rac1 and Vav3 showed GEF activity only towards RhoA. 
Thus, activation of RhoA appears to be required for BCR-induced Ca2+-mobilization while GEF-
activity towards Rac1 supports actin remodeling and phosphorylation of Akt upon stimulation 
of the BCR. Consequently, a new class of catalytic activity, i.e. the GEF-activity of Vav family 
proteins towards different Rho family small G proteins, was identified to be required for BCR-
induced signaling. Moreover, it was shown, that the BCR-induced activation of Akt, actin 
cytoskeleton remodeling and Ca2+-influx were independent from each other. This work 
suggests that Vav family members do not just act as adaptor proteins in the BCR signaling 
cascade but represent central enzymatic coordinators of distinct signaling pathways 
downstream of the BCR.
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2. Introduction 
2.1. The human immune system 
The essential function of the immune system in humans is to protect the organism against 
pathogenic microbes that infiltrate through physical barriers such as the skin or mucous 
membranes1. Therefore, the immune system developed various mechanisms to cope with 
these pathogens, some of which are directed against evolutionary constant and indispensable 
structures of these pathogens whereas others were adopted to new, previously unknown 
patterns2,3. The different parts of the immune system that respond to either class of pathogen-
derived molecules are termed innate immunity and adaptive immunity, respectively. In fact, the 
human immune system is a highly developed “disseminated organ” that is able to discriminate 
between “self” and “foreign”, but also between “harmless” and “harmful” structures4. In contrast 
to most other organs of the human body, the immune system is not a solid organ but is 
distributed across the whole body as primary and secondary lymphoid tissues5. In addition, 
immune cells patrol through the body via blood and lymph stream and reside in various 
tissues1. 
The innate immune system constitutes the first line of defense and consists of several cell 
types like granulocytes, macrophages and dendritic cells that are activated by binding of 
pathogen-derived ligands to specific germ line-encoded so-called pattern recognition receptors 
(PRRs)6,7. This first line of defense is primarily characterized by phagocytosis of pathogens or 
their destruction through release of reactive oxygen species1. Antigenic peptides of 
extracellularly phagocytosed pathogens are furthermore presented on major histocompatibility 
complex class II (MHC II) molecules on the surface of the cells to activate the adaptive immune 
system4. Both processes are supported by defensins and circulating proteins of the 
complement system that are constantly produced by immune cells8,9. Binding of complement 
system factors to a pathogen enhances phagocytosis, a phenomenon known as opsonization8. 
In addition, proteins of the complement system can form a membrane attack complex in the 
plasma membrane of pathogens that ultimately leads to perforation and destruction of the 
pathogen1,8. 
Natural killer cells belong to innate lymphocytes and essentially contribute to the elimination of 
virally infected cells or tumor cells. In addition to the antigen presenting cells of the innate 
immune system, almost every somatic cell type constantly presents peptides derived from 
intracellular proteins bound to MHC I on their surface. During viral infection or upon malignant 
transformation, this presentation of intracellular peptides on MHC I is frequently downregulated 
or blocked to evade immune recognition. However, loss of MHC I on the surface of cells is 
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recognized by natural killer cells which then mediate cytotoxic functions by induction of 
apoptosis through perforin and granzyme B10. 
Adaptive immunity is mediated by B and T lymphocytes and in contrast to innate immune 
mechanisms elicits highly specific immune responses to defined pathogenic molecules 
(antigens). Adaptive immunity furthermore establishes an immunological memory upon first 
encounter with a pathogen, causing a much more robust response on pathogen re-encounter4. 
Despite the differences, innate immunity and adaptive immunity are connected in several 
ways, e.g. through antigen-presenting dendritic cells and the complement system8,11. 
Lymphocyte precursor cells derive from hematopoietic stem cells in the bone marrow and 
undergo subsequent maturation steps in distinct primary lymphoid tissues. Whereas B cells 
remain in the bone marrow for the most part of their development, T precursor cells migrate to 
the thymus for this process4. T cells are responsible for the cell-mediated adaptive immune 
response, that includes clearance of intracellular pathogens after recognition of peptides 
presented on MHC I, which they detect with their clonotypic antigen-specific T cell receptors 
(TCRs). B cells on the other hand mediate the humoral adaptive immune response, 
predominantly by the production of antigen-specific antibodies that have a variety of functions. 
Antibodies can neutralize pathogens, stimulate their phagocytosis via opsonization, and 
activate the complement system3,12,13. Both, B and T cells acquire their antigen specificity via 
a process called somatic recombination of antigen receptor gene segments that takes place 
during cellular maturation. The result of this unique DNA recombination process is a vast 
number of clonotypic T and B lymphocytes, each of which expresses an antigen receptor (TCR 
or BCR, respectively) with a unique specificity14. This random process is necessary since the 
limited number of approximately (approx.) 20,000 to 25,000 genes of the human genome 
would not allow to generate the enormous numbers of adaptive antigen receptor 
specificities3,15. However, since somatic recombination is a random process at the DNA level, 
B and T cells have to pass several checkpoints during their maturation to ensure that the newly 
arranged receptors are functional yet do not detect self-antigens16,17. 
2.2. B cells - origin, maturation, differentiation, effects 
B cells differentiate from hematopoietic stem cells in the bone marrow into precursors of naïve 
B cells followed by further maturation in the same compartment18. To become a functional 
naïve B cell, precursor B cells rearrange gene segments called variable- (VH), diversifying- 
(DH) and joining (JH) segments of the immunoglobulin (Ig) heavy chain locus. Subsequently, 
the VL- and JL-regions of the Ig light chain are rearranged to generate a functional BCR with 
unique specificity14. Besides the membrane-anchored mature immunoglobulin, the BCR 
contains two additional molecules referred to as Igα and Igβ (CD79A and CD79B) that are 
covalently linked to each other via disulfide bonds. After antigen recognition via the membrane-
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anchored immunoglobulin, the intracellular signals are triggered through this heterodimeric, 
integral signaling unit of Igα and Igβ19. In consequence, this multi protein complex has to fulfill 
two functions: antigen recognition in the extracellular milieu followed transmission of signals 
into the cytosol after ligand binding and antigen internalization for processing and subsequent 
presentation of the antigen in MHC II20,21. During somatic recombination of the heavy and light 
chain gene loci, a repertoire of up to 5 x 1013 specificities are generated, which is accompanied 
by apoptosis of a large number of cells having dysfunctional receptors14. At first, in pro-B cells, 
the Ig heavy chain is rearranged and functionality is tested using a surrogate light chain, 
forming the so-called pre-B-cell receptor. Functional rearrangement of the Ig heavy chain 
allows progression to the pre-B cell state in which the light chain regions are rearranged22,23. 
Upon successful generation of fully functional BCRs, B cells are still immature and migrate 
from the bone marrow to the spleen, where they further mature into naïve follicular or marginal 
zone B cells (Figure 2.1)14. Most of the naïve B cells reside in secondary lymphoid organs, 
although recirculation to the blood is possible by attraction through sphingosine-1-phosphate 
(S1P), a lipid present in high concentrations in the blood24. 
 
Figure 2.1 Schematic overview of B cell maturation. B cells originate from hematopoietic stem cells. When a 
functional BCR is rearranged they ultimately differentiate into plasma cells or memory B cells. Bone marrow 
compartment is shaded in light grey and the periphery consisting of secondary lymphoid organs and circulating 
cells is shaded in dark grey. GC = germinal center. 
Naïve B cells are activated by encounter with their cognate antigen resulting in stimulation of 
the BCR. Activation of a B cell ultimately leads to production and secretion of antibodies. 
Importantly, the specificity of the secreted antibody corresponds to the specificity of the 
membrane-bound immunoglobulin4,21. While marginal zone B cells require additional signals 
from PRRs, such as Toll-like receptors for full activation, follicular B cells, in contrast, need 
costimulatory factors provided by T helper cells for proper activation25. The BCR specificities 
of marginal zone B cells are often directed against polysaccharides and glycolipids, whereas 
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the BCRs of follicular B cells recognize protein-based antigens26. Activation of B cells induces 
proliferation (clonal expansion) and the daughter cells undergo two fates: either they further 
differentiate into short-lived plasma cells that secrete low affinity IgM antibodies, or they seed 
in lymphoid follicles to form germinal centers (GCs)27. GCs contain two regions, the dark and 
the light zone. In the dark zone, activated B cells strongly proliferate, allowing somatic 
hypermutation. In this process mutations are introduced into the antigen binding sites 
(rearranged VDJ and VJ regions of the Ig heavy and light chains, respectively) to improve 
binding to their cognate antigen28. In the light zone of GCs, B cells are selected according to 
their affinity of the previously mutated BCR and B cells can undergo class switch 
recombination28. In contrast, a recent report suggests that class switch recombination occurs 
infrequently in GCs, which is supported by the presence of short-lived plasma cells that secrete 
antibodies of IgG isotype29. Ultimately, B cells leaving GCs express BCRs with improved 
affinity and often with a different isotype. Most of these cells further differentiate into antibody 
secreting plasma cells, while some of them differentiate into long-lived memory B cells28. An 
important characteristic of memory B cells is a rapid re-activation upon re-infection with the 
same pathogen, leading to a fast, more robust and thus more effective secondary humoral 
immune response30. 
Soluble antibodies and the membrane-anchored immunoglobulin consist of two equal heavy 
chain and two equal light chain (either κ or λ type) molecules that are linked by disulfide 
bridges. The N-terminal regions of Ig heavy chains with the rearranged VDJ segments in 
combination with rearranged VJ segments of the light chains determine the specificity. The C-
terminal region (Fc-region) of the Ig heavy chains however determines the isotype. To date, 
five different isotypes of antibodies are described, IgM, IgD, IgG, IgA and IgE, each of which 
has unique characteristics26. While antibodies of the IgM isotype are mainly produced after the 
first encounter with an antigen, a high number of activated B cells switch to IgG isotypes during 
the GC reaction27,31. These antibodies, dependent on their IgG subtype, have outstanding 
qualities in opsonization, neutralization and activation of the complement system and 
constitute 75% of all antibodies of the serum. 10% of antibodies in serum are IgM and 15% 
IgA, which mainly act in mucous membranes31. Barely any detectable amounts of both IgD (< 
0.5%) and IgE (< 0.1%) are present in the serum, even though IgE antibodies are widely known 
for their role in protection against helminths and as mediators of allergies31. Furthermore, 
vaccinations trigger the production and secretion of antibodies by B cells and antibodies are 
widely used in research and diagnostic, as well as for treatment of autoimmune and cancer 
diseases32–34. 
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2.3. B cell antigen receptor signaling 
From development of hematopoietic stem cells to the activation of matured B cells, the BCR-
mediated signaling plays an indispensable role for B cells. Currently, two different models of 
BCR activation are discussed. In the crosslinking model it is suggested that individual BCRs 
are distributed all over the surface of B cells, preventing any interactions in the absence of 
antigens. After binding of an antigen, multiple receptors are crosslinked and thereby, due to 
close proximity, the intracellular signal transduction is induced35. On the other hand, the 
association-dissociation model proposes that the BCRs are grouped in islands in the resting 
state and antigen binding triggers dissociation of that complex leading to intracellular signal 
transduction36,37. 
 
Figure 2.2 Schematic overview of the BCR-induced signaling cascade. The BCR signaling cascade is triggered 
by binding of the cognate antigen (Ag) to the BCR, mediating activation. Tyrosine residues inside and outside of 
ITAMs in Igα and Igβ are phosphorylated by Src family kinases like Lyn. Consequently, Syk and SLP-65 are 
recruited. Due to generation of binding sites for SH2 containing proteins by phosphorylation of SLP-65 through Syk, 
the Ca2+ initiation complex is formed consisting of Btk, PLCγ2, CIN85 and Vav1. As a result, Ca2+ is mobilized into 
the cytosol, mediating the nuclear translocation of the transcription factor NFAT. Additionally, the translocation of 
the transcription factor NF-κB into the nucleus is induced and MAPK like Erk, JNK and p38 are activated. Survival 
and proliferation are promoted via the PI3K/Akt pathway. Red arrows indicate phosphorylation processes, solid 
arrows indicate translocation processes and dashed arrows indicate multistep activation processes. Ca2+ is 
indicated as black dots. Kinases are colored in green, adaptor proteins in yellow, PLCγ2 in red, Vav1 in blue, Rho 
GTPases in purple, transcription factors in orange, Ca2+-channels in light brown, phosphatidylinositols and relatives 
in dark grey, the BCR complex with Igα and Igβ in dark blue and the antigen in dark red. 
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However, a recent report using super resolution stimulated emission depletion (STED) 
microscopy showed that BCR clusters are formed after stimulation of the BCR, speaking for 
the crosslinking model38. Certainly, both models have in common that the signal is triggered 
by binding of antigen to the BCR (Figure 2.2). The membrane-anchored immunoglobulin itself 
is not capable of transducing any signals into the cytosol since it has no intracellular signal 
transduction domains. The signal transduction is enabled by the non-covalently but constantly 
associated integral Igα/Igβ heterodimer19. Activation of the BCR mediates phosphorylation of 
intracellular immunoreceptor tyrosine-based activation motifs (ITAMs) in Igα and Igβ by Src 
family kinases like Lyn and the kinase Syk is recruited to those phosphorylated tyrosines39,40. 
Due to this interaction, autoinhibition of Syk is relieved and tyrosine-rich regions that were 
previously masked by the own tandem Src-homology 2 (SH2) domains, become available. 
These tyrosines are auto-phosphorylated leading to full activation of Syk40. While Syk is 
specifically recruited to phosphorylated tyrosine residues of the ITAM in Igα and Igβ, the 
indispensable signaling protein SH2-domain-containing leukocyte adaptor protein of 65 kDa 
(SLP-65, also named BLNK) is recruited to the phosphorylated non-ITAM tyrosine 204, which 
is exclusively found in Igα41–43. On phosphorylation of SLP-65 by Syk, further docking sites are 
generated for additional SH2 domain-containing proteins43. Moreover, SLP-65 contains 
various proline-rich regions that serve as interaction motifs for SH3 domain-containing 
proteins44. These features make SLP-65 the central adaptor platform within the BCR signaling 
cascade45. Mice deficient for SLP-65 expression show strongly reduced numbers of B cells 
and disturbed BCR-induced signaling46. In line with this observation, SLP-65 deficient human 
DG75 B cells are barely capable of Ca2+ signaling compared to parental DG75 B cells47. Cbl-
interacting protein of 85 kDa (CIN85) is a constant, BCR stimulation independent, interaction 
partner of SLP-65 and facilitates membrane recruitment of the SLP-65/CIN85 complex48. 
Absence of this complex in B cells leads to disturbed BCR-induced Ca2+-mobilization and 
impaired activation of nuclear factor ‘kappa-light-chain-enhancer’ of activated B cells (NF-
κB)48. Bruton’s tyrosine kinase (Btk) and the phospholipase γ2 (PLCγ2), together with SLP-65 
and CIN85, form the Ca2+-initiation complex49. A distinct amount of both proteins, Btk and 
PLCγ2, are localized at the plasma membrane due to interactions with phosphatidyl-inositol-
3,4,5-trisphosphate (PIP3) through their PH domains50,51. They furthermore interact via their 
SH2 domains with the phosphorylated tyrosine residues of SLP-6543,52. In addition, Vav family 
members are part of this multimeric protein complex by recruitment via their SH2 domain to 
phosphorylated tyrosine residues of SLP-65, Syk or Igα41,43,47. This membrane-localized 
complex constitutes a branching point of several signaling axes within the BCR-induced 
signaling21,49. 
The kinase Btk activates the phospholipase PLCγ2, which subsequently cleaves phosphatidyl-
inositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol-1,4,5-trisphosphate 
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(IP3)53. While DAG remains in the plasma membrane, the soluble second messenger IP3 
diffuses into the cytosol and translocates to the plasma membrane of the endoplasmic 
reticulum (ER)49. Here, IP3 binds to its IP3-receptors, which are ligand-gated Ca2+-channels54. 
As a consequence of this binding, the Ca2+-channels are opened and Ca2+ is released from 
the ER into the cytoplasm49. This Ca2+-flux is further supported by opening of store-operated 
Ca2+-channels located within the plasma membrane through Ca2+-dependent clustering of 
stromal interaction molecules (STIMs) and the Ca2+ release-activated Ca2+-channel Orai55. 
Elevated intracellular Ca2+-levels lead to the activation of the Ca2+-dependent serine/threonine 
phosphatase Calcineurin. Calcineurin dephosphorylates the cytosolic transcription factor 
nuclear factor of activated T cells (NFAT), thereby releasing its retention in the cytosol due to 
constant phosphorylation and promoting its translocation into the nucleus49.  
At the plasma membrane, protein kinase C-β (PKC-β) is recruited to DAG56. Proper activation 
of PKC-β requires binding of Ca2+ to its C2 domain49. Phosphorylation of various adaptor 
proteins activates the transforming growth factor-β-activated kinase 1 (Tak1), which in turn 
phosphorylates and activates the inhibitor of NF-κB (IκB) kinase (IKK)56. Eventually, this kinase 
phosphorylates and thereby marks IκB, an inhibitory protein which is responsible for the 
cytosolic retention of NF-κB, for proteasomal degradation57. As a result, the transcription factor 
NF-κB translocates into the nucleus49. 
In addition to the previously described formation and effects of the Ca2+-initiation complex, the 
adaptor protein growth factor receptor-bound protein 2 (Grb2) is upon stimulation directly 
recruited to the BCR and responsible for activation of the MAPK Erk58,59. Furthermore, 
activation of the BCR leads to membrane recruitment of phosphoinositide-3 kinase (PI3K) 
family members which phosphorylate their substrate PIP2 to PIP360. Membrane-bound PIP3 not 
only serves as membrane anchor for different PH domain-containing proteins like Btk or 
PLCγ2, it also recruits the kinase Akt (also named protein kinase B, PKB)50,51,61. Recruitment 
of Akt ultimately leads to the activation of metabolism, survival and proliferation pathways60–62. 
In summary, BCR signaling involves a complex interplay of different types of proteins to 
achieve activation of transcription factors such as NF-κB and NFAT, but also activation of 
MAPK like Erk, JNK and p38 as well as promotion of survival and proliferation (Figure 2.2). 
This signaling pathway is of enormous significance for each developmental stage of a B cell. 
Dysregulation might lead to severe diseases such as immunodeficiencies, autoimmunity and 
malignancies, therefore it is required to understand the underlying mechanism in detail63–65. 
2.4. The Vav family of guanine-nucleotide exchange factors 
Vav family proteins belong to the less understood molecules within the BCR signaling cascade. 
However, in T cells Vav family members mediate activation of mitogen-activated protein 
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kinases (MAPK) such as c-Jun N-terminal kinase (JNK) and p3866,67. Vav1 and Vav2 double-
deficient mice were described to be impeded in the development of B and T cells68,69. 
Moreover, loss of Vav1 expression in human DG75 B cells has severe negative effects on 
BCR-induced Ca2+-mobilization47. However, the underlying mechanisms remain to date 
unknown47,68,69. In general, Vav family members are proteins of dual functions, they mediate 
GEF-activity towards Rho family members of small G proteins and exhibit adaptor function70. 
This two-pronged functionality is reflected in the secondary protein structure of Vav proteins 
(Figure 2.3). All family members share the same domain composition, in which the N-terminal 
domains (green frame) are responsible for the mediation and regulation of the GEF-activity 
and the C-terminal domains (blue frame) function as protein-protein interfaces which includes 
intramolecular and intermolecular interactions71,72. 
 
Figure 2.3 Schematic domain architecture of Vav family members. The individual domains of Vav family 
members and their function. Green frame: domains involved in GEF-activity. Blue frame: domains involved in 
protein-protein interaction. N = N-terminal end, C = C-terminal end, CH = Calponin-homology domain, AR = Acidic 
region, DH = Dbl-homology domain, PH = Pleckstrin-homology domain, ZF = Zinc finger region, PR = Proline Rich 
region, SH3 = Src-homology 3 domain, SH2 = Src-homology 2 domain. 
Vav family members have been discovered between 1989 and 1999 by different groups73–75. 
Vav1, the first described isoform, was discovered while searching for new oncogenes. Since 
VAV1 was the sixth oncogene found in this laboratory and the native language of the 
discoverer was Hebrew, they named the protein after the sixth letter of the Hebrew alphabet73. 
Although all three isoforms share similarities of 50% to 60% on amino acid level, expression 
is clearly cell type specific71. Vav2 and Vav3 are ubiquitously expressed in most cells of the 
human body whereas expression of Vav1 is limited to the hematopoietic lineage71. However, 
experiments in mice revealed redundancies in the function of Vav family members. Mice that 
lack expression of Vav1 barely show any abnormalities in B and T cell development or in BCR- 
and TCR-induced signaling compared to wild-type mice, whereas Vav1 and Vav2 double-
deficient mice show significantly impaired B and T cell development and reduced BCR-induced 
Ca2+-signaling69,76. Furthermore, these effects were even more pronounced upon loss of all 
three Vav family members in Vav1/Vav2/Vav3 triple-deficient mice68. In contrast to mice, 
generation of model systems in human B and T cell lines, DG75 and Jurkat, respectively, 
revealed that deletion of Vav1 leads to severely reduced BCR- and TCR-induced Ca2+-
mobilizations47,77. 
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Collectively, these experiments in murine and human model systems have drawn attention to 
the research on Vav family members to understand their role in the generation of lymphocytes, 
BCR and TCR signaling. The underlying mechanism for Vav family members to contribute to 
lymphocyte development and their precise role within the BCR signaling cascade however 
remains unknown. 
2.4.1. Vav family domain architecture and functions 
Vav family members are multi-domain proteins with two functional sections. In brief, domains 
important for the GEF-activity are located within the N-terminal region of Vav family members 
and consist - from N-terminal to C-terminal - of Calponin-homology domain (CH domain), acidic 
region (AR), Dbl-homology domain (DH domain), Pleckstrin-homology domain (PH domain) 
and a zinc finger domain (ZF)71. The C-terminal region mediates protein-protein interactions 
and consists of a proline rich (PR) region followed by an SH2 domain flanked by one SH3 
domain on each site (Figure 2.3)71. Each of the individual domains contribute to different 
extents to BCR-induced Ca2+-mobilization, however, the underlying mechanisms remain 
widely unknown47,72,78. 
2.4.1.1. The adaptor part of Vav proteins 
The C-terminal adaptor part of Vav mediates protein-protein and intramolecular interactions 
via a PR region, one SH2 domain and two SH3 domains71. SH2 domains interact with 
phosphorylated tyrosine residues of active signaling complexes, whereas SH3 domains 
interact with proline rich regions79. Adjacent amino acids closely located to the binding site of 
SH2 or SH3 domains and the surrounding amino acids of the tyrosine of the binding partner 
determine the specificity for recruitment of the SH2 and SH3 domains79. Thus, Vav family 
members are recruited to phosphorylated residues upon stimulation of the BCR through their 
SH2 domains, but they can also serve as additional binding platforms through their SH3 
domains and their PR region72. 
Vav1 is specifically recruited to the BCR after stimulation to the integral signaling unit Igα or to 
Syk and SLP-65 through the SH2 domain41,43,47,80. Similarly, Vav1 is recruited to the TCR and 
its signaling components upon TCR-stimulation through the SH2 domain81. This recruitment is 
indispensable for BCR-induced Ca2+-mobilization in DG75 B cells, since inactivation of the 
SH2 domain leads to BCR-induced Ca2+-profiles representing Vav1-deficient DG75 B cells47. 
The N-terminal SH3 domain (hereinafter referred to as N-SH3) is known to engage in an 
atypical N-SH3-SH3 interaction with the adaptor protein Grb282. Further interaction partners of 
the N-SH3 of Vav family members have not been described so far72. In contrast, the C-terminal 
SH3 domain (C-SH3) of Vav1 establishes intramolecular and intermolecular interactions72. 
Deletion of this domain leads to a loss of GEF-activity in Vav178. A functional relevance of 
 - 11 - 
known C-SH3 interaction partners for the GEF-activity of Vav family members, in the context 
of lymphocyte development or the antigen receptor signaling has not been described so      
far83–85. 
2.4.1.2. GEF-activity of Vav-family members 
Vav family members activate small G proteins of the Rho family due to their GEF-activity that 
is mediated by a functional core consisting of their consecutively arranged DH, PH and ZF 
domains86–88. Upon recruitment of Vav1 to the BCR and its signaling components via its SH2 
domain, Vav1 is phosphorylated and activated by Syk or Src family kinase members80,89. Both, 
the arrangement of the functional core unit and the stimulation depended recruitment via a 
SH2 domain are unique characteristics for GEFs towards Rho family small G proteins72. The 
GEF-activity of Vav family members is tightly controlled. Non-phosphorylated Vav proteins 
exhibit barely any GEF-activity due to their “closed” molecular structure mediated by 
interactions of the catalytic DH-PH-ZF core with the C-SH3 domain as well as the CH domain 
and the AR72. These interactions occlude binding sites for small G proteins and additionally 
force the catalytic core into a conformation that further prevents binding of Rho family 
members72. Furthermore, the PH domain within the catalytic core is in contact with the DH 
domain to stabilize the “closed” structure72. In addition, the PH domain influences the GEF-
activity of Vav proteins by binding to phosphatidyl-inositols90. In vitro experiments revealed that 
binding of PIP2 to the PH domain decreases the catalytic activity of Vav1 while binding of PIP3 
leads to an increased GEF-activity91. The AR of Vav proteins contains several negatively 
charged amino acid residues and forms an inhibitory loop in the “closed” state that blocks the 
active center of Vav proteins78. Currently, the role of the CH domain in the regulation of the 
GEF-activity remains to be elucidated in detail. Classical CH domains (type I and II) naturally 
occur as tandem CH domains and constitute evolutionary conserved actin binding domains to 
mediate binding to the actin cytoskeleton92. These conserved binding regions were lost during 
evolution for CH domain types III, IV and V92. Hence, the exact function of type III, IV, V CH 
domains has not been generalized so far and is proposed to be specific for each individual CH 
domain-containing protein92. Vav family members contain type III CH domains. Deletion of this 
domain resulted in a transformation potential of Vav1 for malignancies, which was manifested 
by an enhanced GEF-activity78,93. In contrast, studies in B and T cells revealed that loss of the 
CH domain leads to disturbed effector functions regarding to BCR and TCR-induced Ca2+-
mobilization or stimulation-dependent activation of NFAT in T cells47,70,94. Classical actin 
binding type I and II CH domains could not functionally replace the endogenous type III CH 
domain in Vav1 regarding BCR-induced Ca2+-mobilization in DG75 B cells47. Thus, the function 
of the CH domain of Vav proteins for Ca2+-mobilization after BCR stimulation is not to bind the 
actin cytoskeleton.  
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For activation, Vav proteins are phosphorylated on several tyrosine residues within different 
domains80,89. The AR of Vav proteins contains three tyrosines that are phosphorylated during 
this activation process. Due to introduction of additional negative charges in the AR, the 
structure of the inhibitory loop is resolved and an “open” conformation of Vav proteins is 
generated78,95. This conformational change to the “open” stage of Vav proteins is further 
supported by phosphorylation of two tyrosine residues within the ZF domain as well as the C-
SH3 domain and ultimately leads to enhanced GEF-activity72.  
Experiments in mice expressing a GEF-inactive variant of Vav1 revealed that the GEF-activity 
of Vav proteins is important for selection of thymocytes and for optimal activation of T cells96. 
TCR-stimulated T cells of these mice showed reduced Rac1 activation and phosphorylation of 
Akt while TCR-induced Ca2+-mobilization however was not affected by the GEF-inactive 
variant of Vav196. In B cells, little is known about the role of the GEF-activity of Vav family 
members towards small G proteins of the Rho family. Vav-dependent activation of Rac is linked 
to cytoskeletal rearrangements and receptor internalization97,98. Furthermore, DG75 B cells 
expressing a Vav1-variant without GEF-activity showed similar BCR-induced Ca2+-profiles as 
DG75 B cells deficient for Vav147,78,99. Conclusively, these experiments indicate that the GEF-
activity of Vav proteins might be important for lymphocyte development and activation. 
2.4.1.2.1. The Rho family of small G proteins 
The Rho family of small G proteins (or GTPases) belongs to the Ras superfamily and consists 
of 20 family members that share amino acid sequence homology between 45% and 95%100,101. 
They are grouped into 8 sub-families, all sharing the characteristic of a Rho-type GTPase-like 
domain101,102. In addition, a structural feature that distinguishes Rho GTPases from other small 
G proteins of the Ras superfamily is the insertion of the Rho insert region between the fifth β 
sheet and the fourth α helix100–102. Rho GTPases are involved in several cellular processes 
such as cytoskeletal rearrangement, cell motility and polarity, vesicle trafficking, cell cycle 
regulation and formation of axons103. Rho GTPases are regulated by three different types of 
proteins, GEFs, GTPase-activating proteins (GAPs) and guanine-nucleotide dissociation 
inhibitors (GDIs)101. GEFs catalyze the nucleotide exchange from guanosine diphosphate 
(GDP) to guanosine triphosphate (GTP), a soluble mediator required for activation of the small 
GTPases104. In contrast, GAPs increase the intrinsic GTP hydrolysis activity, promoting 
inactivation of small G proteins101. GDIs preserve the GDP-bound inactive state of Rho small 
G proteins in the cytosol, preventing their recruitment to adaptor proteins and activation104. In 
vivo studies in mice revealed that different members of Rho GTPases are critical for 
development, maturation and activation of lymphocytes, even though to different extents105. 
For example, mice that were deficient for Rac2 showed reduced B cell and plasma cell 
numbers and defects in BCR-induced signaling106. In contrast, mice deficient for Rac1 were 
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barely affected by the knockout in B cell development and activation105. Mice that were 
deficient for both, Rac1 and Rac2 exhibited an impeded development of B cells in early 
stages107,108. To understand the role of Vav proteins for BCR signaling, it is critical to 
understand which Vav isoform activates which Rho GTPases. 
2.5. Phosphatidylinositol-4-phosphate 5 kinases (PIP5Ks) 
The availability of PIP2 is essential for BCR-induced signaling on two levels. PIP2 as the 
substrate of PLCγ2 is required to induce Ca2+-mobilization along with nuclear translocation of 
the transcription factors NFAT and NF-κB21. Moreover, PIP2 is phosphorylated by PI3K for 
induction of the PI3K/Akt pathway21. Producers of PIP2 are the phosphatidylinositol-4-
phosphate 5-kinases (PIP5Ks), which phosphorylate phosphatidylinositol-4-phosphate (PI4P) 
at the D-5 position of the inositol ring to generate PIP2109. Alternatively, PIP2 is generated by 
phosphatidylinositol-5-phosphate 4-kinases (PIP4Ks) that phosphorylate phosphatidylinositol-
5-phosphate (PI5P) at the D-4 position110. But since the intracellular abundance of PI4P is ten 
times higher than of PI5P, PIP5Ks represent the main producer of PIP2111. PIP5Ks were first 
described in the 1980’s and today three family members are known, PIP5Kα, PIP5Kβ and 
PIP5Kγ112,113. However, the cDNAs of each isoform were cloned in the late 1990’s114–116. The 
activity of PIP5Ks is differentially regulated by different mechanisms for each isoform and they 
play an important role in a variety of signaling pathways113. Activation through Rho GTPases 
loaded with GTP is described by several groups and this activation is further supported by 
phosphorylation through Src family kinases, the latter at least for PIP5Kγ117–119. In addition, 
reports of groups investigating lymphocyte biology revealed a role of PIP5Ks in T cell activation 
and the formation of lipid rafts in the plasma membrane of T cells within the immunological 
synapse120,121. In B cells, it has been demonstrated that co-stimulation of the BCR and CD19, 
a co-receptor of B cells, leads to recruitment of Vav1 and PIP5Ks to CD19122. Furthermore, 
another group reported that upon stimulation of the BCR, PIP5Ks are recruited together with 
Btk to the stimulated BCR123. Both processes lead to locally elevated levels of PIP2 for sufficient 
BCR signaling122,123. Consequently, PIP5Ks represent putative candidates as downstream 
molecules of the GEF-activity towards Rho GTPases of Vav family members. 
2.6. Aims of this thesis 
Using a cellular model system based on Vav1-deficient DG75 B cells, previous results of our 
lab demonstrated that loss of Vav1 severely diminished the ability to mobilize Ca2+ upon 
stimulation of the BCR. However, formation of the Ca2+-initiation complex was not affected. 
We furthermore found that Vav1 and Vav3 supported BCR-induced Ca2+-mobilization whereas 
Vav2 remained inactive47. In addition, Vav1 had to be recruited through its SH2 domain to the 
BCR or other signaling components to exhibit its function. Also, the CH domain was observed 
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to be essential for BCR-stimulated Ca2+-flux into the cytosol47. However, the underlying 
mechanism for Vav family members to control Ca2+-signaling yet remains to be elucidated. 
Therefore, the aim of this thesis was to investigate whether BCR-induced Ca2+-mobilization is 
controlled or influenced by the GEF-activity of Vav family members which might influence the 
function of Rho GTPases. In detail, to address the question whether the GEF-activity is critical 
for BCR-induced signaling, I focused on the following issues on during this Ph.D. project: 
1. To clarify whether differences in BCR-induced signaling capacities originate from different 
recruitments of Vav family members, I tested the association of Vav1, Vav2 and Vav3 to the 
stimulated BCR and its signaling components. 
2. To reveal whether the interaction of Vav1 and Rac1 and the associated GEF-activity is 
required for BCR-induced signaling, I generated Vav family member variants with mutations 
within Vav1-Rac1 interaction interfaces and the resulting constructs were analyzed in Vav1-
deficient DG75 B cells. 
3. To get a clearer understanding of putative differential substrate preferences and the effects 
of the introduced mutations, the GEF-activity towards Rac1, RhoA and Cdc42 for all Vav family 
members and their respective mutant variants was determined. 
4. To uncover whether the inability of Vav2 to support BCR-induced Ca2+-mobilization derives 
from inhibitory effects of the acidic region, I examined this region in detail. 
5. To get insights whether PIP5K family members are required for BCR-induced signaling as 
potential downstream effectors of the GEF-activity of Vav family members, I generated, 
genetically characterized and analyzed DG75 cells deficient for PIP5K family members. 
6. To understand whether other signaling axes within BCR signaling depend on the presence 
of Vav family members and/or their GEF-activity, I tested BCR-induced signaling branches 
such as PI3K/Akt pathway, actin remodeling and activation of MAPK like p38 and Erk.
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3. Material & Methods 
3.1. Material 
3.1.1. Laboratory equipment 
Table 3.1 Laboratory equipment. 
Name Manufacturer 
12-Tube Magnetic Separation Rack NEB 
Agarose Gel Electrophoresis system Peqlab 
Amaxa Nucleofector II Lonza 
Bacterial Incubator Kelvitron T Heraeus 
Bacterial Shaking Incubator Infors Unitron 
Balance BP 61 Sartorius 
Balance TF 612 Sartorius 
Cell Culture Incubator HeraCell 150 Heraeus 
Cell Culture Safety Cabinet Herasafe Heraeus 
Centrifuge 5415D Eppendorf 
Centrifuge 5417R Eppendorf 
Centrifuge Multifuge 3 S-R Heraeus 
Chemi Lux Imager Intas 
Cytation 3 Plate Reader BioTek 
Cytometer LSRII Becton Dickinson 
Electrophoresis Power Supply Amersham Biosciences 
Electrophoresis System Hoefer SE600 Amersham Biosciences 
Freezer HeraFreeze Heraeus 
Freezer Platilab 340 Angelantoni 
Ice Machine Ziegra 
Inverted Microscope Axiovert 35 Zeiss 
Magnetic stirrer M21/1 Framo Gerätetechnik 
Mastercycler EP Gradient Eppendorf 
NanoDrop2000 Spectrophotometer Thermo Scientific 
Neubauer improved Counting Chamber Brand 
pH-Meter inoLab WTW 
Pipettes Eppendorf 
Rotator (Self-Made) Werkstatt (UMG) 
Shaker Duomax 1030 Heidolph 
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Shaker 3005 GFL 
Test-Tube-Rotator 34528 Snijders 
Thermomixer comfort Eppendorf  
Ultra-Low Temperatur Freezer MDF-C2156VAN Panasonic 
Ultrasonic Device Sonoplus Bandelin 
UV-Illuminator Intas 
Vortex Genie 2 Scientific Industries 
Water Bath GFL 
Water Purification System Arium Pro Sartorius 
Western Blot Semidry Transfer Unit TE77 GE Healthcare 
 
3.1.2. Consumables 
Table 3.2 Consumables. 
Name Manufacturer 
Cell Culture Dishes Greiner Bio-One 
Cell Culture Plates Greiner Bio-One 
Cell Culture Serological Pipettes Greiner Bio-One 
Cryo Tubes Greiner Bio-One 
Cuvettes Roth 
FACS Tubes Sarstedt 
Filter Tips Greiner Bio-One 
FLUOTRAC, 96-well plates Greiner Bio-One 
Nitrocellulose Membranes Amersham Biosciences 
Parafilm Bemis 
PCR Tubes Sarstedt 
Pipette Tips Greiner Bio-One 
Polypropylene Tubes Greiner Bio-One 
Reaction Tubes  Greiner Bio-One 
Sterile Filters Sarstedt 
Whatman Blotting Paper GE Healthcare 
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3.1.3. Software and data bases 
Table 3.3 Software. 
Application Software manufacturer 
Agarose Gel Imaging Gel Documentation Software Intas 
Citation Management Software Mendeley Elsevier 
Flow Cytometry Data Acquisition FACSDiva Becton Dickinson 
Flow Cytometry Data Analysis FlowJo 7.6.5 Becton Dickinson 
Graphing and statistical analysis Prism 7 GraphPad 
Illustration Software Illustrator Adobe 
Image editing Photoshop Adobe 
Sequencing Data Analysis FinchTV Geospiza 
Sequencing Data Analysis pDRAW32 Acaclone 
Western Blot Data Acquisition Chemostar Professional Intas 
Western Blot Data Analysis LabImage 1D Kapelanbio 
 
Table 3.4 Data bases. 
Data base Application 
http://primer3.ut.ee Primer design 
https://blast.ncbi.nlm.nih.gov/Blast.cgi Sequence alignment 
https://crispr.mit.edu/ CRISPR/Cas9 guide RNA design 
https://www.ensembl.org/index.html Genomic and mRNA data base 
https://www.uniprot.org Protein data base 
 
3.1.4. Chemicals and reagents 
All chemicals used for the preparation of buffers were purchased from Roth, Sigma or Merck 
if not stated otherwise. Any other chemicals and reagents are listed in Table 3.5. 
Table 3.5 Chemicals and reagents. 
Name Manufacturer 
10x Perm/Wash Buffer I Becton Dickinson 
100x Bovine Serum Albumin (BSA) NEB 
Agarose Peqlab 
Blue Prestained Protein Marker, Broad Range NEB 
Bodipy-FL-GDP Thermo Scientific 
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CytoFix Fixation Buffer Becton Dickinson 
dNTPs Mix NEB 
DNA Ladder GeneRuler 1 kb Fermentas 
Fetal Calf Serum (FCS) Anprotec 
Gel Loading Dye (6x), purple NEB 
GTP Thermo Scientific 
Hexadimethrine Bromide (Polybrene) Sigma 
Indo-1 AM Life Technologies 
InstantBlue Coomassie Protein Stain Expedeon 
Isopropyl-β-D-thiogalactopyranosid (IPTG) Sigma 
L-Glutamine (200 mM) Gibco 
Lysophosphatidylcholine (LPC) Sigma-Aldrich 
NEB buffer 1.1, 2.1, 3.1 & CutSmart NEB 
Penicillin/Streptomycin (100x) Gibco 
Pluronic F-127 Life Technologies 
Protease Inhibitor Cocktail (P2714) Sigma 
Protease Inhibitor Cocktail (cOmplete, EDTA free) Roche 
Puromycin Invivogen 
Roswell Park Memorial Institute (RPMI) 1640 Medium Gibco 
Sodium Pyruvate (100 mM) Gibco 
T4 Ligase Buffer NEB 
TransIT-293 Transfection Reagent Mirus 
Trypsin/EDTA (0.05%) Gibco 
5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-Gal) Roth 
 
3.1.5. Buffers and solutions 
Antibody dilution solution   1% (w/v) BSA 
      0.01% (w/v) NaN3 
      in TBS/T 
Agar plates     2% (w/v) agar 
      in LB-medium 
Blocking solution    10% (w/v) BSA 
      in TBS/T 
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Blotting buffer     48 mM Tris 
      39 mM Glycine 
      0.0375% (w/v) SDS 
      20% (v/v) Methanol 
      in ddH2O 
ECL solution     4 ml ECL solution A 
      400 µl ECL solution B 
      1.5 µl H2O2 (30%) 
ECL solution A    100 mM Tris-HCl (pH 8.6) 
      0.28 mM Luminol 
      in ddH2O 
ECL solution B    6.7 mM p-coumaric acid 
      in DMSO (stored in the dark) 
Freezing media    10% (v/v) DMSO 
      in FCS 
GEF-assay buffer    20 mM Tris-HCl (pH 7.5) 
      50 mM NaCl 
      2 mM EDTA 
      100 µg/ml BSA 
      500 nM DTT 
      600 nM Bodipy-GDP 
      in ddH2O 
Krebs-Ringer buffer    140 mM NaCl 
      10 mM HEPES (pH 7.4) 
10 mM D-glucose 
      4 mM KCl 
      1 mM MgCl2 
      1 mM CaCl2 (freshly added) 
      in ddH2O 
Laemmli buffer (5x)    156.25 mM Tris-HCl (pH 6.8) 
      500 mM DTT 
      50% (v/v) Glycerol 
      15% (w/v) SDS 
      0.05 bromophenol blue 
      in ddH2O 
Lysogeny broth (LB) medium  10 g/l Tryptone 
      5 g/l Yeast Extract 
      5 g/l NaCl (pH 7.0) 
      in ddH2O 
Ni-NTA equilibration buffer   20 mM NaH2PO4 (pH 7.4) 
      300 mM NaCl 
      10 mM Imidazole 
      20% (v/v) Glycerol 
      in ddH2O 
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Ni-NTA wash buffer    20 mM NaH2PO4 (pH 7.4) 
      300 mM NaCl 
      20 mM Imidazole 
      20% (v/v) Glycerol 
      in ddH2O 
NP-40 lysis buffer    137.5 mM NaCl 
      50 mM Tris-HCl (pH 7.8) 
      1 mM sodium-orthovanadate 
      0.5 mM EDTA 
      10% (v/v) Glycerol  
      1% (v/v) NP-40 
      1x Protease Inhibitor Cocktail (freshly added) 
      in ddH2O 
pH10 elution buffer    50 mM Tris-HCl (pH 7.4) 
      300 mM NaCl 
      5 mM EDTA 
      250 mM Saccharose 
      500 mM Imidazole 
      20% (v/v) Glycerol 
      in ddH2O 
pH10 high salt wash buffer   50 mM Tris-HCl (pH 7.4) 
      1.5 M NaCl 
      20 mM Imidazole 
      20% (v/v) Glycerol 
      in ddH2O 
Phosphate buffered saline (PBS)  137 mM NaCl 
      4.3 mM Na2HPO4 
      2.7 mM KCl 
      1.4 mM KH2PO4 (pH 6.6) 
      in ddH2O 
Resolving gel     375 mM Tris-HCl (pH 8.8) 
      3.5 mM SDS 
      10% (v/v) Acrylamide / Bisacrylamide 
      in ddH2O 
RPMI media with 10% FCS (R10)  10% (v/v) heat inactivated FCS 
      1x PenStrep 
      1 mM sodium pyruvate 
      1 mM L-glutamine 
      50 µM β-mercaptoethanol 
      in RPMI-1640 medium 
RPMI media without FCS (R0)  1x PenStrep 
      1 mM sodium pyruvate 
      1 mM L-glutamine 
      50 µM β-mercaptoethanol 
      in RPMI-1640 medium 
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SDS-PAGE buffer    25 mM Tris 
      192 mM Glycine 
      0.1% (w/v) SDS 
      in ddH2O 
Stacking gel     125 mM Tris-HCl (pH 6.8) 
      3.5 mM SDS 
      10% (v/v) Acrylamide / Bisacrylamide 
      in ddH2O 
TAE-buffer     40 mM Tris 
      20 mM glacial acetic acid 
      1 mM EDTA 
      in ddH2O 
TAG-lysis buffer    10 mM Tris-HCl (pH 8.0) 
      50 mM KCl 
      0.45% (v/v) NP-40 
      0.45% (v/v) Tween 20 
      in ddH2O 
Terrific broth (TB) medium   24 g/l Yeast Extract 
      20 g/l Tryptone 
      0.4% (v/v) Glycerol 
      72 mM K2HPO4 
      17 mM KH2PO4 
      in ddH2O 
Tris buffered saline/Tween 20 (TBS/T) 137 mM NaCl 
      20 mM Tris-HCl (Ph 7.6) 
      0.1% (v/v) Tween 20 
      in ddH2O 
3.1.6. Reaction systems (kits) 
Table 3.6 Ready-to-use reactions systems (kits). 
Kit Application Manufacturer 
Amaxa human B cell Nucleofector Kit Nucleofection Lonza 
QiaPrep Spin MiniPrep Kit Plasmid purification Qiagen 
TA cloning Kit Cloning of PCR products Invitrogen 
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3.1.7. Enzymes 
All enzymes were used according to the manufacturer’s instructions. 
Table 3.7 Enzymes. 
Enzyme Manufacturer 
Calf intestine phosphatase (CIP) NEB 
Pfu Polymerase Promega 
Proteinase K Macherey & Nagel  
Q5 Polymerase NEB 
Restriction Endonucleases NEB 
T4 DNA Ligase NEB 
Taq Polymerase NEB 
 
3.1.8. Oligonucleotides 
Synthetic DNA nucleotides were designed with Primer3, ordered at Eurofins Genomics and 
used according to the instructions by Primer3. 
Table 3.8 Standard primer used for sequencing. 
Name Sequence (5’ --> 3’) Purpose 
M13_fwd TGTAAAACGACGGCCAGT Sequencing 
M13_rev CAGGAAACAGCTATGACC Sequencing 
MSCV_fwd CCCTTGAACCTCCTCGTTCGACC Sequencing 
MSCV_rev CAGACGTGCTACTTCCATTTGTC Sequencing 
N-eGFP_rev CGTCGCCGTCCAGCTCGACCAG Sequencing 
QE-fwd GTATCACGAGGCCCTTTCG Sequencing 
QE-rev GTTCTGAGGTCATTACTGG Sequencing 
T7 TAATACGACTCACTATAGGG Sequencing 
U6_fwd GAGGGCCTATTTCCCATGATTCC Sequencing 
 
Table 3.9 Primer used for cloning. 
Name Sequence (5’ --> 3’) Purpose 
AmplPIP5Ka_fwd GGAGTTTTCTTCTGTGATCTTTTAGC
CAC 
Cloning of PIP5K1A’s exon 
3 in pCR2.1 
AmplPIP5Ka_rev GAACTCCTGGCCTAAAATGATCTGC Cloning of PIP5K1A’s exon 
3 in pCR2.1 
AmplE3PIP5Kc_f
wd 
CTCTCTGAAGTGTGCAGTGAGT Cloning of PIP5K1C’s exon 
3 in pCR2.1 
AmplE3PIP5Kc_r
ev 
TGAATCACATCTCAGTAAAACGGTT Cloning of PIP5K1C’s exon 
3 in pCR2.1 
Ampl-E5-
PIP5Kb_fwd 
TGGATCTATGGTGGGACTAGTAAGC Cloning of PIP5K1B’s exon 
5 in pCR2.1 
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Ampl-E5-
PIP5Kb_rev 
TCTCCATATGGTCTTCCAGGCATTC Cloning of PIP5K1B’s exon 





Cloning of mVav1’s GEF-





Cloning of mVav1’s GEF-
mediating domains in pH10 
PIP5Kb-AgeI_fwd TAATACCGGTATGTCTTCTGCTGCT
GAAAATGGAG 










Cloning of Vav1’s GEF-





Cloning of Vav1’s GEF-





Cloning of Vav3’s GEF-





Cloning of Vav3’s GEF-
mediating domains in pH10 
 
Table 3.10 Primer used for site directed mutagenesis. Base pair substitutions are indicated by lowercase letters. 

















Site directed mutagenesis of 





Site directed mutagenesis of 
murine Vav1 in pH10 
PIP5KsCitM->Lfw CTACCGGTCGCCACCcTGGTGAGCA
AGGGCGAG 










































Site directed mutagenesis of 
Vav1 
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Vav1-K374A_rev TGTCTCGTTGTCTCGCgcGACCTCGT
TC 




Site directed mutagenesis of 
Vav1 






















Site directed mutagenesis of 





Site directed mutagenesis of 
Vav1 in pH10 
Vav2deltaAR-fwd CAGAACAAAGGGATCAGCCCTTTTA
TGAAAATGGGCATGACTGAAGAT 










































Site directed mutagenesis of 





Site directed mutagenesis of 
Vav3 in pH10 
 
Table 3.11 Primer used as sgRNA for CRISPR/Cas9-mediated genome editing. 
Name Sequence (5’ --> 3’) Purpose 
PIP5KA-E3-fwd CACCGCATAGAAGTGTTGATTCCTC sgRNA to CRISPR exon 3 of 
PIP5K1A 




sgRNA to CRISPR exon 3 of 
PIP5K1C 
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PIP5Kc-E3-rev AAACTCGAGGTGTGGACGCATCCG
C 
sgRNA to CRISPR exon 3 of 
PIP5K1C 
PIP5Kc-E4-fwd CACCGCTGCATGAGCACGTCGCGTT sgRNA to CRISPR exon 4 of 
PIP5K1C 




CACCGCTTGCTCCAAAACAATGACG Upstream sgRNA to 
CRISPR exon 5 of PIP5K1C 
CRISPR-PIP5Kb-
E5_rev1 
AAACCGTCATTGTTTTGGAGCAAGC Upstream sgRNA to 
CRISPR exon 5 of PIP5K1C 
CRISPR-PIP5Kb-
E5_fwd2 
CACCGTTGTGACAACCCCATATTGA Downstream sgRNA to 
CRISPR exon 5 of PIP5K1C 
CRISPR-PIP5Kb-
E5_rev2 
AAACTCAATATGGGGTTGTCACAAC Downstream sgRNA to 
CRISPR exon 5 of PIP5K1C 
 
3.1.9. Vectors and plasmids 
Table 3.12 Plasmids, vectors and cDNAs used for cloning. 
Name  Source Application 
pcDNA3.1-PIP5Kβ GenScript Cloning of PIP5Kβ 
pCitrine-N1 Michael Engelke C-terminal Citrine-tagging 
pCR2.1 Invitrogen Cloning 
pH10-TEV Hansjörg Götzke His-tagged protein expression 
pMSCV-Puro Clontech Protein expression 
pRetroX-TetOne-Puro Clontech Inducible protein expression 
pSpCas9(BB)-2A-GFP Addgene CRISPR/Cas9-mediated genome editing 
 
Table 3.13 Retroviral expression plasmids. 
Insert  Backbone Source 
eGFP pMSCV-Puro Michael Engelke 
mVav1-Cit pMSCV-Puro Christoffer Hitzing 
mVav1-Cit LK334/335AA pMSCV-Puro This work 
PIP5Kα-Cit pRetroX-TetOne-Puro This work 
PIP5Kβ-Cit pRetroX-TetOne-Puro This work 
PIP5Kγ-Cit pRetroX-TetOne-Puro This work 
Citrine pRetroX-TetOne-Puro This work 
Vav1-Cit pMSCV-Puro Christoffer Hitzing 
Vav1-Cit D376A pMSCV-Puro This work 
Vav1-Cit E201A pMSCV-Puro This work 
Vav1-Cit E201A E378A pMSCV-Puro This work 
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Vav1-Cit E201A N371A pMSCV-Puro This work 
Vav1-Cit E378A pMSCV-Puro This work 
Vav1-Cit K208A pMSCV-Puro This work 
Vav1-Cit K374A pMSCV-Puro This work 
Vav1-Cit L213Q pMSCV-Puro Christoffer Hitzing 
Vav1-Cit N371A pMSCV-Puro This work 
Vav1-Cit Q331A pMSCV-Puro This work 
Vav1-Cit R375A pMSCV-Puro This work 
Vav1Syk(SH2)2-Cit pMSCV-Puro Christoffer Hitzing 
Vav1Syk(SH2)2-Cit E201A pMSCV-Puro This work 
Vav1Syk(SH2)2-Cit N371A pMSCV-Puro This work 
Vav2-Cit pMSCV-Puro Christoffer Hitzing 
Vav2ΔAR-Cit pMSCV-Puro This work 
Vav2-Cit Y142D Y159D Y172D pMSCV-Puro This work 
Vav3-Cit pMSCV-Puro Christoffer Hitzing 
Vav3-Cit E199A pMSCV-Puro This work 
 
Table 3.14 Plasmid used for transient transfection. 
Insert  Backbone Source 
sgRNA (CRISPR exon 3 PIP5Kα)  pSpCas9(BB)-2A-GFP This work 
sgRNA (CRISPR exon 5 PIP5Kβ) 
upstream 
pSpCas9(BB)-2A-GFP This work 
sgRNA (CRISPR exon 5 PIP5Kβ) 
downstream 
pSpCas9(BB)-2A-GFP This work 
sgRNA (CRISPR exon 3 PIP5Kγ) pSpCas9(BB)-2A-GFP This work 
sgRNA (CRISPR exon 4 PIP5Kγ) pSpCas9(BB)-2A-GFP This work 
 
Table 3.15 Plasmids used for bacterial his-tagged fusion protein expression. Murine and human Vav1 
constructs were expressed from amino acid 170 to 575 and human Vav3 constructs from amino acid 169 to 573, 
respectively.  
Insert  Backbone Source 
mVav1 Y174D pH10-TEV This work 
mVav1 Y174D LK334/335AA pH10-TEV This work 
Vav1 Y174D pH10-TEV This work 
Vav1 Y174D E201A pH10-TEV This work 
Vav1 Y174D N371A pH10-TEV This work 
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Vav3 Y173D pH10-TEV This work 
Vav3 Y173D E199A pH10-TEV This work 
 
3.1.10. Antibodies 
Table 3.16 Primary antibodies used for western blot analysis. Antibodies were diluted according to the 
manufacturer’s recommendations in antibody dilution solution. 
Antibody (clone) Species/Isotype Manufacturer 
α Actin (15E9) Rabbit  CST 
α Actin (8H10D10) Mouse IgG2b CST 
α BLNK (SLP-65) (D8R3G) Rabbit CST 
α CD79A (Igα) (EP3618) Rabbit Abcam 
α Erk (16) Mouse IgG2a Becton Dickinson 
α phospho Erk (E10) Mouse IgG1 CST 
α GFP (7.1 & 13.1) Mouse IgG1 Roche 
α p38 Rabbit CST 
α phospho p38 (36/p38) Mouse IgG1 Becton Dickinson 
α PIP5Kα Rabbit CST 
α PIP5Kβ (F-4) Mouse IgG2a Santa Cruz 
α PIP5Kγ Rabbit CST 
α Syk (4D10) Mouse IgG2a Santa Cruz 
α Vav1 Rabbit CST 
 
Table 3.17 Secondary antibodies used for western blot analysis. Antibodies were diluted 1:10000 in TBS/T. 
Antibody Species Manufacturer 
α mouse IgG1-HRPO Goat Southern Biotech 
α mouse IgG2a-HRPO Goat Southern Biotech 
α mouse IgG2b-HRPO Goat Southern Biotech 
α rabbit-HRPO Goat Southern Biotech 
 
Table 3.18 Antibodies used for stimulation. Antibodies were used in a concentration of 20 µg/ml for stimulation. 
Antibody Species Manufacturer 
α human IgM (Fc5µ fragment 
specific) 
Goat Jackson ImmunoResearch 
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Table 3.19 Antibodies used for surface staining. Antibodies were labeled with AlexaFluor 647 and used 
according to the manufacturer’s instructions. 
Antibody Species Manufacturer 
α human kappa light chain Goat Southern Biotech 
 
Table 3.20 Antibodies used for intracellular staining. Antibodies were labeled with AlexaFluor 647 and used 
according to the manufacturer’s instructions. 
Antibody (clone) Species/Isotype Manufacturer 
α phospho Akt (D9E) Rabbit CST 
α phospho Erk (20A) Mouse IgG1 Becton Dickinson 
 
3.1.11. Recombinant proteins 
Table 3.21 Recombinant proteins. All recombinant proteins that were purchased at Cytoskeleton Inc. contained 
N-terminal His-tags. Phalloidin-AlexaFluor 647 was used according to the manufacturer’s instructions. 
Recombinant protein Manufacturer 
Cdc42 Cytoskeleton Inc. 
Phalloidin-AlexaFluor 647 Molecular Probes 
Rac1 Cytoskeleton Inc. 
RhoA Cytoskeleton Inc. 
Vav2 GEF Protein (DH domain) Cytoskeleton Inc. 
 
3.1.12. Affinity purification systems 
Table 3.22 Affinity purification systems. 
Purification system Species Manufacturer 
HisPur Ni-NTA Superflow Agarose - Thermo Scientific 
GFP-Trap Magnetic Agarose Alpaca  Chromotek 
 
3.1.13. Inhibitors 
Table 3.23 Inhibitors. 
Inhibitor Solvent Manufacturer 
EHop-016 (E-Hop) DMSO Calbiochem 
Rhosin DMSO Calbiochem 
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3.1.14. Bacterial strains 
Table 3.24 Chemically competent bacterial strains used. 
Bacterial strain Manufacturer Purpose 
E. coli TOP10F’ Invitrogen Cloning/plasmid amplification 
E. coli BL21 CodonPlus Agilent Technologies Protein expression 
 
3.1.15. Mammalian cell lines 
DG75 EcoBlast (EB) 
Human Burkitt lymphoma DG75 B cells (DSMZ: ACC 83) were originally harvested from pleural 
effusion of a 10-year-old boy with refractory, terminal Burkitt lymphoma in 1975. This cell line 
is described to be negative for Epstein-Barr virus (EBV) and expresses membrane-bound IgM 
along with the κ light chain on the cell surface124. 
DG75EB cells are equipped with the receptor for Moloney murine leukemia virus (MMLV), the 
murine cationic amino acid transporter SLC7A1, by retroviral transduction. The cells were 
selected with the antibiotic blasticidin and used for retroviral gene transfer with MMLV-derived 
particles produced by the packaging cell line Platinum-E125,126. Since no differences were 
detected between DG75 and DG75EB cells regarding signaling pathways or culturing of these 
cells, DG75EB are henceforth referred to as DG75.  
DG75EB Vav1-/-#2 
DG75EB Vav1-/-#2 (hereinafter referred to as Vav1-deficient DG75) cells originated from DG75 
cells and were made deficient for Vav1 by TALEN mutagenesis47. For analysis of Vav family 
members, these cells were retrovirally transduced with plasmids encoding for various Vav 
protein variants. All of the transduced variants of Vav proteins contained C-terminal Citrine 
tags. Citrine is a fluorescent protein with excitation at a wavelength of 516 nm and emission at 
529 nm. Thus, protein expression of Citrine, Citrine-tagged proteins and eGFP (excitation at a 
wavelength of 488 nm and emission at 507 nm) is detectable by flow cytometry in the FITC 
channel127,128. 
Platinum-E (PlatE) 
PlatE cells are retroviral packaging cells based on HEK293 cells. They contain the MMLV’s 
env, gag & pol genes under the control of the EF1α promotor. Additionally, the insertion of 
internal ribosome entry sites (IRES) between those three genes ensures high titers of MMLV 
produced by these cells126. 
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3.2. Methods 
3.2.1. Molecular biology 
3.2.1.1. Isolation and purification of nucleic acids 
3.2.1.1.1. Isolation of genomic DNA 
To isolate genomic DNA, 1 x 106 cells were lysed in 200 µl TAG-lysis buffer (for composition 
see section 3.1.5.). Subsequently, 1 µl of Proteinase K (20 mg/ml, Macherey & Nagel) was 
added and the mixture was incubated for 3 h at 56°C. This step was followed by heat-
inactivation of Proteinase K at 95°C for 30 min. The isolated DNA was stored at -20°C. 
3.2.1.1.2. Isolation of plasmid DNA 
Plasmid DNA was purified from E. coli TOP10F’ bacteria. One bacterial colony was inoculated 
in 4 ml of LB medium (for composition see section 3.1.5.) containing the respective selective 
antibiotic (ampicillin with 100 µg/ml or kanamycin with 30 µg/ml) and incubated overnight at 
37°C in a bacterial shaker. Subsequently, plasmid DNA was isolated using QiaPrep Spin 
MiniPrep Kit (Qiagen) according to the manufacturer’s instructions. DNA concentration and 
purity were determined using the NanoDrop2000 spectrophotometer. 
3.2.1.2. Cloning techniques 
In molecular biology, cloning is defined by transition of DNA fragments into different vectors 
for various purposes like sequencing or gene expression in distinct cells. The open reading 
frame (ORF) of a gene of interest is amplified by polymerase chain reaction (PCR) and either 
directly transferred into the final vector or transferred into an intermediate vector. This transfer 
is called cloning and requires generation of specific overhangs by restriction enzymes at both 
ends of the gene. Subsequently, DNA fragments with similar overhangs in the vector are 
ligated to form a plasmid. 
3.2.1.2.1. Polymerase chain reaction 
The PCR is a well-established method to amplify specific DNA fragments in vitro129. The 
amplicon is determined by primers. Generally, the PCR includes three steps. At first, the 
template DNA is denaturated, which allows annealing of primers in the second step. In the 
third and final step, the annealed primers are elongated using a polymerase. All three steps 
require different temperatures and the conditions of the PCR are adjusted to the used 
polymerase. Repetition of these three steps leads to amplification of the desired DNA 
fragment. 
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In this project, the Q5 polymerase was used to amplify DNA fragments according to the 
manufacturer’s recommendations. Primers were designed for annealing temperatures of 
approx. 65°C using the online database Primer3. Furthermore, restriction sites were added to 
primers that were used for cloning. 
Table 3.25 Standard PCR conditions. bp = base pairs, min = minutes, sec = seconds 
Step Temperature Time Cycles 
Initial denaturation 98°C 2 min      1 
Denaturation 98°C 20 sec  
Annealing 65°C 30 sec      35 
Elongation 72°C 20 sec per 1000 bp  
Final elongation 72°C 40 sec per 1000 bp      1 
 
3.2.1.2.2. Agarose gel electrophoresis 
Agarose gel electrophoresis was conducted to separate DNA fragments by size using 1% 
agarose gels containing 1 µg/ml ethidium bromide in TAE buffer (for composition see section 
3.1.5.). Samples were mixed with one fifth of 6x DNA loading buffer (NEB) and subsequently 
loaded onto the agarose gel. Fragments were separated at 100 V, 110 mA for 50 min. To 
determine the size of the DNA fragments, a 1 kb DNA ladder (Fermentas) was used as a 
reference. 
3.2.1.2.3. Agarose gel extraction 
The desired DNA fragment was cut out after separation by agarose gel electrophoresis and 
the DNA was extracted using the Wizard SV Gel and PCR Clean Up System (Promega) 
according to the manufacturer’s instructions. 
3.2.1.2.4. TA cloning (Invitrogen) 
25.5 µl of the isolated DNA were mixed with 3 µl of 10x ThermoPol buffer (NEB), 1 µl of dATPs 
(1 mM, NEB) and 0.5 µl of Taq polymerase. This mixture was incubated for 30 min at 72°C in 
a PCR cycler. This reaction generates adenine overhangs at the 3’ end of the DNA fragments 
(A-tailing), which are required for ligation to an intermediate vector named pCR2.1 (Invitrogen). 
To ligate the A-tailed DNA fragments into pCR2.1, 4 µl of the A-tailing reaction were mixed 
with 3.5 µl of ddH2O, 1 µl of 10x T4 Ligase buffer (NEB), 1 µl of linear pCR2.1 and 0.5 µl of T4 
Ligase. The mixture was incubated overnight at 14°C. 
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3.2.1.2.5. Transformation of competent cells 
Transformation of chemically competent E. coli TOP10F’ was performed with 3.5 µl of the 
ligation reaction. After addition of the DNA, the bacteria were incubated for 30 min on ice 
followed by a heat shock for 45 sec at 42°C. Subsequently, the bacterial cells were cooled on 
ice for another 2 min before addition of 450 µl of prewarmed (37°C) LB medium and incubation 
for 1 h at 37°C with mild agitation. Afterwards, the bacteria were plated on agar plates 
containing 100 µg/ml of ampicillin or 30 µg/ml of kanamycin and incubated overnight at 37°C. 
Transformation of E. coli TOP10F’ with plasmids that have a pCR2.1 backbone allows for blue-
white-screening. Therefore, an agar dish was coated with 50 µl of X-Gal and IPTG before 
plating the bacteria. Successfully cloned colonies either remained white or became blue when 
TA cloning was not successful. Thus, white colonies were picked after over-night incubation 
and DNA was isolated according to chapter 3.2.1.1.2. 
3.2.1.2.6. Sequencing of plasmids 
After isolation of plasmid DNA from E. coli TOP10F’ bacteria, the plasmid DNA of potential 
clones was sent for sequencing to confirm the insertion of the desired DNA fragment into 
pCR2.1. Briefly, 12 µl containing 800 - 1200 ng of DNA were mixed with 3 µl of the sequencing 
primers (10 µM). Sequencing was performed by the Seqlab company. 
3.2.1.2.7. Restriction digestion of DNA for cloning into expression backbones 
DNA fragments cloned into pCR2.1 cannot be used for expression, neither in bacterial nor in 
eukaryotic cells. Hence, the desired DNA fragments (= inserts) were cloned into three different 
expression backbones. Two backbones were used for protein expression in mammalian cell 
lines, pMSCV-Puro and pRetroX-TetOne-Puro (Clontech), and one for inducible protein 
expression in bacteria, pH10-TEV (kindly provided by Hansjörg Götzke, NanoTag 
Biotechnologies). Protein expression using the pMSCV-Puro backbone in mammalian cells 
leads to a permanent expression of the respective protein, whereas protein expression using 
pRetroX-TetOne-Puro is inducible with doxycycline. 
Each backbone contains a unique multiple cloning site (MCS), hence restriction digestions 
need to be adapted to those. To generate complementary overhangs, the backbone and the 
pCR2.1 construct carrying the desired insert were digested for 2 h according to the 
manufacturer’s instructions for each restriction enzyme. Depending from the insert, either one 
restriction enzyme cleaved at both ends of the insert or two different restriction enzymes were 
used for cleavage at either end of the inserts. Subsequently, the digested DNA was loaded 
onto an agarose gel. The DNA was separated within the gel and the band at the predicted size 
was isolated according to sections 3.2.1.2.2. and 3.2.1.2.3., respectively. 
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3.2.1.2.8. Treatment with calf intestine phosphatase 
If only one restriction enzyme was used, incubation of the backbone with calf intestine 
phosphatase (CIP) became necessary to avoid any undesired re-ligation of the backbone 
instead of ligation with the insert during the ligation reaction. In brief, 1 µl of CIP was added to 
the digest, followed by an incubation of 1 h at 37°C. This step was skipped if two different 
restriction enzymes were used for cloning. 
3.2.1.2.9. Cloning ligation 
For ligation of the insert into the expression backbone, 4 µl of the cut out and purified insert 
were mixed with 3.5 µl of ddH2O, 1 µl of linearized and purified backbone, 1 µl of 10x T4 Ligase 
buffer and 0.5 µl of T4 Ligase. Subsequently, the mixture was incubated overnight at 14°C 
followed by transformation and plasmid purification according to chapters 3.2.1.2.5. and 
3.2.1.1.2., respectively. To confirm the correct insertion and orientation of the insert, the 
isolated plasmids of the potential clones were sequenced (described in section 3.2.1.2.6.). 
3.2.1.2.10. Site directed mutagenesis 
To investigate the importance of amino acids or regions within Vav family members, mutations 
or deletions were introduced into the respective isoforms. Those mutations were generated 
using specific primers through PCR using the Pfu polymerase (Promega). Primers for site 
directed mutagenesis were designed with one to four mismatches for the mutations and ten to 
fifteen complementary base pairs at each site to ensure annealing to the desired region.  
Table 3.26 PCR reaction for site directed mutagenesis. bp = base pairs, min = minutes, sec = seconds 
Step Temperature Time Cycles 
Initial denaturation 95°C 2 min      1 
Denaturation 95°C 30 sec  
Annealing 55°C 1 min      25 
Elongation 72°C 2 min per 1000 bp  
Final elongation 72°C 4 min per 1000 bp      1 
 
During that process, the whole plasmid including the mutation was amplified by Pfu 
polymerase. Subsequently, the PCR mixture was digested with DpnI, an endonuclease that 
exclusively digests methylated DNA. Methylation is a process that occurs in both, bacteria and 
eukaryotes, but not during in vitro PCR. Accordingly, only the template DNA that lacked the 
mutation was digested but not the mutated amplified plasmids containing the desired mutation 
by the primers via PCR. The DpnI-digested DNA was afterwards transformed, purified and 
sequenced as described before in sections 3.2.1.2.5., 3.2.1.1.2. and 3.2.1.2.6., respectively. 
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3.2.2. Protein biochemistry 
3.2.2.1. Preparation of cleared cellular lysates 
Cleared cellular lysates (CCLs) were prepared from DG75 B cells to investigate expression of 
different proteins by western blot analysis. Before lysis, cells were washed twice in ice-cold 
PBS (for composition see section 3.1.5.). Then, 20 µl of NP-40 lysis buffer (for composition 
see section 3.1.5.) were used per 1 x 106 cells. For lysis, cells were incubated for 10 min on 
ice. The lysates were subsequently centrifuged at 20,000 x g at 4°C for 10 min to clear them 
from cell debris. Finally, the supernatants constituting the cleared lysates were mixed with one 
fourth of 5x Laemmli buffer (for composition see section 3.1.5.), boiled for 10 min at 95°C and 
were either used for SDS-PAGE for further analysis or stored at -20°C. 
3.2.2.2. Stimulation of B cells 
To examine and to determine interaction partners of Vav family members, which are recruited 
after stimulation of the BCR, 50 x 106 of the investigated cells were harvested. For starvation, 
cells were resuspended in 35 ml of R0 (for composition see section 3.1.5.) and were incubated 
for 30 min at 37°C and 5% CO2. Before stimulation with 20 µg/ml anti-human IgM F(ab’)2 
fragments, the volume of R0 was reduced to 1 ml by centrifugation. Cells were either left 
untreated or stimulated for 1, 3 or 10 min. Stimulation was stopped by centrifugation, R0 was 
removed, 1 ml of NP-40 lysis buffer was added and for lysis, treated cells were incubated for 
10 min on ice, followed by clearance of the lysate by centrifugation (20,000 x g, 10 min, 4°C). 
100 µl (equals 5 x 106 cells) were mixed with 25 µl of 5x Laemmli buffer, were boiled for 10 
min at 95°C and stored at -20°C for later usage as input fractions. The remaining 900 µl of the 
CCL were used for immunoprecipitation assays. 
3.2.2.3. Immunoprecipitation assays using GFP-Trap 
To purify Vav family members and their interaction partners from CCLs, the GFP-Trap 
Magnetic Agarose System was used. As the name indicates, this system is suitable for 
purifications of GFP-coupled proteins or cognates like eGFP, YFP and Citrine (Cit). For this 
purpose, alpaca nanobodies coupled to magnetic agarose beads were purchased from 
Chromotek. Before addition of these nanobody-coupled beads to CCLs of unstimulated and 
BCR-stimulated cells, 25 µl of beads per sample were washed twice with ice-cold NP-40 lysis 
buffer for equilibration, followed by incubation for 2 h on a rotator at 4°C. The beads were then 
captured using a magnetic separation rack (NEB) and were washed four times with NP-40 
lysis buffer after the supernatant had been removed. Proteins were afterwards eluted from the 
beads by addition of 40 µl 2x Laemmli buffer (diluted 1:2.5 from 5x Laemmli buffer). The eluates 
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containing the proteins of interest were boiled at 95°C for 10 min and either subjected to SDS-
PAGE for further analysis or stored at -20°C. 
3.2.2.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate 
denaturated and reduced proteins obtained from CCLs (see section 3.2.2.1.) or 
immunoprecipitation assays (see section 3.2.2.3.) by size130. Therefore, proteins in Laemmli 
buffer were loaded onto a 5% polyacrylamide stacking gel and were separated in a 10% 
polyacrylamide resolving gel (for compositions see section 3.1.5.). To determine the molecular 
weight of the analyzed proteins, a prestained protein ladder (NEB, broad range) was used. 
3.2.2.5. Western Blot transfer 
For identification of proteins with specific antibodies, proteins separated by SDS-PAGE were 
transferred onto a nitrocellulose membrane using western blot transfer131. Two Whatman 
papers, the gel and a nitrocellulose membrane were equilibrated in blotting buffer (for 
composition see section 3.1.5.). The gel was placed on top of the membrane between the two 
Whatman papers. The transfer was conducted at 230 V and 1 mA per cm2 of membrane for 
2 h. 
3.2.2.6. Immunostaining 
After successful transfer of the proteins onto the nitrocellulose membrane, the membrane was 
incubated for at least 3 h in blocking solution (for composition see section 3.1.5.) to block any 
unspecific binding of antibodies eventually resulting in undesired and unspecific staining. The 
antibodies were diluted according to the manufacturer’s recommendations in antibody dilution 
solution (for composition see section 3.1.5.) and were incubated with the membrane overnight 
on a rocker at 4°C. After incubation, the membrane was washed three times for 15 min with 
TBS/T under constant agitation, followed by 1 h of incubation on a rocker at room temperature 
with horse-radish peroxidase (HRPO)-coupled secondary antibodies, that detect the constant 
region (Fc region) of the respective primary antibodies. After washing the membrane for three 
more times with TBS/T for 15 min, the proteins of interest stained with primary antibodies were 
visualized via the HRPO-coupled secondary antibodies using enhanced chemiluminescence 
(ECL) solution (for composition see section 3.1.5.) in combination with the Chemi Lux Imager 
(Intas). 
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3.2.2.7. Expression and purification of recombinant His-tagged fusion proteins 
To generate His-tagged fusion protein, parts of ORFs of Vav family members, that encode for 
the domains which mediate the GEF-activity, were cloned into pH10-TEV backbone according 
to chapters 3.2.1.2.7. and 3.2.1.2.9. Correct in-frame insertion and presence of the stop-codon 
were checked by sequencing (described in chapter 3.2.1.2.6.). 
2 ng of the resulting plasmid were transformed into E. coli BL21 CodonPlus bacteria (according 
to section 3.2.1.2.5.) for IPTG induced expression. Therefore, a single transformed colony was 
inoculated in 4 ml of LB medium supplemented with kanamycin (30 µg/ml) and incubated 
overnight at 37°C in a bacterial shaking incubator. Subsequently, the bacterial culture was 
transferred into 200 ml of TB medium supplemented with 30 µg/ml kanamycin (for composition 
see section 3.1.5.) before incubation at 37°C in a bacterial shaking incubator until the culture 
reached an OD595 of approx. 0.6. Afterwards, protein expression in bacteria was induced by 
addition of 100 nM IPTG and cells were incubated for 4 h at 25°C in a shaking incubator. 
Subsequently, the bacteria were pelleted by centrifugation (4,000 x g, 15 min, 4°C), the 
supernatant was discarded and the pellets were stored at -80°C.  
For purification of the expressed recombinant His-tagged fusion protein, bacterial pellets were 
resuspended in 10 ml Ni-NTA equilibration buffer (for composition see section 3.1.5.) 
containing freshly added protease inhibitors (cOmplete, EDTA free). The cells were lysed by 
sonication (intensity: 75%, pulse: 5, duration: 30 sec) and lysis was subsequently supported 
by supplementation of Triton-X-100 in a final concentration of 1%. Bacterial lysates were then 
cleared by centrifugation (20,000 x g, 10 min, 4°C). In the meantime, 80 µl of HisPur Ni-NTA 
Superflow Agarose beads (50% slurry, Thermo Scientific) were equilibrated by washing them 
twice in Ni-NTA equilibration buffer (700 x g, 5 min, 4°C). The bacterial lysates were added to 
the beads and incubated for 4 h on a rotator at 4°C to purify the His-tagged proteins. After 
purification, the beads were washed three times with ice-cold Ni-NTA wash buffer and once in 
ice-cold pH10 high salt wash buffer (for compositions see section 3.1.5.). Elution of the purified 
protein was achieved using 200 µl pH10 elution buffer (for composition see section 3.1.5.) for 
10 min at room temperature. To determine elution efficacy, 10 µl of the eluate were analyzed 
by SDS-PAGE (see section 3.2.2.4.) and staining with InstantBlue (Expedeon). Herein, BSA 
was used as a reference and the remaining 190 µl of eluted proteins were stored at 4°C.  
3.2.2.8. In vitro GEF-activity assay 
To determine the ability of Vav family members to catalyze the exchange of GDP to GTP for 
small G proteins of the Rho family, in vitro GEF-activity was determined using Bodipy-GDP 
(Thermo Scientific). Fluorescence of the Bodipy labeled GDP is excited at a wavelength of 503 
nm with a detectable emission at 512 nm. Considerably higher intensities are achieved when 
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bound to small G proteins. Respectively, the exchange of GDP to GTP can be indirectly tracked 
by the loss of signal intensity. To measure GEF-activity, 400 nM of either Rac1, RhoA or Cdc42 
was added to Bodipy-GDP containing GEF-assay buffer (for composition see section 3.1.5.) 
for 20 min at 25°C. To lock the loading of the Rho GTPase with Bodipy-GDP, MgCl2 was added 
to a final concentration of 5 mM. Additionally, to allow the exchange to GTP, GTP was added 
to a final concentration of 500 nM. Per sample, 90 µl of the mixture was transferred into a 
FLUOTRAC 96-well plate (Greiner Bio-One) and fluorescence was measured every 30 sec for 
2 min. The mean of those first 5 values represented the baseline. Then, 10 µl of purified GEF-
mediating domains of Vav family members (for procedure see section 3.2.2.7.) with a 
concentration of 8 µM were added to the mixture and the fluorescence was measured for 
another 20 min. 
3.2.3. Cell biology 
3.2.3.1. Cell culture 
3.2.3.1.1. Cell culture and maintenance of non-adherent cells 
Non-adherent DG75 cells and all sub-clones derived from these cells were cultured in R10 (for 
composition see section 3.1.5.) at 37°C and 5% CO2 in a cell culture incubator. Every two 
days, 1.5 x 106 cells were seeded in a culture dish with a diameter of 10 cm for maintenance. 
For experiments on cellular basis, a different number of cells was seeded for each experiment. 
3.2.3.1.2. Cell culture and maintenance of adherent cells 
Adherent PlatE cells were cultured in R10 at 37°C and 5% CO2 in a cell culture incubator. For 
maintenance, cells were washed once with PBS and were detached using a 0.05% 
Trypsin/EDTA solution (Gibco). Every Monday, 1 x 106 cells were seeded in 10 cm cell culture 
dish and every Friday 2.5 x 106 cells. PlatE cells were exclusively used as a retroviral 
packaging cell line which allows infection of DG75 and sub-clones with MMLV-derived 
particles. 
3.2.3.1.3. Storage and revitalization of cells 
For long-term storage of mammalian cells, 10 x 106 cells were harvested by centrifugation (300 
x g, 5 min, RT) and resuspended in 2 ml of freezing medium (for composition see section 
3.1.5.). 1 ml of cell suspension per cryo tube were stored at -150°C. 
Frozen cells were thawed at 37°C and were washed once with R10 before seeding in 10 ml of 
R10 medium for revitalization. 
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3.2.3.2. Transfection methods 
3.2.3.2.1. Nucleofection (Amaxa) 
Nucleofection was performed using the Amaxa human B cell Nucleofector Kit (Lonza) to 
introduce the plasmids for CRISPR/Cas9-mediated genome editing into the target cells. 2 x 
106 cells were harvested by centrifugation (90 x g, 10 min, RT). Meanwhile, 82 µl of human B 
cell Nucleofector Solution were mixed with 18 µl of Supplement 1 as well as 2 µg of the desired 
plasmid. Subsequently, the cells were resuspended in this transfection mixture and were 
transferred into the provided cuvettes. Nucleofection was achieved using program T-015 of 
Amaxa Nucleofector II. After nucleofection, the cells were first transferred into 3 ml of 
prewarmed R10 using a Pasteur pipette and were then placed into a cell culture incubator. 
3.2.3.2.2. Retroviral transduction 
To overexpress particular proteins in DG75 B cells, plasmids were introduced into the genome 
of the cells through retroviral transduction. For this purpose, 3 x 105 cells of the retroviral 
packaging cell line PlatE were plated in 6 cm cell culture dishes three days before transfection. 
On the day of transfection, 8 µl of TransIT transfection solution (Mirus) were diluted in 250 µl 
of R0 medium, the mixture was incubated for 15 min at RT followed by addition of 4 µg of the 
plasmid encoding for the gene of interest. The preparation was further incubated for 30 min at 
RT. The R10 medium of PlatE cells was replaced with 2.5 ml fresh, pre-warmed R10, the 
transfection solution was added carefully, and PlatE cells were placed into a cell culture 
incubator for the production of viruses. Per transfection, 5 x 105 DG75 B cells or sub-clones 
(= target cells) were seeded in 10 ml of R10. 24 h later, 1.5 ml of pre-warmed R10 was added 
to virus-producing PlatE cells. Another 24 h later, target cells and virus containing supernatants 
of PlatE cells were centrifuged separately at 300 x g for 5 min at RT. The supernatants were 
discarded from the pelleted target cells, followed by resuspending these cells in 3.5 ml of the 
virus containing supernatant of PlatE cells. Subsequently, 1.5 ml of pre-warmed R10 and 
polybrene (final concentration 4 µg/ml) were added to the target cells before overnight 
incubation at 37°C and 5% CO2. The next day, the virus containing medium for infection was 
replaced with fresh, pre-warmed R10. The following day, the R10 medium was replaced with 
R10 medium containing 1 µg/ml of the antibiotic puromycin for selection of transduced cells. 
The cells were cultured in R10 medium supplemented with puromycin for 10 days. 
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3.2.3.3. Flow cytometry 
3.2.3.3.1. Expression analysis of ectopically expressed fluorescent proteins 
To analyze expression of ectopically expressed fluorescent proteins, 5 x 105 cells were 
harvested and washed twice with PBS. The cells resuspended in 300 µl of PBS were 
subsequently analyzed by flow cytometry. Citrine and eGFP are fluorescent proteins. Citrine 
is excited at a wavelength of 516 nm and emits light at a wavelength of 529 nm, while eGFP 
is excited at a wavelength of 488 nm and emits light at a wavelength of 507 nm. Thus, protein 
expression of Citrine, Citrine-tagged proteins and is detectable by flow cytometry in the FITC 
channel127,128. 
3.2.3.3.2. Analysis of intracellular Ca2+-concentration 
To analyze the cytosolic Ca2+-concentration in DG75 B cells and sub-clones, the fluorescent 
dye Indo-1 AM (Life Technologies) was used. This dye is excited at 350 nm and emits lights 
at two distinct wavelengths, dependent on whether or not Ca2+ is bound. If Ca2+ is bound to 
Indo-1, light at a wavelength of 400 nm (violet) is emitted, whereas the emitted light without 
Ca2+ is at a wavelength of 475 nm (blue). Hence, the ratio of the mean fluorescence intensities 
(MFI) of violet and blue light is representative for the cytosolic Ca2+-concentration. 
The day before the measurement, 1 x 106 cells were seeded in 10 ml R10. After 20 to 24 h, 
cells were harvested by centrifugation (300 x g, 5 min, RT), resuspended in 500 µl of R10 
containing 1 µM of Indo-1 AM and 0.015% pluronic acid (Life Technologies) and incubated for 
30 min at 30°C under mild agitation. The cells were then washed twice in 1 ml of Krebs-Ringer 
buffer (for composition see section 3.1.5.) and were finally resuspended in 650 µl of Krebs-
Ringer buffer and rested for 30 min at 30°C with mild agitation. 300 µl of rested cells were 
transferred into FACS tubes and 25 sec of Indo-1 fluorescence were recorded for 
determination of the baseline, followed by stimulation with 20 µg/ml anti-human IgM F(ab’)2 
fragments. In total, the fluorescence was recorded for 5 min. Additionally, the fluorescence of 
the cells in the FITC channel was recorded which allows gating for subsequent analysis. Data 
analysis was done with FlowJo, Microsoft Excel and GraphPad Prism. 
3.2.3.3.3. Intracellular staining of phosphorylated proteins 
Phosphorylation of Akt and Erk in BCR-stimulated DG75 B cells was determined by flow 
cytometry analysis through intracellular staining. 
24 h before the measurement, 1.5 x 106 cells were seeded in 10 ml of R10 in 10 cm cell culture 
dishes. On the day of the measurement, the cells were harvested by centrifugation and 
resuspended in R0 to a concentration of 10 x 106 per ml. Per sample, 1 x 106 were rested for 
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30 min. Subsequently, the cells were either left untreated or stimulated with 20 µg/ml of anti-
human IgM F(ab’)2 fragments for 3 min. Stimulation was stopped by addition of 100 µl CytoFix 
(Becton Dickinson). After 10 min of fixation at 37°C under mild agitation, the cells were pelleted 
by centrifugation (500 x g, 8 min, RT), resuspended in 400 µl Perm/Wash buffer I (Becton 
Dickinson) for permeabilization and incubated for 20 min at 22°C under mild agitation. Again, 
another 400 µl of Perm/Wash buffer I were added and the cells were pelleted (500 x g, 8 min, 
RT). During centrifugation, a master mix containing AlexaFluor 647 coupled phospho-specific 
antibodies was prepared according to the manufacturer’s instructions in Perm/Wash buffer I. 
Pelleted cells were resuspended in 100 µl of staining master mix and incubated for 45 min at 
22°C with mild agitation. After addition of 1 ml of Perm/Wash buffer to each sample, cells were 
centrifuged (500 x g, 8 min, RT) and resuspended in 300 µl Perm/Wash buffer I, followed by 
flow cytometry analysis. The gating strategy is shown in Figure 3.1 with Vav1-deficient DG75 
B cells reconstituted with Vav1-Cit as an example. The MFI of red fluorescence (blue tinted 
peaks, third panels from the left) are related to protein phosphorylation and were used for 
calculations. Data analysis was done with FlowJo, Microsoft Excel and GraphPad Prism. 
 
Figure 3.1 Gating strategy for intracellular staining of phosphorylated proteins. (A and B) Gating strategy for 
intracellular staining of phosphorylated Akt or Erk of unstimulated (A) or BCR-stimulated cells (B). Cells were 
harvested, left untreated or stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM), followed by 
fixation, permeabilization and staining. Fluorescence (green and red) was measured for 50.000 events. 
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3.2.3.3.4. Actin polymerization assays 
To analyze polymerization of globular actin (G-actin) to filamentary actin (F-actin), the 
fluorescently labeled (AlexaFluor 647) toxin phalloidin was used. This toxin isolated from 
poisonous Amanita mushrooms specifically stains F-actin132,133. 
2.5 x 106 of FITC-negative (DG75 or Vav1-deficient DG75 B cells) and 2.5 x 106 of FITC-
positive (reconstituted Vav1-deficient DG75 B cells) were seeded in 10 ml of R10 in 10 cm cell 
culture dishes. The following day, 5 x 105 cells of each cell line were mixed in a 1:1 ratio in a 
total volume of 100 µl of R0 to ensure similar stimulation conditions. After a resting period of 
20 min at 37°C, the cells were either left untreated or stimulated for 30 sec, 1, 3 or 7 min with 
20 µg/ml of anti-human IgM F(ab’)2 fragments. Stimulation was stopped by addition of an equal 
volume of CytoFix containing 50 µg/ml lysophosphatidylcholine (LPC, Sigma-Aldrich) and 
0.5 U phalloidin-AlexaFluor 647 (Thermo Scientific). Fixation, permeabilization and staining 
was achieved after 20 min of incubation at 37°C under mild agitation. Afterwards, cells were 
washed with 1.5 ml of PBS containing 2% FCS, followed by flow cytometry analysis. The gating 
strategy is shown in Figure 3.2 with Vav1-deficient DG75 B cells mixed with those cells 
reconstituted with Vav1-Cit as an example. The MFI of red fluorescence (black and blue tinted 
peaks, third panels from the left) are related to the amount of filamentary actin and were used 
for calculations. Data analysis was done with FlowJo, Microsoft Excel and GraphPad Prism. 
 
Figure 3.2 Gating strategy for actin polymerization assays. (A and B) Gating strategy for actin polymerization 
assays of unstimulated (A) or BCR-stimulated cells (B). Cells were harvested, left untreated or stimulated with 20 
µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM), followed by fixation, permeabilization and staining. 
Fluorescence (green and red) was measured for 100.000 events. 
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3.2.3.3.5. Receptor internalization assays  
To measure stimulation-induced BCR internalization, the expression of membrane-bound IgM 
on the surface of DG75 B cells was measured using κ light chain specific antibodies labeled 
with AlexaFluor 647. 
2.5 x 106 of FITC-negative (DG75 or Vav1-deficient DG75 B cells) and 2.5 x 106 of FITC-
positive (reconstituted Vav1-deficient DG75 B cells) were seeded in 10 ml of R10 in 10 cm cell 
culture dishes. The next day, 5 x 105 cells of each cell line were mixed in a 1:1 ratio in a total 
volume of 100 µl of R0 to ensure similar stimulation conditions. After a resting period of 20 min 
at 37°C, the cells were either left untreated or stimulated for 5, 10, 15 or 20 min with 20 µg/ml 
anti-human IgM F(ab’)2 fragments. Stimulation was stopped by addition of 100 µl of CytoFix 
and the cells were incubated for 20 min at 37°C under mild agitation. Afterwards, the cells were 
washed with 1 ml of PBS containing 2% FCS, followed by an additional incubation period of 
10 min on ice with anti-human κ light chain antibodies in PBS containing 2% FCS on ice. 
Subsequently, the cells were washed with 1.5 ml PBS containing 2% FCS and were subjected 
to flow cytometry analysis. The gating strategy is shown in Figure 3.3 with Vav1-deficient DG75 
B cells mixed with those cells reconstituted with Vav1-Cit as an example. The MFI of red 
fluorescence (black and blue tinted peaks, third panels from the left) are related to the amount 
of IgM (BCR) left on the cell surface and were used for calculations. Data analysis was done 
with FlowJo, Microsoft Excel and GraphPad Prism. 
 
Figure 3.3 Gating strategy for receptor internalization assays. (A and B) Gating strategy for receptor 
internalization assays of unstimulated (A) or BCR-stimulated cells (B). Cells were harvested, left untreated or 
stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM), followed by fixation and staining. 
Fluorescence (green and red) was measured for 100.000 events. 
 - 43 - 
3.2.3.4. Genome editing techniques 
3.2.3.4.1. CRISPR/Cas9-mediated genome editing 
For CRISPR/Cas9-mediated genome editing and specific introduction of double strand breaks 
by Cas9, single guide RNAs (sgRNA) for were cloned into pSpCas9(BB)-2A-GFP (Addgene) 
and electroporated into the nucleus of DG75 B cells according to section 3.2.3.2.1. The Cas9-
mediated double strand breaks are repaired by the non-homologous end joining (NHEJ) repair 
mechanism of the cells. In contrast to homology directed repair (HDR) mechanisms, NHEJ 
might cause mutations due to the lack of templates. For CRISPR/Cas9-mediated genome 
editing, this feature of NHEJ is used to introduce insertion or deletion (Indel) mutations into the 
genomic DNA, which ultimately may lead to frame shifts and premature stop codons134. Two 
days after nucleofection, GFP-positive cells were sorted (cell sorting facility, University Medical 
Center Göttingen). After recovery, 1 x 106 cells were harvested to isolate genomic DNA (see 
section 3.2.1.1.1.). The isolated genomic DNA served as a template for a PCR-based activity 
test of Cas9. For this purpose, an amplicon covering the targeted exon was amplified by PCR 
(see section 3.2.1.2.1.) and Cas9 activity was determined by restriction analysis or was directly 
identified through examination of a shift in the size of the resulting PCR product. When Cas9 
activity was detected, single cells were plated on 96-well plates in 150 µl of R10 medium using 
the minimal dilution approach. Subsequently, the cells were cultured until a sufficient number 
of cells was reached for western blot analysis.
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4. Results 
Previous results in our lab identified a crucial role of Vav family members in BCR-induced Ca2+-
mobilization independent of phosphorylation of PLCγ2 or the formation of the Ca2+-initiation 
complex. These results were obtained from a cellular model system based on Burkitt 
lymphoma-derived human DG75 B cells deficient for Vav1. Those Vav1-deficient DG75 B cells 
endogenously express only low amounts of Vav2 and barely any Vav347. Furthermore, the 
results revealed that Vav1 and Vav3, but not Vav2, control the BCR-induced Ca2+-influx into 
the cytosol and that Vav1 needs to be recruited to the BCR or its signaling components to 
execute its function47. However, the recruitment of Vav2 and Vav3 to the stimulated BCR and 
its signaling proteins and the underlying mechanism, by which Vav family members control 
Ca2+-mobilization after stimulation of the BCR, remained unclear. Therefore, I analyzed the 
recruitment kinetics to the BCR and its signaling components of all Vav family members and 
their enzymatic GEF-activity. Moreover, potential molecules downstream of Vav were 
investigated. Additionally, I examined different signaling axes within the BCR signal cascade 
in order to determine further processes in which Vav family members might be involved. 
4.1. Vav family members are recruited to the BCR and signaling 
components to different extents  
Figure 4.1 shows the different signaling capacities for the three Vav isoforms. To this end, 
either Vav1 or Vav2 or Vav3 were individually expressed in Vav1-deficient DG75 B cells. All 
generated Vav-constructs were equipped with a C-terminal Citrine tag (Vav1-Cit, Vav2-Cit and 
Vav3-Cit). Vav1-deficient DG75 B cells expressing eGFP, which shares 97% amino acid 
similarities with Citrine, were used as negative control. They essentially represented Vav1-
deficient cells but had undergone the same retroviral transduction and selection processes like 
cells transduced with Vav family members and mutants thereof. Fluorescence of the Citrine 
tag and the eGFP protein both directly correspond with the expression level of the respective 
protein. Thus, protein expression was determined by flow cytometry analysis and cells that 
were not successfully transduced were easily excluded by gating on FITC-positive cells. 
The constructs encoding for wild-type Vav1 and Vav2 were expressed in amounts similar to 
eGFP. However, the construct encoding wild-type Vav3 was expressed approx. five times less 
efficiently (Figure 4.1 B). By monitoring the intracellular Ca2+-concentration upon stimulation of 
the BCR (Figure 4.1 A), previously generated data of our group were successfully confirmed47. 
Wild-type Vav1 (blue line) and Vav3 (brown line) were able to compensate the loss of Vav1 in 
DG75 B cells, whereas cells expressing Vav2 (dark green line) showed similar BCR-induced 
Ca2+-kinetics as the control cells expressing eGFP (green line). 
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Figure 4.1 Vav1 and Vav3, but not Vav2, control BCR-induced Ca2+-mobilization. (A) Analysis of intracellular 
BCR-induced Ca2+-mobilization of Vav1-deficient DG75 B cells expressing either Vav1-Cit (blue line), Vav2-Cit 
(dark green line), Vav3-Cit (brown line) or eGFP (green line). Cells were loaded with the Ca2+-sensitive fluorophore 
Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, the cells were stimulated with 20 µg/ml of anti-human-
IgM F(ab’)2 fragments (α IgM) and the fluorescence was monitored for a total time of 5 min. The graphs are 
representative for 1 of 3 independent experiments. (B) Green fluorescence of cells analyzed in (A). The grey filled 
peak represents cells negative for green fluorescence. 
To test whether the differences in BCR-induced Ca2+-mobilization were due to different 
recruitment to the BCR or other signaling components, I analyzed the association of all three 
Vav family members with the activated BCR and proteins involved in its signaling cascade by 
affinity purification assays with the GFP-Trap Magnetic Agarose System (Chromotek). This 
system is suitable for both, the Citrine-tagged Vav fusion proteins and the eGFP protein. The 
resulting western blots of cleared cellular lysates (Figure 4.2 A and C, “Inputs”) and those of 
the purified proteins (Figure 4.2 B and D, “Affinity purifications”) were stained with antibodies 
to the known Vav interaction partners SLP-65 (BLNK) and Syk as proof of concept controls41,80. 
Additionally, the western blots were stained with antibodies against Igα (CD79A) which 
previously had been identified as interaction partner for Vav1 in our group47. For affinity 
purifications, barely any signal was detected for Syk, SLP-65 or Igα on western blots of 
unstimulated Vav1-deficient DG75 B cells expressing Citrine-tagged Vav1 (Figure 4.2 B, lane 
1), indicating that Vav1 is hardly associated with any of the tested signaling proteins in resting 
B cells. The signals for SLP-65 and Igα (third and lower panel) were strongest after 1 min of 
BCR stimulation and the intensity decreased with the time of stimulation. The signal intensities 
of Syk (second panel) were highest for 1 and 3 min of BCR stimulation and slightly weaker for 
10 min of stimulation. Western blots of Vav1-deficient DG75 B cells expressing Vav2-Cit 
(Figure 4.2 B, lanes 5 to 8) exhibited similar signal patterns, but with stronger intensities. 
However, by contrast, the band intensities of Syk (second panel) and SLP-65 (third panel) only 
marginally decreased with the time of stimulation, but the strength of the signal decreased with 
the time of stimulation for Igα (fourth panel). Western blots of DG75 cells deficient for Vav1 
with reconstituted Citrine-tagged Vav3 (Figure 4.2 D, lanes 1 to 4) showed similar signal 
patterns as those from cells reconstituted with Vav1-Cit, but to a reduced extent. For Vav1 
 - 46 - 
knockout DG75 B cells expressing eGFP (Figure 4.2 D, lanes 5 to 8) barely any signals were 
detected, except for Syk (second panel). 
 
Figure 4.2 Differential recruitment kinetics of wild-type Vav family members. (A) and (C) Immunoblot analysis 
of cleared cellular lysates of Vav1-deficient DG75 B cells expressing either Vav1-Cit, Vav2-Cit, Vav3-Cit or eGFP. 
The cells were either left untreated or stimulated for 1, 3 or 10 min with 20 µg/ml of anti-human-IgM F(ab’)2 fragments 
(α IgM). Proteins were separated by SDS-PAGE and analyzed by western blot using antibodies specific for GFP, 
Sky, SLP-65, Igα and Actin, respectively. The molecular weight of marker proteins is indicated on the left in kDa. 
(B) and (D) Immunoblot analysis of immunoprecipitations of cells from (A) and (C) using GFP-Trap Magnetic 
Agarose beads. Subsequently, proteins were analyzed as in (A) and (C). The molecular weight of marker proteins 
is indicated on the left in kDa. 
Recruitment kinetics of wild-type Vav family members to the stimulated BCR and its signaling 
components unveiled that the inability of Vav2 to support BCR-induced Ca2+-mobilization in 
Vav1-deficient B cells (Figure 4.1 A, dark green line) is not caused by the absence of this 
protein at the BCR or signaling components such as SLP-65, Syk or Igα in BCR-stimulated B 
cells. In contrast, Vav2 is recruited more efficiently compared to Vav1 upon stimulation of the 
BCR (Figure 4.2 B and D). 
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4.2. The catalytic activity of Vav family members is required for BCR-
induced Ca2+-mobilization 
Considering that Vav2 was not able to compensate for the loss of Vav1 regarding BCR-induced 
Ca2+-mobilization in DG75 B cells, but was recruited to proteins involved in B cell antigen 
receptor signaling to an even higher extent compared to Vav1, I investigated the influence of 
Vav family-dependent GEF-activity on BCR-induced Ca2+-mobilization. Since the ability of Vav 
proteins to interact with Rho GTPases is indispensable for the activation of these small G 
proteins, various amino acids of Vav1 which are known to form hydrogen bonds with Rac1 
were mutated86,87. Furthermore, a mutant variant which is supposed to fully abrogate the GEF-
activity of Vav1 was investigated99. 
4.2.1. Intact Rac1 binding sites are required for full BCR-induced Ca2+-
mobilization 
The DH domain of Vav family members contains several amino acids which are responsible 
for the interaction with small G Proteins of the Rho family. Most of the studies that aimed to 
determine interaction sites between Vav proteins and Rho family members focused on Vav1 
and Rac1. So far, three regions within the DH domain of Vav1 have been described to be 
required for the interaction with Rac186,87. Based on these data, I generated variants of human 
Vav1, in which specific amino acids of the Vav1-Rac1 interaction interfaces were replaced with 
alanine. The first interaction interface is located at the N-terminus of the DH domain of Vav1 
and consists of the amino acid glutamate at position 201. This amino acid forms a hydrogen 
bond to each of the amino acids tyrosine 32 and valine 36 of Rac1, respectively86. Hence, a 
Vav1 variant carrying the glutamate-to-alanine substitution at position 201 was expressed as 
Citrine-tagged fusion protein (Vav1-Cit E201A) in Vav1-deficient DG75 B cells and its ability to 
mobilize Ca2+ upon stimulation of the BCR was analyzed. In addition, leucine at position 213 
was substituted with glutamine since this mutant has been widely used in the past as loss of 
function variant with regard to enzymatic activity of Vav1 (Vav1-Cit L213Q)99. To complete this 
set of mutations within the first interaction interface of Vav1 and Rac1, a lysine-to-alanine 
mutation was introduced at position 208 of Vav1 (Vav1-Cit K208A). This mutation served as a 
control since this amino acid is oppositely charged compared to glutamate at position 201 and 
is not described to be involved in the binding of Vav1 to Rac1. Thus, this mutation should not 
affect interactions of Rac1 and Vav1. 
All mutant variants of Vav1 were expressed in Vav1-deficient cells, while Citrine-tagged wild 
type Vav1 and eGFP served as controls. Apart from the L213Q variant, all proteins were 
expressed in similar amounts. The Vav1-construct carrying the L213Q mutation was 
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expressed approx. ten times less efficiently compared to the other Vav1-constructs (Figure 4.3 
B and C). 
 
Figure 4.3 Mutation in Vav1-Rac1 interaction site diminish BCR-induced Ca2+-mobilization. (A) Analysis of 
intracellular BCR-induced Ca2+-mobilization of Vav1-deficient DG75 B cells expressing either Vav1-Cit (blue line), 
Vav1-Cit E201A (red line), Vav1-Cit K208A (dark yellow line), Vav1-Cit L213Q (purple line) or eGFP (green line). 
Cells were loaded with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, 
the cells were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was 
monitored for a total time of 5 min. The graphs are representative for 1 of 3 independent experiments. (B) Green 
fluorescence of cells analyzed in (A). The grey filled peak represents cells negative for green fluorescence. (C) 
Immunoblot analysis of cleared cellular lysates of Vav1-deficient DG75 B cells expressing either Vav1-Cit, Vav1-
Cit E201A, Vav1-Cit K208A, Vav1-Cit L213Q or eGFP. Proteins were separated by SDS-PAGE and analyzed by 
western blot using antibodies specific for GFP, Vav1 and Actin. The molecular weight of marker proteins is indicated 
on the left in kDa. 
Expression data acquired by flow cytometry (Figure 4.3 B) strongly correlated with those 
obtained by western blot analyses (Figure 4.3 C) with specific antibodies to either GFP (upper 
panel) or Vav1 (middle panel). Staining for Actin (lower panel) was used as loading control. 
Intriguingly, the mutation in the Rac1 binding site of Vav1 at position 201 (Figure 4.3 A, red 
line) reduced the BCR-induced Ca2+-mobilization approx. by half. In cells expressing the Vav1 
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L213Q variant (Figure 4.3 A, purple line), the Ca2+-kinetics essentially represented the 
knockout phenotype of Vav1-deficient DG75 B cells expressing eGFP. The K208A mutation in 
Vav1 (Figure 4.3 A, dark yellow line) did not negatively affect BCR-induced Ca2+-mobilization. 
The second Rac1 interaction interface of Vav1 examined in the following experiments is 
located at the C-terminal end of the DH domain and consists of four amino acids: asparagine 
at position 371, lysine at position 374, arginine at position 375 and glutamate at position 378. 
These amino acids form hydrogen bonds with aspartate at position 65 and arginine at position 
66 of Rac187. 
 
Figure 4.4 Mutations in Vav1-Rac1 interactions sites reduce BCR-induced Ca2+-mobilization. (A) Analysis of 
intracellular BCR-induced Ca2+-mobilization of Vav1-deficient DG75 B cells expressing either Vav1-Cit (blue line), 
Vav1-Cit N371A (orange line), Vav1-Cit K374A (olive-yellow line), Vav1-Cit R375A (pink line), Vav1-Cit E378A (dark 
green) or eGFP (green line). Cells were loaded with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of 
basal Ca2+-levels for 25 sec, the cells were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) 
and the fluorescence was monitored for a total time of 5 min. The graphs are representative for 1 of 3 independent 
experiments. (B) Green fluorescence of cells analyzed in (A). The grey filled peak represents cells negative for 
green fluorescence. (C) Immunoblot analysis of cleared cellular lysates of Vav1-deficient DG75 B cells expressing 
either Vav1-Cit, Vav1-Cit N371A, Vav1-Cit K374A, Vav1-Cit R375A, Vav1-Cit E378A or eGFP. Proteins were 
separated by SDS-PAGE and analyzed by western blot using antibodies specific for GFP, Vav1 and Actin. The 
molecular weight of marker proteins is indicated on the left in kDa. 
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Whereas lysine at position 374 of Vav1 forms only one hydrogen bond to Rac1, the other three 
amino acids each form two hydrogen bonds to Rac187. To test whether also this interface is 
required for BCR-induced Ca2+-mobilization, I substituted each of the mentioned amino acids 
in Vav1 with alanine and analyzed the resulting cells as before. All Citrine-tagged Vav1-
constructs were expressed in similar amounts (Figure 4.4 B and C). The expression data 
acquired by flow cytometry (Figure 4.4 B) again corresponded to the data generated by 
western blot analysis (Figure 4.4 C). Because of this conformity, in the following only flow 
cytometry data are shown for expression of Vav variants (yet expression of Vav variants was 
routinely analyzed by western blot analysis to determine correct protein specificity and 
molecular weight). Analysis of BCR-induced Ca2+-mobilization (Figure 4.4 A) revealed that 
introduction of alanine in Vav1 at positions 371 (N371A, orange line) or 378 (E378A, dark 
green line) severely attenuated BCR-induced Ca2+ flux. The Ca2+-phenotypes of cells 
expressing Vav1-Cit with single amino acid substitutions on position 374 (K374A, olive-yellow 
line) or 375 (R375A, pink line) were almost similar to cells expressing wild-type Vav1-Cit (blue 
line). These results suggested that amino acids of Vav1 which form hydrogen bonds to Rac1 
are important for BCR-induced Ca2+-signaling. 
The third interaction interface of Vav1 and Rac1 is located between the first and the second 
interface, but closer to the C-terminus of the DH domain of Vav1. It is constituted by the amino 
acid glutamine at position 331 and forms a hydrogen bond to asparagine 39 of Rac186. 
Furthermore, three dimensional structural analysis of Vav1 revealed that aspartate 376 is not 
responsible for any interactions to Rac1, but forms intramolecular hydrogen bonds to threonine 
539 and phenylalanine 540 within the zinc finger domain of Vav186,87. To analyze whether 
BCR-induced Ca2+-mobilization is affected by the third Vav1-Rac1 interface or by putative 
disruption of intramolecular hydrogen bonds, the respective amino acids at positions 331 and 
376 were substituted with alanine. The resulting variants of Vav1 were expressed in Vav1-
deficient DG75 B cells and again their capacity to mobilize Ca2+ upon stimulation of the BCR 
was tested. 
The Citrine-tagged Vav1 protein carrying the D376A mutation (pink line) which forms two 
intramolecular hydrogen bonds, was expressed approx. four times less efficiently compared to 
wild-type Vav1-Cit (blue line), Vav1-Cit Q331A (olive line) or eGFP (green line) (Figure 4.5 B). 
In line with previous results (Figure 4.3 A and Figure 4.4 A), the construct carrying the Q331A 
mutation, affecting a Rac1 interaction site of Vav1 showed a diminished BCR-induced Ca2+-
mobilization (Figure 4.5 A, olive line). Almost the same reduction by half compared to Vav1-
deficient cells that were reconstituted with wild-type Vav1 (Figure 4.5 A, blue line) was 
measured for those cells expressing Vav1 D376A protein (Figure 4.5 A, pink line). 
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Figure 4.5 Mutation in Vav1-Rac1 interaction site or affection of the stability of Vav1 diminish BCR-induced 
Ca2+-mobilization. (A) Analysis of intracellular BCR-induced Ca2+-mobilization of Vav1-deficient DG75 B cells 
expressing either Vav1-Cit (blue line), Vav1-Cit Q331A (olive line), Vav1-Cit D376A (pink line) or eGFP (green line). 
Cells were loaded with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, 
the cells were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was 
monitored for a total time of 5 min. The graphs are representative for 1 of 3 independent experiments. (B) Green 
fluorescence of cells analyzed in (A). The grey filled peak represents cells negative for green fluorescence. 
Given that mutations at the N-terminus and mutations at the C-terminus of the DH domain of 
Vav1 within the Rac1 interaction interfaces diminished BCR-induced Ca2+-mobilization, the 
question arose whether this drop in Ca2+-influx can be further reduced. This question was 
addressed by generation of double-mutants carrying alanine substitutions in both termini of 
the DH domain. The resulting double-mutant variants of Vav1 were characterized by alanine 
residues at position 201 (E201A) and additionally either on position 371 (E201A N371A) or 
378 (E201A E378A). 
Both double-mutant Vav1 variants were expressed in amounts similar to the single amino 
substations and wild-type Vav1 (Figure 4.6 B and D). However, no further reduction of BCR-
induced Ca2+-mobilization was detected for Vav1 variants carrying amino acid substitutions to 
alanine either on positions 201 and 371 (Vav1-Cit E201A E371A, dark yellow line) or on 
positions 201 and 378 (Vav1-Cit E201 E378A, pink line). Furthermore, this experiment 
revealed that mutations in the second interaction interface of Vav1 for Rac1 (Figure 4.6 A and 
C, N371A, orange line and E378A, dark green line, respectively) reduced the Ca2+-influx upon 
stimulation of the BCR to a stronger extent compared to the mutation in the first interaction 
interface (Figure 4.6 A and C, E201A, red line).  
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Figure 4.6 Double mutations in the Rac1 interaction site of Vav1 do not further reduce BCR-induced Ca2+-
mobilization as compared to single mutations. (A & C) Analysis of intracellular BCR-induced Ca2+-mobilization 
of Vav1-deficient DG75 B cells expressing either Vav1-Cit (blue line), Vav1-Cit E201A (red line), Vav1-Cit N371A 
(orange line), Vav1-Cit E201A N371A (dark yellow line), E378A (dark green line), Vav1-Cit E201A E378A (pink line) 
or eGFP (green line). Cells were loaded with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of basal 
Ca2+-levels for 25 sec, the cells were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the 
fluorescence was monitored for a total time of 5 min. The graphs are representative for 1 of 3 independent 
experiments. (B) Green fluorescence of cells analyzed in (A) and (C), respectively. The grey filled peaks represent 
cells negative for green fluorescence. 
Previous results of our group revealed that expression of murine wild-type Vav isoforms lead 
to similar BCR-induced Ca2+-kinetics compared to their human counterparts in our human 
DG75 B cell model system47. For murine Vav1 (mVav1), an additional Rac1 interaction 
interface has been described, which consists of the amino acids leucine 334 and lysine 335. 
Mutations of these amino acids to alanine (LK334/335AA) have been reported to fully abolish 
the GEF-activity of mVav1 towards murine Rac196. Based on these data, I generated a Citrine-
tagged construct of mVav1 carrying the LK334/335AA double mutation and the resulting 
construct was expressed in Vav1-deficient DG75 B cells, while wild-type mVav1 and eGFP 
served as controls.  
All variants of mVav1 were expressed in comparable amounts (Figure 4.7 B). However, while 
murine wild-type Vav1 was capable to compensate for the loss of human Vav1 in human DG75 
B cells (Figure 4.7 A, purple line), cells expressing the murine LK334/335AA double-mutant 
variant (Figure 4.7 A, turquoise line) showed an attenuated BCR-induced Ca2+-mobilization. 
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Figure 4.7 Mutations in mVav1-Rac1 interactions sites attenuate BCR-induced Ca2+-mobilization. (A) 
Analysis of intracellular BCR-induced Ca2+-mobilization of Vav1-deficient DG75 B cells expressing either mVav1-
Cit (purple line), mVav1-Cit LK334/335AA (turquoise line) or eGFP (green line). Cells were loaded with the Ca2+-
sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, the cells were stimulated with 20 
µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was monitored for a total time of 5 min. 
The graphs are representative for 1 of 3 independent experiments. (B) Green fluorescence of cells analyzed in (A). 
The grey filled peak represents cells negative for green fluorescence. 
On balance, various mutations on human or murine Vav1-Rac1 interaction sites reduced BCR-
induced Ca2+-mobilization approx. by half upon reconstitution compared to their respective 
wild-type counterparts in Vav1-deficient DG75 B cells. To test whether these amino acid 
substitutions are accompanied with altered GEF-activity of human and murine Vav1, the 
mediated enzymatic activity of the wild-type isoforms and mutant variants was tested. 
4.2.2. Loss of GEF-activity of Vav1 and mVav1 results in diminished BCR-
induced Ca2+-mobilization in DG75 B cells 
Having shown that mutations in Rac1 interaction interfaces of Vav1 caused diminished BCR-
induced Ca2+-mobilization and since an interaction of Vav1 and Rac1 is absolutely required for 
activation of GTPases, the hypothesis that the catalytic GEF-activity of Vav family members 
towards members of the Rho family is critical for this signaling pathway was postulated. 
To examine this hypothesis, I established an in vitro GEF-activity assay which is based on the 
fluorophore Bodipy FL coupled to GDP (Bodipy-GDP) (for exact procedure see section 
3.2.2.8.). To determine the ability of human and murine Vav1 to mediate the exchange from 
GDP to GTP for the most commonly used members of Rho GTPases in research, Rac1, RhoA 
and Cdc42, the GEF-mediating domains from amino acid 170 to 575 (acidic region to zinc 
finger domain) were expressed in E. coli, followed by purification (for exact procedure see 
section 3.2.2.7.). Besides the wild-type variants of human and murine Vav1, some of the 
mutations in the Vav1-Rac1 interface were introduced that caused a reduced BCR-induced 
Ca2+-mobilization (E201A, Figure 4.3 A and N371A, Figure 4.4 A for human Vav1 and 
LK334/335AA, Figure 4.7 A for murine Vav1). Furthermore, to mimic the stimulated state of 
Vav1, I introduced a tyrosine-to-aspartate substitution at position 174 (Y174D). This amino 
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acid is known to be involved in the relief of autoinhibition upon phosphorylation by Src family 
kinases and to promote the GEF-activity of Vav195. 
 
Figure 4.8 Mutations in Vav1-Rac1 interactions sites abolish GEF-activity of Vav1. (A, B and C) Analysis of 
GEF-activity of different variants of Vav1. The indicated small G proteins were loaded with 0,3 µM Bodipy-GDP. 
The mean of the first five measurements is timepoint 0. Upon addition of the indicated Vav1 variants or buffer, the 
fluorescence was measured every 30 sec for 20 min. All values are normalized to the mean value of timepoint 0. 
The graphs are representative for 1 of 3 independently performed experiments. 
In line with previous results of another group, these experiments revealed that Vav1 exhibited 
the strongest GEF-activity towards Rac1 (Figure 4.8 A, blue line), an intermediate GEF-activity 
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towards RhoA (Figure 4.8 B, blue line) and little activity towards Cdc42 (Figure 4.8 C, blue 
line)87. Most strikingly, single amino acid substitutions to alanine either at position 201 (Vav1 
E201A, Figure 4.8, red lines) or at position 371 (Vav1 N371A, Figure 4.8, orange lines) in Vav1 
fully abolished Vav1-mediated GEF-activity towards all three tested Rho GTPases. 
 
Figure 4.9 Mutations in mVav1-Rac1 interactions sites abolish GEF-activity of mVav1. (A, B and C) Analysis 
of GEF-activity of different variants of mVav1. The indicated small G proteins were loaded with 0,3 µM Bodipy-GDP. 
The mean of the first five measurements is timepoint 0. Upon addition of the indicated mVav1 variants or buffer, 
the fluorescence was measured every 30 sec for 20 min. All values are normalized to the mean value of timepoint 
0. The graphs are representative for 1 of 3 independently performed experiments. 
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Next, I tested wild-type mVav1 as well as the LK334/335AA variant thereof. Barely any 
differences in the mediated activation of Rac1, RhoA or Cdc42 were detected between wild-
type Vav1 (Figure 4.8) and wild-type mVav1 (Figure 4.9). Interestingly, mVav1 carrying amino 
acid substitutions to alanine at positions 334 and 335 lost the ability to catalyze the exchange 
from GDP to GTP for all three tested small G proteins of the Rho family. 
In summary, alanine substitution of amino acids involved in binding of Vav1 to Rac1 either on 
the N- or the C-terminal end of the DH domain or alanine substitutions in described critical 
amino acids of mVav1 for the GEF-activity towards Rac1, fully abolish the mediated activation 
of Rac1, RhoA and Cdc42. 
4.2.3. The GEF-activity of a Vav1 variant selectively recruited to the BCR and of 
Vav3 is required for full BCR-induced Ca2+-mobilization 
To further analyze the role of GEF-activity of Vav1 for BCR-induced Ca2+-mobilization, an 
artificial Vav1-construct was used. The resulting protein, in which the endogenous SH2 domain 
was replaced by the tandem SH2 domains of Syk (Vav1Syk(SH2)2), is specifically and 
exclusively recruited to Igα and Igβ upon stimulation of the BCR and causes an elevated Ca2+-
mobilization with barely any decrease within the first five min of stimulation compared to wild-
type Vav1 (Figure 4.10 A, dark blue line)47. To test whether this sustained Ca2+-phenotype is 
based on the GEF-activity of Vav1, I introduced the mutations E201A and N371A and the 
function of the resulting mutant variants were characterized in Vav1-deficient DG75 B cells as 
before. 
 
Figure 4.10 Mutations in Vav1-Rac1 interactions sites reduce BCR-induced Ca2+-mobilization. (A) Analysis 
of intracellular BCR-induced Ca2+-mobilization for Vav1-deficient DG75 B cells expressing either Vav1-Cit (blue 
line), Vav1Syk(SH2)2-Cit (dark blue line), Vav1Syk(SH2)2-Cit E201A (dark red line), Vav1Syk(SH2)2-Cit N371A 
(light orange line) or eGFP (green line). Cells were loaded with the Ca2+-sensitive fluorophore Indo-1 AM. After 
recording of basal Ca2+-levels for 25 sec, cells were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments 
(α IgM) and the fluorescence was monitored for a total time of 5 min. The graphs are representative for 1 of 3 
independent experiments. (B) Green fluorescence of cells analyzed in (A). The grey filled peak represents cells 
negative for green fluorescence. 
All generated constructs were expressed in similar amounts (Figure 4.10 B). Only few cells 
expressed Vav1Syk(SH2)2 variant carrying the E201A mutation, but in a similar amount to cells 
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expressing the other constructs (dark red line). Analysis of BCR-induced Ca2+-mobilization of 
the resulting cells (Figure 4.10 A) confirmed that the Vav1Syk(SH2)2 chimera (dark blue line) 
exhibited enhanced Ca2+-mobilization upon stimulation of the BCR compared to wild-type 
Vav1. This enhanced ability was partly reduced by the loss of GEF-activity (Vav1Syk(SH2)2-
Cit E201A, dark red line and Vav1Syk(SH2)2-Cit N371A, light orange line). These two variants 
of Vav1Syk(SH2)2 were still able to mobilize Ca2+ but showed a diminished peak in the first 
sec after stimulation of the BCR. The intracellular Ca2+-concentration increased rather slowly 
and almost reached the level of Vav1Syk(SH2)2 without loss-of-GEF-activity mutations 1 min 
after stimulation. 
Considering that the loss of GEF-activity of human Vav1, murine Vav1 and Vav1Syk(SH2)2 led 
to reduced Ca2+-mobilization upon stimulation of the BCR, the question arose whether also the 
GEF-activity of Vav3 was required for BCR-induced Ca2+-mobilization. Therefore, I introduced 
a single amino acid substitution at position 199 from glutamate to alanine in Vav3 (Vav3 
E199A). This amino acid of Vav3 corresponds to glutamate at position 201 of Vav1 and showed 
a reduced ability in BCR-induced Ca2+-mobilization (Figure 4.3 A). Furthermore, amino acid 
substitution at this position in Vav1 appeared to not exhibit any GEF-activity towards Rac1, 
RhoA or Cdc42 (Figure 4.8). The resulting construct was expressed as Citrine-tagged fusion 
protein in Vav1-deficient DG75 B cells, while expression of wild-type Vav3 and eGFP served 
as controls. 
 
Figure 4.11 Mutation in Vav3-Rac1 interactions site attenuate BCR-induced Ca2+-mobilization. (A) Analysis 
of intracellular BCR-induced Ca2+-mobilization for Vav1-deficient DG75 B cells expressing either Vav3-Cit (brown 
line), Vav3-Cit E199A (grey line) or eGFP (green line). Cells were loaded with the Ca2+-sensitive fluorophore Indo-
1 AM. After recording of basal Ca2+-levels for 25 sec, cells were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 
fragments (α IgM) and the fluorescence was monitored for a total time of 5 min. The graphs are representative for 
1 of 3 independent experiments. (B) Green fluorescence of cells analyzed in (A). The grey filled peak represents 
cells negative for green fluorescence. 
Both Vav3 variants were expressed in similar amounts (Figure 4.11). Interestingly, Vav3 
E199A (Figure 4.11 A, grey line) showed a reduced ability to mobilize Ca2+ upon stimulation of 
the BCR compared to wild-type Vav3 (Figure 4.11 A, brown line). The intracellular Ca2+-
concentration was reduced approx. by half throughout the measurement. To check whether 
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the differences in BCR-induced Ca2+-mobilization were due to the loss of the catalytic GEF-
activity, Vav3 variants were recombinantly expressed in bacteria and purified to perform in vitro 
GEF-activity assays as described before. 
 
Figure 4.12 Mutation of the corresponding amino acid in Rac1 interaction site of Vav3 and Vav1 abolishes 
the GEF-activity of Vav3. (A, B and C) Analysis of GEF-activity of different variants of Vav3. The indicated small 
G proteins were loaded with 0,3 µM Bodipy-GDP. The mean of the first five measurements is timepoint 0. Upon 
addition of the indicated Vav3 variants or buffer, the fluorescence was measured every 30 sec for 20 min. All values 
are normalized to the mean value of timepoint 0. The graphs are representative for 1 of 3 independently performed 
experiments. 
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The cloned Vav3 constructs encompassed amino acids 169 to 573 of the human protein. As 
for Vav1, a tyrosine to aspartate substitution at position 173 (Y173D) within the acidic region 
was introduced to mimic phosphorylation of this residue. Analysis of the GEF-activity of Vav3 
(Figure 4.12) revealed that the wild-type fragment of Vav3 (brown lines) barely exhibited any 
GEF-activity towards Rac1 or Cdc42, but showed moderate GEF-activity towards RhoA. This 
effect was similarly observed for human Vav1 (Figure 4.8) and mVav1 (Figure 4.9). This GEF-
activity towards RhoA was fully abolished by the E199A single amino acid substitution (grey 
lines). 
Having shown that the loss of GEF-activity towards Rac1, RhoA and Cdc42 of human and 
murine Vav1 and Vav3 led to reduced BCR-induced Ca2+-kinetics, the role of the downstream 
Rho GTPases was examined. 
4.2.4. Inhibition of small G proteins reduces BCR-induced Ca2+-mobilization 
So far, the results of this work demonstrated that the GEF-activity of Vav family members is 
critical for bona fide BCR-induced Ca2+-mobilization. Rho GTPases are the substrates of the 
enzymatic GEF-activity of Vav family members resulting in activation of the small G proteins72. 
To further confirm the role of Vav proteins as GEFs within this signaling axis, activation of Rho 
family small G proteins was pharmacologically inhibited. Previous attempts in our lab to 
generate reliable knockout cell lines for Rho GTPases were rather less successful47. DG75 B 
cells deficient for either Rac1 or Rac2 were generated, B cell clones for RhoA deficient or Rac1 
and Rac2 double-deficient were however not obtained47. Given that Rho family members share 
high similarities on amino acid level and that their functions particularly within the subfamilies 
are described to be redundant, the generated cell lines might not constitute the best model 
system for the loss of a subfamily101,102. Instead, activation of Rho GTPases was inhibited in 
DG75 parental cells and in Vav1-deficient DG75 cells by using two independent 
pharmacological inhibitors named EHop-016 (E-Hop) and Rhosin. E-Hop is described to be 
specific for Rac1 and Rac3 at low concentrations (≤ 5 µM). However, at higher concentrations 
it also inhibits the closely related Rho GTPase Cdc42135. Rhosin is reported to be specific for 
RhoA and RhoC136. Both, E-Hop and Rhosin bind to and thereby block binding sites of the 
respective Rho member to their GEFs135,137. 
Initially, the minimal effective concentrations for both inhibitors were acquired using DG75 
parental cells. The concentrations ranged from 1 µM to 30 µM for E-Hop and 20 µM to 60 µM 
for Rhosin. The respective inhibitor was added at the indicated concentrations five min before 
the Ca2+-measurement (Figure 4.13). Both inhibitors for Rho family members acted in a dose-
dependent manner with E-Hop showing no effect at a concentration of 1 µM while BCR-
induced Ca2+-mobilization was completely abolished at a concentration of 30 µM (Figure 
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4.13 A). However, since the cells at an E-Hop concentration of 30 µM showed increased 
forward scatter/side scatter signals and slightly elevated baseline Ca2+-levels, I conducted 
further experiments with a concentration of 20 µM. 
 
Figure 4.13 Rac1/RhoA/Cdc42 inhibitors reduce BCR-induced Ca2+-mobilization. (A and B) Analysis of 
intracellular BCR-induced Ca2+-mobilization for DG75 B cells. Cells were loaded with the Ca2+-sensitive fluorophore 
Indo-1 AM. 5 min before stimulation, E-Hop or Rhosin were added at the indicated concentrations. After recording 
of basal Ca2+-levels for 25 sec, cells were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) 
and the fluorescence was monitored for a total time of 5 min. The graphs are representative for 1 of 3 independent 
experiments. 
Inhibition of Rho family members with Rhosin also led to a reduced BCR-induced Ca2+-
mobilization (Figure 4.13 B). Pre-incubation of 20 µM Rhosin substantially reduced the ability 
to mobilize Ca2+ upon stimulation of the BCR (brown line). This reduction was further increased 
by addition of higher concentrations of Rhosin (grey and olive lines) without affecting the 
forward and side scatter of the cells. In contrast to E-Hop, inhibition with Rhosin did not affect 
the baseline of DG75 B cells. In the following, a concentration of 60 µM of Rhosin was applied 
in the subsequent experiments. Cytotoxic effects by the solvent DMSO were excluded by 
application of DMSO to the cells as vehicle control (blue and red lines). 
Next, the effects on BCR-induced Ca2+-mobilization resulting from inhibition of Rho family 
members through E-Hop and Rhosin with the previously determined concentrations were 
examined in parental DG75 cells and the Vav1-deficient subline (Figure 4.14). 
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Figure 4.14 Rac1/RhoA/Cdc42 inhibitors reduce BCR-induced Ca2+-mobilization. (A and B) Analysis of 
intracellular BCR-induced Ca2+-mobilization for DG75 B cells in (A) and Vav1-deficient DG75 B cells in (B). Cells 
were loaded with the Ca2+-sensitive fluorophore Indo-1 AM. 5 min before stimulation, E-Hop or Rhosin were added 
at the indicated concentrations. After recording of basal Ca2+-levels for 25 sec, cells were stimulated with 20 µg/ml 
of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was monitored for a total time of 5 min. The 
graphs are representative for 1 of 3 independent experiments. 
Treatment of Vav1-deficient DG75 B cells with E-Hop and Rhosin negatively influenced their 
BCR-induced Ca2+-mobilization, but to a lower extent compared to parental DG75 B cells 
(Figure 4.14 A and B). These results implied, that activation of Rho GTPases is required for 
BCR-induced Ca2+-mobilization. However, this activation seemed not to be exclusively 
dependent on Vav1 since the Ca2+-mobilization after BCR stimulation was also reduced upon 
pharmacological inhibition of Rho GTPases in Vav1-deficient DG75 B cells. 
Collectively, loss of Vav-mediated GEF-activity achieved either through mutations in reported 
Rac1 interaction sites within Vav family members or via pharmacological inhibition of Rho 
GTPases substantially reduced BCR-induced Ca2+-mobilization in DG75 B cells. 
4.3. The acidic region of Vav2 prevents the support of this molecule 
for BCR-induced Ca2+-mobilization in DG75 B cells 
Previous results of this work strongly pointed to a role of the GEF-activity of Vav proteins on 
BCR-induced Ca2+-signaling. Briefly, Vav1 and Vav3, but not Vav2 supported BCR-induced 
Ca2+-mobilization in Vav1-deficient DG75 B cells. This finding together with previous results of 
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this thesis raised the question as to whether Vav2 was not able to compensate for the loss of 
Vav1 in Ca2+-mobilization due to its ability to mediate GEF-activity. Either for all or just for 
specific members of the Rho family. 
4.3.1. Deletion of the acidic region enables the ability of Vav2 for BCR-induced 
Ca2+-mobilization in DG75 B cells 
The acidic region in Vav family members is described as a negative regulatory module for their 
GEF-activity. As the name indicates, this region contains several negatively charged amino 
acid residues but also three tyrosines in each of the family members. Three-dimensional 
analysis revealed that this region forms an inhibitory loop that blocks the active center of the 
DH domain in resting cells78. Upon activation of Vav family members by Src family kinases, 
the tyrosine residues are phosphorylated, resulting in a disintegration of the auto-inhibited 
structure and an enhanced GEF-activity95. To test whether this resolution of auto-inhibition is 
crucial for BCR-induced Ca2+-mobilization, I deleted the acidic region ranging from amino acid 
130 to amino acid 183 in Vav2 and the resulting construct (Vav2ΔAR) was expressed as a 
Citrine-tagged fusion protein in Vav1-deficient DG75 B cells, while wild-type Vav2 and eGFP 
served as controls (Figure 4.15). 
 
Figure 4.15 Deletion of the acidic region in Vav2 leads to strong BCR-induced Ca2+-mobilization. (A) Analysis 
of intracellular BCR-induced Ca2+-mobilization for Vav1-deficient DG75 B cells expressing either Vav2-Cit (dark 
green line), Vav2ΔAR-Cit (pink line) or eGFP (green line). Cells were loaded with the Ca2+-sensitive fluorophore 
Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, cells were stimulated with 20 µg/ml of anti-human-IgM 
F(ab’)2 fragments (α IgM) and the fluorescence was monitored for a total time of 5 min. The graphs are 
representative for 1 of 3 independent experiments. (B) Green fluorescence of cells analyzed in (A). The grey filled 
peak represents cells negative for green fluorescence. 
Most strikingly, even though Vav2ΔAR (pink lines) was expressed (Figure 4.15 B) approx. ten 
times less efficiently compared to wild-type Vav2 (dark green lines), this variant of Vav2 
exhibited strong and sustained BCR-induced Ca2+-mobilization (Figure 4.15 A). These data 
indicated that the ability of Vav2 to support Ca2+-signaling upon stimulation of the BCR is 
prevented by its own acidic region. 
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4.3.2. Imitation of acidic region tyrosine phosphorylation in Vav2 allows BCR-
induced Ca2+-mobilization DG75 B cells 
Since deletion of the acidic region turned Vav2 into an active molecule for Ca2+-mobilization 
upon stimulation of the BCR, the underlying mechanism was analyzed in more detail. Because 
deletion of the entire acidic region was a significant alteration of Vav2, I selectively substituted 
potentially critical amino acids within this region of the protein. These critical amino acids are 
three tyrosines that are responsible for the structural resolution upon phosphorylation95. 
Hence, to mimic the phosphorylated state, the tyrosines at positions 142, 159 and 172 were 
substituted with aspartate, respectively, and the resulting variant was analyzed as a Citrine-
tagged fusion protein in Vav1-deficient DG75 B cells as before (Figure 4.16). 
 
Figure 4.16 “Phosphorylation” of the acidic region of Vav2 leads to an increased BCR-induced Ca2+-
mobilization. (A) Analysis of intracellular BCR-induced Ca2+-mobilization for Vav1-deficient DG75 B cells 
expressing either Vav2-Cit (dark green line), Vav2-Cit Y142D Y159D Y172D (magenta line) or eGFP (green line). 
Cells were loaded with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, 
cells were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was 
monitored for a total time of 5 min. The graphs are representative for 1 of 3 independent experiments. (B) Green 
fluorescence of cells analyzed in (A). The grey filled peak represents cells negative for green fluorescence. 
Like Vav2ΔAR, the Vav2 protein carrying the three tyrosine to aspartate amino acid 
substitutions within the acidic region (magenta line) was expressed five times less efficiently 
(Figure 4.16 B) compared to wild-type Vav2 (dark green line). Nevertheless, this variant of 
Vav2 was able to support BCR-induced Ca2+-mobilization. 
Both variants of Vav2, either without acidic or with “phosphorylated” acidic region, supported 
BCR-induced Ca2+-mobilization in a sustained manner upon reconstitution in Vav1-deficient 
DG75 B cells. These experiments led to the question, whether those alterations in the acidic 
region of Vav2 corresponded to the ability to mediate GEF-activity of the Vav2 variants. 
4.3.3. The DH domain of Vav2 activates Rac1 and Cdc42, but not RhoA 
Next, the GEF-activity of the different Vav2 variants was supposed to be determined. 
Unfortunately, variants of Vav2 consisting of amino acids 168 to 581, which correspond to the 
constructs for Vav1 (Figure 4.8), mVav1 (Figure 4.9) or Vav3 (Figure 4.12), were not expressed 
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recombinantly and purified in amounts required for GEF-activity measurements. However, to 
get at least some insights into the GEF-activity of Vav2, I used a commercially available 
recombinant DH domain consisting of amino acids 189 to 374 of human Vav2 for determination 
of its GEF-activity (Figure 4.17). 
 
Figure 4.17 The DH domain of Vav2 mediates intermediate GEF-activity towards Rac1 and Cdc42, but shows 
barely any GEF-activity towards RhoA. (A, B and C) Analysis of GEF-activity of the DH domain of Vav2. The 
indicated small G proteins were loaded with 0,3 µM Bodipy-GDP. The mean of the first five measurements is 
timepoint 0. Upon addition of the DH domain of Vav2 or buffer, the fluorescence was measured every 30 sec for 20 
min. All values are normalized to the mean value of timepoint 0. The graphs are representative for 1 of 3 
independently performed experiments. 
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GEF-activity analysis revealed that the DH domain of Vav2 mediated intermediate activation 
of Rac1 and Cdc42, but hardly any towards RhoA (Figure 4.17).  
In conclusion, the results in this chapter demonstrated that the acidic region of Vav2 limits its 
function in BCR-induced Ca2+-mobilization in Vav1-deficient DG75 B cells. When the acidic 
region was deleted or when the phosphorylated state was mimicked through three amino acid 
substitutions from tyrosine to aspartate, Vav2 was turned into an active molecule for Ca2+-
influx into the cytosol upon stimulation of the BCR. Furthermore, the isolated DH domain of 
Vav2 was determined to have intermediate GEF-activity towards Rac1 and Cdc42, but barely 
any towards RhoA. 
4.4. PIP5Ks as potential downstream molecules of activated Rho 
GTPases 
Considering that the GEF-activity of Vav1 and Vav3 as well as activation of Rho family small 
G proteins were crucial for optimal BCR-induced Ca2+-mobilization in DG75 B cells, the 
question arose which molecules could be potential downstream effectors of the small G 
proteins. One potential group of downstream targets were PIP5Ks and PIP4Ks, which are 
responsible for the generation of PIP2, the substrate for PLCγ2109,110. Since the amount of PI4P 
in cells is ten times higher than the amount of PI5P and since activated small G proteins of the 
Rho family are reported to enhance the kinase activity of PIP5Ks, I started investigations on 
potential downstream targets with the PIP5Ks111,117. To date, three family members of PIP5Ks 
have been identified, named PIP5Kα, PIP5Kβ and PIP5Kγ138. 
4.4.1. Overexpression of PIP5Ks partially compensates for the loss of Vav1 in 
BCR-induced Ca2+-mobilization 
To examine whether PIP5Ks were able to recover for the loss of Vav1 regarding BCR-induced 
Ca2+-mobilization, all three family members were expressed individually in Vav1-deficient 
DG75 cells. Since previous experiments in our group with PIP5Ks revealed that constitutive 
expression of these enzymes might be harmful to DG75 B cells, an inducible expression 
system was used. This system allows for expression of genes of interest upon addition of 
doxycycline. Cell lines containing the coding sequences for individual PIP5K isoforms were 
generated and gene expression was induced by addition of 1 µM doxycycline for 10 h. All 
PIP5Ks were equipped with a C-terminal Citrine tag. Accordingly, inducible expression of 
Citrine was used as a negative control (Figure 4.18).  
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Figure 4.18 Validation of the induction model with doxycycline of PIP5K family members. Immunoblot 
analysis of cleared cellular lysates of Vav1-deficient DG75 B cells transduced with constructs for inducible 
expression of PIP5Kα, PIP5Kβ, PIP5Kγ or Citrine. The cells were either left untreated or were incubated with 1 µM 
of doxycycline 10 h before lysis. Proteins were separated by SDS-PAGE and analyzed by western blot using 
antibodies specific for GFP, PIP5Kα, PIP5Kβ, PIP5Kγ and Actin. The molecular weight of marker proteins is 
indicated on the left in kDa. 
All three PIP5K isoforms were expressed to different extents upon doxycycline-induction 
(Figure 4.18, lanes 6 to 9). Without addition of doxycycline, no expression for PIP5K family 
members was detected (Figure 4.18, lanes 1 to 4). Signals for PIP5Kα and PIP5Kγ appeared 
at the predicted molecular weights after detection with antibodies for GFP (Figure 4.18, upper 
panel, lanes 6 and 8). Protein specificity as well as expression of PIP5Kβ was confirmed using 
specific antibodies to the respective family member (second, third and fourth panes, lanes 6 
to 8). The only endogenously expressed isoform in Vav1-deficient DG75 B cells was PIP5Kα 
(second panel from the top). 
Next, I investigated the effects of this exogenous expression of PIP5K family members for 
BCR-induced Ca2+-mobilization in Vav1-deficient DG75 B cells. Hence, these cells were pre-
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incubated for 10 h before the Ca2+-measurement with 1 µM of doxycycline to induce protein 
expression.  
 
Figure 4.19 Expression of PIP5Kα or PIP5Kγ increase BCR-induced Ca2+-mobilization in Vav1-deficient 
DG75 B cells. (A and C) Analysis of intracellular BCR-induced Ca2+-mobilization for Vav1-deficient DG75 B cells 
with and without additional expression of PIP5Ks. The cells were either left untreated or were incubated for 10 h 
with 1 µM of doxycycline. Subsequently, cells were loaded with the Ca2+-sensitive fluorophore Indo-1 AM. After 
recording of basal Ca2+-levels for 25 sec, cells were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments 
(α IgM) and the fluorescence was monitored for a total time of 5 min. The graphs are representative for 1 of 3 
independent experiments. (B and D) Green fluorescence of cells analyzed in (A) and (C), respectively. The grey 
filled peaks represent cells negative for green fluorescence. 
The expression data acquired by flow cytometry (Figure 4.19 B and D) in this experiment 
strongly correlated with those generated by western blot analysis (Figure 4.18). Without 
induction of protein expression with doxycycline, all cells showed the same Ca2+-phenotype 
upon stimulation of the BCR (Figure 4.19 A), essentially representing DG75 B cells lacking 
expression of Vav1. Expression of either PIP5Kα (Figure 4.19 C, blue line) or PIP5Kγ (Figure 
4.19 C, red line), yet not PIP5Kβ, led to a higher capacity to mobilize Ca2+ upon stimulation of 
the BCR. While the typical peak approx. 30 sec after BCR-stimulation was not restored, Vav1-
deficient DG75 B cells expressing either PIP5Kα or PIP5Kγ showed constant increase of 
intracellular Ca2+-concentrations after prolonged measurements. 
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4.4.2. Generation of PIP5Kα-deficient DG75 cells 
Considering that PIP5Kα was the only endogenously expressed isoform of PIP5Ks in DG75 B 
cells (Figure 4.18) and that exogenous expression of PIP5Kα improved BCR-induced Ca2+-
mobilization in the absence of Vav1, I generated PIP5Kα-deficient DG75 B cells to further 
analyze a potential role of PIP5Ks within the Ca2+-axis of BCR signaling. For the generation of 
PIP5Kα-deficient DG75 B cells, CRISPR/Cas9-mediated genome editing was used (for details 
see sections 3.2.3.2.1. and 3.2.3.4.1.). The resulting single cell clones were screened for 
expression of all PIP5K family members (Figure 4.20). As positive controls for PIP5Kβ and 
PIP5Kγ, either lysates from DG75 B cells inducibly expressing PIP5Kβ or from Jurkat T cells, 
respectively, were used (Figure 4.20). 
 
Figure 4.20 Generation of PIP5Kα-deficient DG75 B cells. Immunoblot analysis of cleared cellular lysates of 
DG75 B cell sub-clones transfected with plasmids to CRISPR PIP5Kα. Proteins were separated by SDS-PAGE and 
analyzed by western blot using antibodies specific for PIP5Kα, PIP5Kβ, PIP5Kγ and Actin. The molecular weight of 
marker proteins is indicated on the left in kDa. As a positive control for antibodies to PIP5Kβ (+ (β)), lysates from 
Vav1-deficient DG75 B cells with induced expression of Citrine-tagged PIP5Kβ were used. As a positive control for 
antibodies to PIP5Kγ (+ (γ)), lysates from Jurkat cells were used. 
Staining with antibodies to PIP5Kα revealed that several clones (#7, #10, #12, #13, #25, #33, 
#40) had lost expression of PIP5Kα (Figure 4.20, upper panel). Intriguingly, while none of the 
clones expressed detectable amounts of PIP5Kβ (second panel from the top), staining with 
antibodies to PIP5Kγ (third panel from the top) showed that in almost all of the clones that lost 
expression of PIP5Kα, higher amounts of PIP5Kγ were detected in comparison to parental 
DG75 B cells. 
Next, I analyzed the Ca2+-mobilization kinetics of several PIP5Kα-deficient clones. 
Unfortunately, the tested DG75 sub-clones produced inconsistent results ranging from 
significantly impaired to considerably enhanced Ca2+-kinetics compared to parental cells 
(Figure 4.21).  
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Figure 4.21 BCR-induced Ca2+-phenotypes of PIP5Kα-deficient DG75 sub-clones. Analysis of intracellular 
BCR-induced Ca2+-mobilization for DG75 B cells lacking the expression of PIP5Kα. Cells were loaded with the Ca2+-
sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, cells were stimulated with 20 µg/ml 
of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was monitored for a total time of 4 min. 
Nevertheless, two of the obtained knockout clones were genetically analyzed, either showing 
higher (clone #13) or lower (clone #25) Ca2+-mobilization upon BCR stimulation. For 
characterization, PCR amplicons covering the CRISPR/Cas9-targeted PIP5K1A exon 3 from 
genomic DNA of clones #13 and #25 were amplified and sequenced. Successful Cas9-
mediated double strand breaks followed by erroneous cellular DNA repair was supposed to 
destroy a Bsu36I restriction site in that exon.  
 
Figure 4.22 Genetic characterization of DG75 PIP5Kα knockout clones #13 and #25. (A) Restriction analysis 
of the amplicon covering exon 3 of PIP5K1A. The amplicon was amplified by PCR, the resulting DNA was separated 
by agarose gel electrophoresis and extracted from the gel. Half of the DNA was left untreated whereas the other 
half was incubated with Bsu36I. After this incubation period, the DNA was separated on an agarose gel and was 
visualized using ethidium bromide. The size of marker DNA is indicated on the left. (B and C) Sequencing data of 
exon 3 of PIP5K1A for clones #13 and #25. The amplicon was amplified by PCR, the resulting DNA was separated 
in an agarose gel and extracted from the gel. The DNA was cloned into the pCR2.1 plasmid and the insert was 
sequenced. Differences to the wild-type sequences are highlighted in red. 
The size of the PCR product for parental cell and for PIP5Kα-deficient clone #25 matched the 
expected size of the amplicon (Figure 4.22 A, lanes 1 and 5), whereas the amplicon amplified 
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from genomic DNA of clone #13 however had a size of only about 300 base pairs (Figure 4.22 
A, lane 3). While the parental derived amplicon was cleaved upon incubation with Bsu36I (lane 
2), incubation with the same restriction enzyme did not affect the size of the amplicons for 
clones #13 and #25 (lanes 4 and 6). Clone #13 showed a deletion of approx. 300 base pairs 
on both alleles within the amplicon containing the targeted exon (Figure 4.22 B). This deletion 
led to a frame shift from amino acid 58 on protein level, which results in a truncated protein 
ranging to amino acid 84. For clone #25, on one allele a deletion of two base pairs was 
sequenced, which resulted in a frame shift from amino acid 59 and disrupted protein 
expression shortly afterwards. For the second allele of clone #25, several base pair 
substitutions and insertions occurred. Those alterations led to a frame shift starting from amino 
acid 55 and resulted in a premature stop codon at position 74. 
Even though the generation of PIP5Kα-deficient DG75 B cells was successful, they showed 
inconsistencies regarding BCR-induced Ca2+-mobilization. Since western blot analysis 
revealed that most of the resulting PIP5Kα-deficient DG75 B cell sub-clones showed elevated 
levels of PIP5Kγ, PIP5Kα and PIP5Kγ double-deficient DG75 B cells were generated. 
4.4.3. Generation of DG75 B cells lacking expression of PIP5Kα and PIP5Kγ 
In Vav1-deficient DG75 B cells, both isoforms, PIP5Kα and PIP5Kγ showed the same potency 
in enhancing BCR-induced Ca2+-mobilization (Figure 4.19). I used the previously generated 
and characterized PIP5Kα-deficient DG75 clones #13 and #25 for nucleofection with plasmids 
targeting either exon 3 or exon 4 of the PIP5K1C gene for CRISPR/Cas9-mediated genome 
editing. The resulting single cell sub-clones originating from PIP5Kα-deficient clone #25 were 
screened for expression of PIP5Kγ using specific antibodies (Figure 4.23 A). Furthermore, the 
obtained clones lacking the expression of both, PIP5Kα and PIP5Kγ (Figure 4.23 B, C and D) 
were genetically characterized and checked for their ability to mobilize Ca2+ upon stimulation 
of the BCR (Figure 4.23 E). Genetic analysis of PIP5Kα-deficient clone #25 derived clones #1 
and #5 lacking the expression of PIP5Kγ (Figure 4.23 A) revealed that in each clone both 
mutant alleles led to early frame shifts resulting in premature stop codons (Figure 4.23 C and 
D). However, the capacity to mobilize Ca2+ upon stimulation of the BCR was not altered for 
double-deficient DG75 B cells (Figure 4.23 E, turquoise and grey lines) compared to their 
parental precursor #25 with no expression of PIP5Kα (Figure 4.23 E, red line). 
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Figure 4.23 Targeting exon 3 of PIP5KC successfully generated double-deficient DG75 B cells for PIP5Kα 
and PIP5Kγ. (A) Immunoblot analysis of cleared cellular lysates of DG75 B cell sub-clones transfected with 
plasmids to CRISPR PIP5Kγ. Proteins were separated by SDS-PAGE and analyzed by western blot using 
antibodies specific for PIP5Kγ and Actin. The molecular weight of marker proteins is indicated on the left in kDa. 
(B) Restriction analysis of the amplicon covering exon 3 of PIP5K1C. The amplicon was amplified by PCR, the 
resulting DNA was separated by agarose gel electrophoresis and extracted from the gel. Half of the DNA was left 
untreated whereas the other half was incubated with TaqI. After this incubation period, the DNA was separated on 
an agarose gel and was visualized using ethidium bromide. The size of marker DNA is indicated on the left. (C and 
D) Sequencing data of exon 3 of PIP5K1C for clones #1 and #5. The amplicon was amplified by PCR, the resulting 
DNA was separated in an agarose gel and extracted from the gel. The DNA was cloned into the pCR2.1 plasmid 
and the insert was sequenced. Differences to the wild-type sequences are highlighted in red. (E) Analysis of 
intracellular BCR-induced Ca2+-mobilization for DG75 B cells lacking the expression of PIP5Kα and PIP5Kγ. Cells 
were loaded with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, cells 
were stimulated with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was monitored for 
a total time of 5 min. 
I repeated the same procedure to generate double-deficient cells for PIP5Kα and PIP5Kγ 
originating from PIP5Kα-deficient cell clone #13, this time targeting exon 3 of PIP5K1C (Figure 
4.24). 
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Figure 4.24 Targeting exon 3 of PIP5KC successfully generated double-deficient DG75 B cells for PIP5Kα 
and PIP5Kγ. (A) Immunoblot analysis of cleared cellular lysates of DG75 B cell sub-clones transfected with 
plasmids to CRISPR PIP5Kγ. Proteins were separated by SDS-PAGE and analyzed by western blot using 
antibodies specific for PIP5Kγ and Actin. The molecular weight of marker proteins is indicated on the left in kDa. 
(B) Restriction analysis of the amplicon covering exon 3 of PIP5K1C. The amplicon was amplified by PCR, the 
resulting DNA was separated by agarose gel electrophoresis and extracted from the gel. Half of the DNA was left 
untreated whereas the other half was incubated with TaqI. After this incubation period, the DNA was separated on 
an agarose gel and was visualized using ethidium bromide. The size of marker DNA is indicated on the left. (C) 
Sequencing data of exon 3 of PIP5K1C for clone #3. The amplicon was amplified by PCR, the resulting DNA was 
separated in an agarose gel and extracted from the gel. The DNA was cloned into the pCR2.1 plasmid and the 
insert was sequenced. Differences to the wild-type sequences are highlighted in red. (D) Analysis of intracellular 
BCR-induced Ca2+-mobilization for DG75 B cells lacking the expression of PIP5Kα and PIP5Kγ. Cells were loaded 
with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, cells were stimulated 
with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was monitored for a total time of 
5 min. 
Genetic characterization (Figure 4.24 B and C) of the obtained PIP5Kα and PIP5Kγ double-
deficient knockout clone #3 (Figure 4.24 A) revealed early frame shifts resulting in premature 
stop codons on both alleles. However, as before, the clone showed the same ability to mobilize 
Ca2+ upon stimulation of the BCR (Figure 4.24 D, olive line) compared to its PIP5Kα-deficient 
precursor #13 (Figure 4.24 D, orange line). 
To verify the successful genetic inactivation of PIP5Kα and PIP5Kγ in the generated knockout 
clones and to investigate a possibly undesired upregulation of PIP5Kβ expression, western 
blot analyses were conducted for each of the PIP5K family members (Figure 4.25).  
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Figure 4.25 PIP5Kα and PIP5Kγ double-deficient DG75 B cells do not express any member of the PIP5K 
family. Immunoblot analysis of cleared cellular lysates of parental DG75 B cells or DG75 B cells deficient for either 
Vav1, PIP5Kα (α-ko) or PIP5Kα and PIP5Kγ (γ-ko). Proteins were separated by SDS-PAGE and analyzed by 
western blot using antibodies specific for PIP5Kα, PIP5Kβ, PIP5Kγ and Actin. The molecular weight of marker 
proteins is indicated on the left in kDa. As a positive control for antibodies to PIP5Kβ (+ (β)), lysates from Vav1-
deficient DG75 B cells with induced expression of Citrine-tagged PIP5Kβ were used. 
None of the three generated PIP5Kα and PIP5Kγ double-deficient DG75 B cell clones (Figure 
4.25, lanes 5 to 7), either originating from PIP5Kα-deficient clone #13 (Figure 4.25, lane 3) or 
from clone #25 (Figure 4.25, lanes 4), expressed detectable amounts of PIP5K family 
members, thus most likely representing total PIP5K-negative cells. 
4.4.4. Generation of DG75 cells deficient for all three members of the PIP5K 
family, PIP5Kα, PIP5Kβ and PIP5Kγ 
The previously generated PIP5Kα and PIP5Kγ double-deficient DG75 B cells showed 
heterogeneous BCR-induced Ca2+-profiles. Although induced expression of PIP5Kβ did not 
affect BCR-induced Ca2+-mobilization in Vav1-deficient B cells (Figure 4.19), I generated DG75 
B cells deficient for expression of all PIP5K family members, PIP5Kα, PIP5Kβ and PIP5Kγ, to 
exclude any effects that might be mediated by PIP5Kβ (even though this isoform was not 
detected in DG75 B cells by western blot analysis). The previously generated PIP5Kα and 
PIP5Kγ double-deficient cell clone #3, derived from PIP5Kα-deficient clone #13 (PIP5Kα-/-#13 
PIP5Kγ-/-#3), and clone #1 originating from PIP5Kα-deficient clone #25 (PIP5Kα-/-#25 PIP5Kγ-
/-#1) were used for these experiments. Since no endogenous expression of PIP5Kβ was 
detectable in neither of the tested cell lines by western blot analysis, I deleted the whole exon 
5 of PIP5K1B. Deletion of the whole exon allows screening for knockout cells via PCR due to 
a predictable shift of the amplified amplicon and further promotes an early frame shift followed 
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by a premature stop codon. Hence, two sgRNAs were designed, one which guides Cas9 to 
the intronic downstream region and another one that guides Cas9 to the intronic upstream 
region of exon 5 in the PIP5K1B locus. 
 
Figure 4.26 Successful generation of DG75 B cells deficient for all members of the PIP5K family derived 
from PIP5Kα-deficient cell clone #13. (A) PCR-based screening of DG75 sub-clones transfected with sgRNAs to 
delete exon 5 of PIP5K1B. The amplicon was amplified by PCR, the resulting DNA was separated by agarose gel 
electrophoresis and DNA was visualized using ethidium bromide. The size of marker DNA is indicated on the left. 
(B) Sequencing data of exon 5 of PIP5K1B for clone #1. The amplicon was amplified by PCR, the resulting DNA 
was separated in an agarose gel and extracted from the gel. The DNA was cloned into the pCR2.1 plasmid and the 
insert was sequenced. Base pairs of exon 4 are displayed in green, those of exon 5 in blue and those of exon 6 in 
orange. Differences to the wild-type protein sequence are highlighted in red. (C) Analysis of intracellular BCR-
induced Ca2+-mobilization for DG75 B cells lacking the expression of PIP5K family members. Cells were loaded 
with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, cells were stimulated 
with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was monitored for a total time of 
5 min. 
The predicted size of the amplicon surrounding exon 5 of PIP5K1B was approx. 660 base pairs 
(Figure 4.26 A, lane 1). When exon 5 was successfully deleted, the size of the amplicon was 
predicted to decrease about 360 base pairs. For clones #1 and #2 (Figure 4.26 A, lanes 3 and 
4), this expected shift in the size of the amplicon was observed. Clones #4, #10 and #12 (Figure 
4.26 A, lanes 6, 12 and 14) showed a prominent band at the size of 360 base pairs, but also 
weaker bands corresponding to 660 base pairs. Further characterization of the resulting clone 
#1 (PIP5Kα-/-#13 PIP5Kγ-/-#3 PIP5Kβ-/-#1) revealed that the deletion of exon 5 in PIP5K1B was 
successful (Figure 4.26 B). However, no differences in the ability to mobilize Ca2+ upon 
stimulation of the BCR were found compared to double-deficient PIP5Kα and PIP5Kγ deficient 
cells from which this clone originated (Figure 4.26 C, purple and olive lines). 
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Next, the same procedure was used to generate and characterize triple-deficient DG75 B cells 
for all members of the PIP5Ks originating from DG75 PIP5Kα-/-#25 PIP5Kγ-/-#1 (Figure 4.27). 
 
Figure 4.27 Successful generation of DG75 B cells deficient for all members of the PIP5K family derived 
from PIP5Kα-deficient cell clone #25. (A) PCR-based screening of DG75 sub-clones transfected with sgRNAs to 
delete exon 5 of PIP5K1B. The amplicon was amplified by PCR, the resulting DNA was separated by agarose gel 
electrophoresis and DNA was visualized using ethidium bromide. The size of marker DNA is indicated on the left. 
(B) Sequencing data of exon 5 of PIP5K1B for clone #1. The amplicon was amplified by PCR, the resulting DNA 
was separated in an agarose gel and extracted from the gel. The DNA was cloned into the pCR2.1 plasmid and the 
insert was sequenced. Base pairs of exon 4 are displayed in green, those of exon 5 in blue and those of exon 6 in 
orange. Differences to the wild-type protein sequence are highlighted in red. (D) Analysis of intracellular BCR-
induced Ca2+-mobilization for DG75 B cells lacking the expression of PIP5K family members. Cells were loaded 
with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, cells were stimulated 
with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was monitored for a total time of 
5 min. 
Deletion of exon 5 within PIP5K1B was proven by PCR in clones #1 to #4, #11 and #12 (Figure 
4.27 A, lanes 3 to 6, 13 and 14). Sequencing of clone #1 (PIP5Kα-/-#25 PIP5Kγ-/-#1 PIP5Kβ-/-
#1) additionally confirmed that the deletion had indeed occurred in this clone (Figure 4.27 B). 
BCR-induced Ca2+-mobilization (Figure 4.27 C, brown line) however seemed not to be different 
compared to DG75 PIP5Kα-/-#25 PIP5Kγ-/-#1 double-deficient cells (Figure 4.27 C, turquoise 
line). 
Finally, I analyzed expression levels of the PIP5K family members of the previously generated 
and genetically characterized PIP5Ks-deficient sub-clones on protein level by western blot 
analysis. 
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Figure 4.28 No detection of PIP5K family members in triple-deficient DG75 B cells. Immunoblot analysis of 
cleared cellular lysates of parental DG75 B cells or DG75 B cells deficient for either Vav1, PIP5Kα (α-ko), PIP5Kα 
and PIP5Kγ (γ-ko) or PIP5Kα, PIP5Kγ and PIP5Kβ (β-ko). Proteins were separated by SDS-PAGE and analyzed 
by western blot using antibodies specific for PIP5Kα, PIP5Kβ, PIP5Kγ and Actin. The molecular weight of marker 
proteins is indicated on the left in kDa. As a positive control for antibodies to PIP5Kβ (+ (β)), lysates from Vav1-
deficient DG75 B cells with induced expression of Citrine-tagged PIP5Kβ were used. 
Western Blot analysis (Figure 4.28) showed that PIP5Kα was only expressed by parental 
DG75 B cells and Vav1-deficient DG75 B cells (upper panel, lanes 1 and 2). PIP5Kβ was not 
expressed in neither of the tested cell clones (second panel from the top). PIP5Kγ was 
expressed at low levels in parental DG75 B cells as well as Vav1-deficient DG75 B cells and 
in PIP5Kα-deficient DG75 B cell clone #13 (third panel, lanes 1 to 3). PIP5Kγ appeared to be 
stronger in DG75 PIP5Kα-/-#25 (third panel, lane 4). All other tested cell clones did not express 
PIP5Kγ. 
In summary, this chapter showed that expression of either PIP5Kα or PIP5Kγ enhances BCR-
induced Ca2+-mobilization in Vav1-deficient DG75 B cells after prolonged times of stimulation. 
Moreover, genetically determined DG75 single cell clones deficient for all three known 
members of the PIP5K family were successfully generated. Although the resulting triple 
knockout cell clones were not able to express functional PIP5K enzymes, they exhibited 
inconsistent BCR-induced Ca2+-phenotypes. However, these experiments indicated that 
expression of PIP5Ks in DG75 B cells is dispensable for BCR-induced signaling. 
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4.5. Vav family members constitute branching points for distinct BCR 
signaling pathways 
Considering that Vav family members supported BCR-induced Ca2+-mobilization to different 
extents, the question arose whether other signaling axes of the BCR signaling cascade (Figure 
2.2) are affected by the loss of Vav1 and whether they are also differentially regulated by 
distinct Vav family members. 
Previous reports showed that Vav family members are involved in the activation of MAPK like 
JNK, p38 and Erk by activating upstream MEKs through their GEF-mediated activation of Rho 
GTPases66,99. Furthermore, various groups published a connection between Vav and 
cytoskeletal rearrangement, a process essentially depending on small G proteins of the Rho 
family75,97,139. Finally, correlations between Vav3 and the activation of the PI3K/Akt pathway 
are reported in a chicken B cell line140. 
4.5.1. BCR-induced actin remodeling is controlled by Vav family members 
The actin cytoskeleton plays a crucial role in BCR signaling. In the resting B cell, the BCR is 
anchored through interactions between Igβ and the cytoskeleton, limiting diffusion of the BCR. 
Upon stimulation of the BCR, actin remodeling is induced and mobility of the BCR is enhanced. 
Hence, the cytoskeletal organization is important for the resting as well as for the activated 
state of B cells75,97,139,141,142. 
To analyze BCR-induced actin remodeling, I used fluorescently labeled Phalloidin that binds 
filamentary actin (F-actin) but not globular actin (G-actin). Thus, fluorescence signal intensities 
correlate to the amount of filamentary actin in the analyzed cells (for detailed procedure see 
section 3.2.3.3.4.).  
 
Figure 4.29 BCR-induced actin remodeling is controlled by Vav1. (A and B) Kinetics of F-actin formation in 
BCR-stimulated DG75 B cells, Vav1-deficient DG75 B cells and Vav1-deficient B cells reconstituted with Citrine-
tagged wild-type Vav1. 20 min before stimulation, the cells were mixed in a 1:1 ratio before resting. Then, the cells 
were either left untreated or stimulated for 30 sec, 1 min, 3 min or 7 min with 20 µg/ml of anti-human-IgM F(ab’)2 
fragments (α IgM). Subsequently, the cells were fixed, permeabilized and stained with Phalloidin-AlexaFluor 647. 
The MFI were determined by flow cytometry and the MFI of unstimulated Vav1-deficient DG75 B cells expressing 
Vav1-Cit was set to 1. All other MFI were normalized to this reference value. Error bars indicate standard deviation 
of three independently performed experiments. Significances were calculated using two-way ANOVA followed by 
Sidak’s multiple comparison test. ****: p<0.0001, ***: p<0.001. 
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Both cell lines, parental DG75 cells and Vav1-deficient DG75 B cells, are negative for 
fluorescence detected by flow cytometry in the FITC channel. Thus, a direct comparison in the 
same tube of one experiment between these two cell lines is not possible. To compare both 
FITC-negative cell lines, Vav1-deficient DG75 B cells expressing Vav1-Cit, that are thus FITC-
positive, were used as reference cells. Hence, parental DG75 B cells and Vav1-deficient DG75 
B cells were mixed individually with Vav1-deficient DG75 B cells reconstituted with Vav1-Cit 
for this set of experiments. For analysis, all values in the following experiment were normalized 
to the MFI value of unstimulated DG75 Vav1-ko Vav1-Cit cells (Figure 4.29). Vav1-deficient 
cells reconstituted with Vav1-Cit induced actin remodeling upon stimulation of the BCR (Figure 
4.29, blue lines). The highest amount of BCR-induced filamentary actin was measured 30 sec 
after stimulation with approx. 1.3-fold of the amount detected in unstimulated cells. The amount 
of filamentary actin decreased with the time of stimulation reaching the basal level 3 to 7 min 
after stimulation. However, parental DG75 B cells were capable of actin remodeling after 
stimulation of the BCR in a similar pattern as the reference cells, but to a lower extent (Figure 
4.29 A, grey line). Strikingly, loss of Vav1 in DG75 B cells (Figure 4.29 B, black line) fully 
abolished the ability of actin remodeling in BCR-stimulated cells. 
Having shown that the ability for BCR-induced actin remodeling is controlled by the presence 
of Vav1 in DG75 cells, the question arose whether this significant drop was due to the loss of 
GEF-activity mediated by Vav1.  
4.5.2. Loss of GEF-activity in Vav1 and Vav3 diminishes BCR-induced actin 
remodeling and internalization of the BCR 
Considering that BCR-induced actin remodeling was dependent on expression of Vav1 (Figure 
4.29), I examined the involvement of the GEF-activity of Vav proteins in this process. For this 
purpose, wild-type Vav1, mVav1 and Vav3 as well as their respective mutants lacking GEF-
activity were tested. Those mutant variants were Vav1 E201A, mVav1 LK334/335AA, 
Vav1Syk(SH2)2 N371A and Vav3 E199A. For analysis of the following experiments, the MFI 
value of unstimulated DG75 cells lacking the expression of Vav1 was set to 1 and all other MFI 
values were normalized to that reference value (Figure 4.30). 
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Figure 4.30 Loss of GEF-activity of Vav family members reduces the BCR-induced actin remodeling. (A to 
H) Kinetics of F-actin formation in BCR-stimulated Vav1-deficient DG75 B cells and Vav1-deficient B cells 
reconstituted with Citrine-tagged wild-type Vav1, mVav1, Vav1Syk(SH2)2 or Vav3 and their respective mutants 
without GEF-activity towards Rac1, RhoA and Cdc42. 20 min before stimulation, the cells were mixed in a 1:1 ratio 
before resting. Then, the cells were either left untreated or stimulated for 30 sec, 1 min, 3 min or 7 min with 20 µg/ml 
of anti-human-IgM F(ab’)2 fragments (α IgM). Subsequently, the cells were fixed, permeabilized and stained with 
Phalloidin-AlexaFluor 647. The MFI were determined by flow cytometry and the MFI of unstimulated Vav1-deficient 
DG75 B cells was set to 1. All other MFI were normalized to this reference value. Error bars indicate standard 
deviation of three independently performed experiments. Significances were calculated using two-way ANOVA 
followed by Sidak’s multiple comparison test. ****: p<0.0001, ***: p<0.001, **: p<0.01, *: p<0.05, ns: not significant. 
All tested Vav family members were able to compensate for the loss of Vav1 in DG75 B cells, 
even though to different extents. Vav1-deficient DG75 B cells expressing wild-type (Figure 
4.30 A, blue line) and mVav1 (Figure 4.30 C, purple line) were equally capable to mediate 
BCR-induced actin remodeling. Cells expressing either Vav1Syk(SH2)2 (Figure 4.30 E, dark 
blue line) or wild-type Vav3 (Figure 4.30 G, brown line) showed an increased and prolonged 
actin remodeling phenotype. Remarkably, all Vav1-deficient DG75 B cells expressing GEF-
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inactive Vav variants were significantly impaired to mediate actin remodeling upon stimulation 
of the BCR compared to their wild-type counterparts (Figure 4.30 B, D, F and H). 
Internalization of the BCR upon stimulation is reportedly one consequence of actin remodeling 
and was thus monitored to determine any influence of Vav1 and its GEF-activity (for exact 
procedure see section 3.2.3.3.5.)98,143. 
 
Figure 4.31 Loss of GEF-activity in Vav1 attenuates BCR-induced receptor internalization. (A and B) Kinetics 
of receptor internalization in BCR-stimulated Vav1-deficient DG75 B cells and Vav1-deficient B cells reconstituted 
with Citrine-tagged wild-type Vav1 or Vav1 E201A. 20 min before stimulation, the cells were mixed in a 1:1 ratio 
before resting. Then, the cells were either left untreated or stimulated for 30 sec, 1 min, 3 min or 7 min with 20 µg/ml 
of anti-human-IgM F(ab’)2 fragments (α IgM). Subsequently, the cells were fixed and stained with AlexaFluor 647-
coupled antibodies to the κ light chain of the BCR. The MFI were determined by flow cytometry and the MFI of each 
unstimulated cell line was set to 1. All other MFI were normalized to the respective reference values. Error bars 
indicate standard deviation of three independently performed experiments. Significances were calculated using 
two-way ANOVA followed by Sidak’s multiple comparison test. ****: p<0.0001, ***: p<0.001, ns: not significant. 
All three tested cell lines internalized the BCR in a stimulation time-depend manner. Vav1-
deficient DG75 B cells internalized up to 70% of their receptors on their surface within the first 
20 min of BCR stimulation (Figure 4.31, black bars), whereas those cells reconstituted with 
wild-type Vav1 internalized up to 90% of their receptors on the cell surface. (Figure 4.31 A, 
blue bars). Notably, this significant difference in the ability of BCR-induced receptor 
internalization was not detected for Vav1-deficient DG75 B cells in comparison with Vav1-
deficient DG75 B cells expressing Vav1 E201A (Figure 4.31 B, red bars). 
These experiments suggested that the presence of Vav1 or Vav3 is critical for BCR-induced 
actin remodeling. Moreover, loss of GEF-activity in these isoform led to significantly attenuated 
actin remodeling phenotypes. Consequently, internalization of the BCR after stimulation is also 
diminished with the loss of GEF-activity, at least for Vav1. 
4.5.3. Vav2 mediates BCR-induced actin remodeling 
Wild-type Vav2 was not able to compensate for the loss of Vav1 in DG75 B cells regarding 
BCR-induced Ca2+-mobilization (Figure 4.1). Thus, the question whether Vav2 was able to 
mediate BCR-induced actin remodeling was addressed. I conducted these experiments with 
Vav1-deficient DG75 B cells reconstituted with either wild-type Vav2, Vav2 without acidic 
region or the construct of Vav2 containing tyrosine to aspartate amino acid substitutions within 
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the acidic region, from which the last two supported BCR-induced Ca2+-mobilization in Vav1-
deficient DG75 B cells (Figure 4.32). 
 
Figure 4.32 Vav2 supports the BCR-induced actin remodeling. (A to C) Kinetics of F-actin formation in BCR-
stimulated DG75 B cells, Vav1-deficient DG75 B cells and Vav1-deficient B cells reconstituted with Citrine-tagged 
wild-type Vav2, Vav2ΔAR or Vav2 Y142D Y159D Y172D. 20 min before stimulation, the cells were mixed in a 1:1 
ratio before resting. Then, the cells were either left untreated or stimulated for 30 sec, 1 min, 3 min or 7 min with 20 
µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM). Subsequently, the cells were fixed, permeabilized and stained 
with Phalloidin-AlexaFluor 647. The MFI were determined by flow cytometry and the MFI of unstimulated Vav1-
deficient DG75 B cells was set to 1. All other MFI were normalized to this reference value. Error bars indicate 
standard deviation of three independently performed experiments. Significances were calculated using two-way 
ANOVA followed by Sidak’s multiple comparison test. ****: p<0.0001, **: p<0.01. 
Surprisingly, wild-type Vav2 was fully capable of inducing actin remodeling upon stimulation of 
the BCR (Figure 4.32 A, olive-green line) to an extent comparable to Vav1 and Vav3 (Figure 
4.30 A, C and G). This ability of mediating BCR-induced actin remodeling was further 
increased by deletion of the acidic region (Figure 4.32 B, pink line) or imitation of the 
phosphorylated state for the acidic region of Vav2 (Figure 4.32 C, magenta line), even though 
these proteins were expressed less efficiently (Figure 4.15 B and Figure 4.16 B). Furthermore, 
compared to Vav1-deficient DG75 B cells, a 1.9-fold increase in the amount of filamentary 
actin was already present in unstimulated cells. This amount of filamentary actin was further 
increased by BCR activation and was approx. 2.5-fold higher at its maximum compared to the 
unstimulated Vav1-deficient reference cells. 
In summary, the previous experiments demonstrated that in DG75 B cells the presence of Vav 
family members is required for BCR-induced actin remodeling and at least Vav1 for optimal 
BCR-induced receptor internalization. 
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4.5.4. Vav1 contributes to BCR-induced activation of MAPK like p38 and Erk 
Vav family members reportedly play a role in the activation of MAPK like p38, JNK and Erk72. 
To test whether Vav family members are involved in the activation of Erk, intracellular staining 
of phosphorylated Erk with a fluorescently labeled phospho-specific antibody was used. 
Moreover, western blot analysis was used to verify the results acquired by flow cytometry and 
additionally to analyze BCR-induced activation of p38 (Figure 4.33 and Figure 4.34). 
 
Figure 4.33 Vav1 contributes to the BCR-induced phosphorylation of Erk. (A to C) Analysis of Erk1/2 
phosphorylation on positions 202 (threonine) and 204 (tyrosine) in DG75 B cells, Vav1-deficient DG75 B cells and 
Vav1-deficient DG75 B cells expressing either Vav1-Cit, Vav1-Cit E201A, Vav1-Cit L213Q or eGFP. The cells were 
either left untreated or stimulated for 3 min with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM). (A and C) 
Subsequently, the cells were fixed, permeabilized and stained with pErk-AlexaFluor 647. The MFI were determined 
by flow cytometry and the MFI of unstimulated Vav1-deficient DG75 B cells (A) or of Vav1-deficient DG75 B cells 
expressing eGFP (C) were set to 1. All other MFI were normalized to the respective reference value. Error bars 
indicate standard deviation of three independently performed experiments. Significances were calculated using 
two-way ANOVA followed by Tukey’s multiple comparison test. ****: p<0.0001, **: p<0.01, *: p<0.05, ns: not 
significant. (B) Immunoblot analysis of cleared cellular lysates of unstimulated or stimulated (α IgM) cells used in 
(A). Proteins were separated by SDS-PAGE and analyzed by western blot using antibodies specific for phospho 
Erk and Erk. The molecular weight of marker proteins is indicated on the left in kDa. Band intensities were 
determined with the LabImage 1D software (Intas). The signal intensity ratio for phospho Erk divided by Erk of 
stimulated Vav1-deficient B cells was set to 1. 
Statistically significant differences were measured between BCR-stimulated Vav1-proficient 
and -deficient DG75 B cells (Figure 4.33). The latter cells were reduced in their ability to 
activate Erk upon stimulation of the BCR (Figure 4.33 A). Western Blot analysis of the same 
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cells using antibodies against phosphorylated Erk verified the data acquired by flow cytometry 
(Figure 4.33 B). Vav1-deficient DG75 B cells expressing Vav1-Cit E201A showed similar BCR-
induced phosphorylation of Erk to Vav1-deficient cells expressing wild-type Citrine-tagged 
Vav1. Additionally, those cells that were reconstituted with Vav1-Cit L213Q barely showed a 
BCR-induced increase in the phosphorylation of Erk compared to cells expressing eGFP 
(Figure 4.33 C). Since the L213Q variant of Vav1 was expressed ten-fold less efficiently 
compared to the E201A variant or the wild-type isoform of Vav1 (Figure 4.3), activation of Erk 
seemed to be dependent on Vav1 expression rather than on its GEF-activity. Next, I examined 
the BCR-induced phosphorylation of p38 (Figure 4.34) 
 
Figure 4.34 Vav1 enhances BCR-induced phosphorylation of p38. Immunoblot analysis of cleared cellular 
lysates of unstimulated or stimulated (α IgM) DG75 B cells, Vav1-deficient DG75 B cells and Vav1-deficient B cells 
expressing either Vav1-Cit or eGFP. Proteins were separated by SDS-PAGE and analyzed by western blot using 
antibodies specific for phospho p38 and p38. The molecular weight of marker proteins is indicated on the left in 
kDa. Band intensities were determined with the LabImage 1D software (Intas). The signal intensity ratio for phospho 
p38 divided by p38 of unstimulated Vav1-deficient B cells was set to 1. 
The amount of basally phosphorylated p38 was detectable for unstimulated cells (Figure 4.34, 
lanes 1 to 4). A ratio between phosphorylated p38 and p38 was calculated and was set to 1 
for Vav1-deficient DG75 B cells (Figure 4.34, lane 2). In comparison, BCR-stimulated DG75 
and Vav1-deficient cells reconstituted with Vav1-Cit exhibited a 5.8- and 6.1-fold increase in 
phosphorylation of p38 (Figure 4.34, lanes 5 and 7). In contrast, for cells that were deficient 
for expression of Vav1 expression, the relative change of phosphorylated p38 was lower (3.6-
fold for Vav1-deficient DG75 B cells and 4.7-fold for Vav1-deficient DG75 B cells expressing 
eGFP, Figure 4.34, lane 6 and 8). 
These data implied that the activation of the MAPK Erk and p38 is supported by the presence 
of Vav1. While activation of Erk seemed not to be dependent on the catalytic GEF-activity of 
Vav1, the involvement of the enzymatic activation of Rho GTPases by Vav1 remains to be 
elucidated for the phosphorylation of p38. 
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4.5.5. Vav family members enhance BCR-induced activation of Akt 
Results from a previous study using the chicken B cell line DT40 implicated that Vav3 regulates 
PI3K activity, however, Vav proteins seem to be dispensable in that context in primary murine 
B cells140,144. To shed light on the question, whether BCR-induced activation of Akt depends 
on Vav family members, I checked the phosphorylation of the serine/threonine kinase Akt on 
serine 473 using our established cellular model system. 
 
Figure 4.35 Vav family members enhance the BCR-induced phosphorylation of Akt. (A to F) Analysis of Akt 
phosphorylation on position 473 (serine) in DG75 B cells and Vav1-deficient DG75 B cells expressing different Vav 
family members and their variants. The cells were either left untreated or stimulated for 3 min with 20 µg/ml of anti-
human-IgM F(ab’)2 fragments (α IgM). Subsequently, the cells were fixed, permeabilized and stained with pAkt-
AlexaFluor 647. The MFI were determined by flow cytometry and the MFI of unstimulated Vav1-deficient DG75 B 
cells expressing eGFP was set to 1. All other MFI were normalized to this reference value. Error bars indicate 
standard deviation of three independently performed experiments. Significances were calculated using two-way 
ANOVA followed by Tukey’s multiple comparison test. ****: p<0.0001, **: p<0.01, *: p<0.05, ns: not significant. 
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Indeed, the BCR-induced phosphorylation of Akt was enhanced in cells that expressed Vav1 
(Figure 4.35 A). The relative BCR-induced phosphorylation of Akt in parental DG75 B cells or 
in Vav1-deficient DG75 B cells expressing wild-type Vav1-Cit was approx. ten-fold higher 
compared to unstimulated Vav1-deficient DG75 B cells expressing eGFP. As already seen for 
BCR-induced actin remodeling (Figure 4.30 and Figure 4.32), also wild-type Vav2 (Figure 4.35 
E and F) and Vav3 (Figure 4.35 D) as well as mVav1 (Figure 4.35 B) were able to compensate 
for the loss of Vav1 in DG75 B cells regarding BCR-induced activation of Akt, even though to 
different extents. Strikingly, reduced BCR-induced Akt phosphorylation was detected in Vav1-
deficient DG75 B cells expressing variants of Vav which lacked GEF-activity compared to their 
respective wild-type counterpart (Figure 4.35 A to D). Furthermore, in cells expressing Vav2 
variants with elevated Ca2+-mobilization profiles (Figure 4.15 and Figure 4.16) and enhanced 
actin remodeling kinetics (Figure 4.32), phosphorylation of Akt was enhanced as well (Figure 
4.35 E and F). These experiments indicated that the BCR-induced activation is enhanced by 
the presence of Vav isoforms. Furthermore, the loss of GEF-activity in Vav1, mVav1 and Vav3 
led to diminished BCR-induced activation of Akt. Since the activation profiles of BCR-induced 
actin remodeling and activation of Akt for Vav family member strongly correlated, both 
processes are possibly regulated by the same mechanism. 
4.5.6. Ca2+-influx, actin remodeling and activation of Akt within the BCR 
signaling are independent from each other 
So far, I demonstrated that activation of different axes within the BCR signaling cascade were 
either controlled or enhanced by the presence of Vav family members. BCR-induced actin 
remodeling and phosphorylation of Akt was supported by each isoform of the Vav proteins. 
However, by contrast, proper BCR-induced Ca2+-mobilization required expression of either 
Vav1 or Vav3. These differences in the support of the signaling axes within BCR signaling 
raised the question, as to whether these signaling axes depend on each other. 
To answer the question, whether BCR-induced Ca2+-mobilization is dependent on actin 
remodeling as proposed by an earlier report, the actin polymerization inhibitor LatrunculinA 
(LatA) was used141. This inhibitor binds to monomeric G-actin, thereby preventing its 
polymerization to F-actin. It was reported that application of LatA per se induces Ca2+-influx 
into the cytosol of primary B cells142. To determine the minimal effective concentration of LatA 
in DG75 B cells, I generated a dose response curve using the established actin polymerization 
assay. To this end, Vav1-expressing DG75 B cells were treated for 5 min before stimulation 
with different concentrations of the inhibitor LatA or DMSO as a vehicle control (Figure 4.36). 
Subsequently, the cells were stimulated for 30 sec as this had been determined as the optimal 
stimulation time for the highest effect in BCR-induced actin remodeling (Figure 4.30 A). 
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Figure 4.36 LatrunculinA inhibits the BCR-induced actin remodeling. Dose response curve of F-actin formation 
in BCR-stimulated Vav1-deficient DG75 B cells reconstituted with Vav1-Cit. Pre-incubation with either DMSO or the 
indicated concentrations of LatA for 5 min before stimulation. The cells were either left untreated or stimulated for 
30 sec with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM). Subsequently, the cells were fixed, permeabilized 
and stained with Phalloidin-AlexaFluor 647. The MFI were determined by flow cytometry and the MFI of 
unstimulated cells was set to 1. All other MFI were normalized to this reference value. N = 1 for this experiment. 
LatA concentrations higher than 0.5 µM specifically impeded BCR-induced actin remodeling 
(Figure 4.36). The following experiments were hereafter conducted with LatA concentrations 
of 0.5 µM and 1 µM. The same concentrations have already been used in previous 
studies141,142,145. Pharmacological inhibition of actin polymerization with LatA was subsequently 
used to investigate the dependencies between BCR-induced Ca2+-mobilization and actin 
remodeling. For this purpose, the change of intracellular Ca2+ was monitored for 5 min after 
addition of DMSO or LatA, followed by stimulation of the BCR (Figure 4.37). 
 
Figure 4.37 Application of LatrunculinA barely affects BCR-induced Ca2+-mobilization. (A) Analysis of 
intracellular BCR-induced Ca2+-mobilization for Vav1-deficient DG75 B cells expressing Vav1-Cit. Cells were loaded 
with the Ca2+-sensitive fluorophore Indo-1 AM. After recording of basal Ca2+-levels for 25 sec, cells were either left 
untreated or DMSO or LatA was added in the indicated concentrations. 270 sec later, cells were stimulated with 20 
µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM) and the fluorescence was monitored for a total time of 10 min. 
The graphs are representative for 1 of 3 independent experiments. (B) Green fluorescence of cells analyzed in (A). 
The grey filled peak represents cells negative for green fluorescence. 
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A minor influx of Ca2+ into the cytosol was detected upon addition of LatA in both 
concentrations. However, no substantial differences were observed for the IgM-dependent 
activation of the BCR and induction of Ca2+-mobilization. Hence, treatment with LatA of Vav1-
expressing DG75 B cells barely influenced BCR-induced Ca2+-mobilization. The solvent 
DMSO did not have detectable effects on the experiment (Figure 4.37, blue and orange lines). 
To gain further insights in processes that might depend on actin remodeling, I analyzed the 
potential of Vav1-proficient DG75 B cells to mediate BCR-induced phosphorylation of Akt in 
the presence of LatA. In detail, Vav1-deficient DG75 B cells reconstituted with Vav1-Cit were 
used and DMSO or LatA was added in the previously acquired concentrations 5 min before 
stimulation to the cells (Figure 4.38). 
 
Figure 4.38 BCR-induced phosphorylation of Akt is not dependent on actin remodeling. Analysis of Akt 
phosphorylation on position 473 (serine) in Vav1-deficient DG75 B cells expressing Vav1-Cit. The cells were either 
left untreated, incubated for 5 min with DMSO or the indicated concentrations of LatA. Subsequently, the cells were 
either left untreated or stimulated for 3 min with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM). Afterwards, 
the cells were fixed, permeabilized and stained with pAkt-AlexaFluor 647. The MFI were determined by flow 
cytometry and the MFI of unstimulated Vav1-deficient DG75 B cells was set to 1. All other MFI were normalized to 
this reference value. Error bars indicate standard deviation of three independently performed experiments. 
Significances were calculated using two-way ANOVA followed by Tukey’s multiple comparison test. **: p<0.01, ns: 
not significant. 
Unexpectedly, pre-incubation with DMSO led to an increased phosphorylation of Akt already 
in unstimulated DG75 B cells. Even though application of LatA in both concentrations did not 
affect BCR-induced phosphorylation of Akt, LatA significantly increased phosphorylation of Akt 
in unstimulated cells in a dose-dependent manner (Figure 4.38). Thus, for BCR-induced 
phosphorylation of Akt the ability to mediate actin remodeling is negligible, but inhibition of the 
actin cytoskeleton in resting DG75 B cells led to a strong and significant phosphorylation of 
Akt. 
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So far, the results of this chapter demonstrated that BCR-induced Ca2+-mobilization was 
neither induced by nor dependent on actin remodeling (Figure 4.37). Vice versa, BCR-induced 
actin remodeling was independent from Ca2+-mobilization since Vav1-deficient DG75 B cells 
expressing Vav2 were able to mediate actin remodeling but failed to support Ca2+-mobilization 
(Figure 4.1 and Figure 4.32). Moreover, the results suggested that BCR-induced 
phosphorylation of Akt did not rely on actin remodeling, whereas inhibition of the actin 
cytoskeleton with LatA in resting DG75 B cells resulted in strong activation of Akt. However, 
lastly the dependencies between BCR-induced Ca2+-mobilization and phosphorylation of Akt 
were elucidated. 
To investigate whether BCR-induced Akt phosphorylation requires Ca2+-mobilization, I used a 
cellular knockout model system based on PLCγ1 and PLCγ2 double-deficient DG75 B cells 
that are incapable of BCR-induced Ca2+-mobilization58. Hence, these cells were compared with 
parental DG75 B cells and Vav1-deficient B cells regarding their ability to mediate BCR-
induced phosphorylation of Akt (Figure 4.39). 
 
Figure 4.39 BCR-induced phosphorylation of Akt does not rely on Ca2+-mobilization. Analysis of Akt 
phosphorylation on position 473 (serine) in DG75 B cells, Vav1-deficient DG75 B cells and PLCγ1/2 double-deficient 
DG75 B cells. The cells were either left untreated or stimulated for 3 min with 20 µg/ml of anti-human-IgM F(ab’)2 
fragments (α IgM). Subsequently, the cells were fixed, permeabilized and stained with pAkt-AlexaFluor 647. The 
MFI were determined by flow cytometry and the MFI of unstimulated Vav1-deficient DG75 B cells was set to 1. All 
other MFI were normalized to this reference value. Error bars indicate standard deviation of three independently 
performed experiments. Significances were calculated using two-way ANOVA followed by Tukey’s multiple 
comparison test. ****: p<0.0001 
BCR-induced phosphorylation of Akt was possible in PLCγ1/2 double-deficient (PLCγ1/2-dko) 
DG75 B cells and was significantly higher compared to parental DG75 B cells (Figure 4.39). 
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These results indicated that in DG75 B cells BCR-induced phosphorylation of Akt was 
independent of the second messenger Ca2+. 
Finally, I addressed the question whether BCR-induced Ca2+-mobilization and actin 
remodeling depend on phosphorylation of Akt. To investigate these dependencies however no 
inhibitor for Akt was used since experiments to determine the optimal time of stimulation for 
BCR-induced phosphorylation of Akt revealed that Akt was phosphorylated most efficiently 
between the first and the third minute of stimulation (Figure 4.40). While BCR-induced Ca2+-
mobilization and actin remodeling already peaked approx. 30 sec after stimulation, a 
dependency on activation of Akt for these signaling pathways seemed to be rather unlikely. 
 
Figure 4.40 Stimulation kinetic of BCR-induced phosphorylation of Akt. Analysis of Akt phosphorylation on 
position 473 (serine) in Vav1-deficient DG75 B cells and parental DG75 B cells. The cells were either left untreated 
or stimulated for 1, 3 or 10 min with 20 µg/ml of anti-human-IgM F(ab’)2 fragments (α IgM). Afterwards, the cells 
were fixed, permeabilized and stained with pAkt-AlexaFluor 647. The MFI were determined by flow cytometry and 
the MFI of unstimulated Vav1-deficient DG75 B cells was set to 1. All other MFI were normalized to this reference 
value. N = 1 for this experiment. 
Taken together, the recent results demonstrated that different signaling axes within the BCR 
signaling were controlled by Vav family members or were at least enhanced when Vav family 
members are present. Furthermore, those affected signaling axes were functionally 
independent from one another and Vav family members were thereby identified as a branching 
point within the BCR signaling cascade.
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5. Discussion 
Even though the signaling reactions initiated by BCR stimulation have been studied in 
considerable detail in the past, the exact mechanism(s) by which Vav family proteins are 
involved in BCR-proximal signal initiations remain unclear21,47,149,49,58,68,69,76,146–148. However, 
results regarding the capacity of BCR-induced Ca2+-mobilization of primary B cells isolated 
from Vav1 and Vav2 double-deficient mice were inconsistent and did not provide an 
explanation by which mechanism(s) Vav family members support Ca2+ signaling69,76,142. Using 
a cellular model system based on human Vav1-deficient DG75 B cells, our working group 
recently validated a crucial role for Vav family members in BCR-induced Ca2+-signaling. These 
cells do not express Vav1, barely express Vav3 and show only low expression of Vav2, thus 
they constitute a suitable model system to study Vav isoforms regarding their function in BCR 
signaling. While Vav1 and Vav3 supported BCR-induced Ca2+-mobilization upon 
reconstitution, Vav2 failed to promote this process47. However, the underlying mechanism(s) 
by which Vav isoforms contribute to this signaling axis remained partly unknown. This work 
demonstrated that BCR-induced Ca2+-mobilization involves the catalytic GEF-activity of Vav 
family members. Furthermore, additional signaling pathways downstream of the BCR, such as 
actin remodeling and activation of the PI3K/Akt-pathway, require the presence and the 
enzymatic activity of Vav proteins.  
5.1. The enzymatic GEF-activity of Vav family members is required 
for BCR-induced Ca2+-mobilization 
One possible mechanism explaining the different properties of Vav family members in 
supporting BCR-inducible Ca2+-mobilization would be a differential GEF-activity of Vav1, Vav2 
and Vav3 towards different small G proteins of the Rho family. In B cells, little is known about 
the role of the GEF-activity of Vav proteins. Most of the published studies focused on the 
presence of Vav proteins in mice or in B cell lines rather than on the GEF-activity itself47,68,69,76. 
While Vav1-deficient mice barely show any differences to their wild-type counterparts 
regarding lymphocyte development and BCR-induced Ca2+-mobilization, both processes are 
greatly impaired in Vav1 and Vav2 double-deficient mice69,76. This effect is even more 
pronounced in mice deficient for all three Vav proteins68. However, the underlying mechanism 
by which Vav proteins contribute to B cell development and signaling remained unknown68,69,76. 
In contrast, another group showed that isolated primary B cells from the same Vav1 and Vav2 
double-deficient mice essentially exhibited comparable BCR-induced Ca2+-mobilization 
kinetics to primary B cells isolated from wild-type mice142. To date, no clear connection 
between the GEF-activity of Vav family members and B cell development or BCR induced 
signaling has been drawn. On the other hand, mice deficient for Rac2 showed reduced B and 
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plasma cell numbers and isolated primary B cells were less able to mobilize Ca2+ upon BCR 
stimulation106. Rac1 and Rac2 double-deficient mice exhibited blockade in early B cell 
development while Rac1 deficient mice were barely affected in these processes107,108,150. 
This work demonstrated that amino acid residues in Vav1, mVav1 and Vav3 that are involved 
in binding of Rac1 are essential for full BCR-induced Ca2+-mobilization. While amino acid 
substitutions at positions leucine 334 and lysine 335 in mVav1 considerably reduced the ability 
to promote BCR-induced Ca2+-mobilization in Vav1-deficient DG75 B cells, this negative effect 
was not observed in the corresponding variant of human Vav147. Thus, there appear to be 
species-specific differences of Vav proteins regarding BCR-induced Ca2+-mobilization. For all 
variants of Vav1, mVav1 and Vav3 that exhibited diminished BCR-induced Ca2+-kinetics, this 
reduction was manifested approx. by half. Since the expression of the Vav1 L213Q-mutant 
was significantly lower compared to wild-type Vav1, this variant does not represent a reliable 
“tool” to investigate loss-of-GEF-activity effects in Vav1, at least not in DG75 B cells. 
To date, little is known about substrate specificities of Vav family members toward small 
GTPases. Vav1 is reported to mediate the highest GEF-activity towards Rac1, intermediate 
GEF-activity towards RhoA and the lowest activity towards Cdc42, while Vav2 shows the 
highest activity towards Rac1 and Cdc42 and lower activity towards RhoA86–88. So far, 
preferences for Vav3 remain to be elucidated. Mutations in Rac1 interaction interfaces fully 
disrupted any GEF-activity mediated by Vav1 or Vav3. Based on these results I concluded that 
the GEF-activity of Vav family members is required for full BCR-induced Ca2+-mobilization. 
Furthermore, since wild-type human Vav1, murine Vav1 and Vav3 supported BCR-induced 
Ca2+-mobilization in DG75 B cells and shared GEF-activity towards RhoA, this small G proteins 
is most likely involved in Ca2+-mobilization upon stimulation of the BCR. This notion is 
supported by the data from the murine B cell line A20 expressing a dominant negative variant 
of RhoA leading to reduced BCR-induced Ca2+-profiles151. In this context, the functions of RhoA 
and Rac2, which is almost exclusively expressed in the hematopoietic lineage, are most likely 
redundant since mice deficient for Rac2 show similarly reduced BCR-induced Ca2+-
mobilization105,106,152. Interestingly, Rac2 is described to be involved in proper activation of 
PLCγ2 by protein-protein interactions153,154. A PLCγ2 variant which is unable to interact with 
Rac2 led to reduced BCR-induced Ca2+-kinetics in DG75 B cells (Christoffer Hitzig, 
unpublished data). Hence, the additional activation besides phosphorylation of PLCγ2 appears 
to be important for BCR-induced Ca2+-mobilization. Conclusively, I hypothesized that the GEF-
activity of Vav isoforms towards RhoA - and most likely Rac2 - leads to full activation of PLCγ2 
and thereby the complete potential of BCR-induced Ca2+-mobilization is exploited. This 
hypothesis would also explain why T cells were reportedly not affected in TCR-induced Ca2+-
mobilization by the expression of a GEF-inactive variant of Vav196. In contrast to B cells, T 
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cells express PLCγ1 but no PLCγ2 and the requirement of optimal activation by Rho GTPases 
applies to PLCγ2 but not PLCγ196,155. More recently, Cdc42 has been described to play an 
important role for B cell differentiation and BCR-signaling156. However, since Vav1 and Vav3 
did not strongly activate this Rho GTPase, the effects on B cell differentiation and BCR 
signaling likely rather depend on the Cdc42-specific GEF DOCK8157. 
Consistently, loss of GEF-activity in Vav1 led to a reduction of BCR-induced Ca2+-mobilization 
approx. by half in comparison with Vav1-deficient DG75 B cells and those cells reconstituted 
with the respective wild-type Vav isoform. Therefore, the GEF-activity is not the only 
mechanism by which Vav proteins support BCR-induced Ca2+-signaling. Loss of the N-terminal 
CH domain in Vav1 reportedly leads to reduced Ca2+-kinetics in antigen receptor-stimulated B 
and T cells47,94. By contrast, loss of the CH domain leads to enhanced GEF-activity and results 
in oncogenic potential of Vav for the cells78,93. To date, the mechanism by which the CH domain 
supports BCR-induced Ca2+-mobilization remains unclear. Since the intramolecular 
localization at either termini of the protein showed normal BCR-induced Ca2+-kinetics in DG75 
B cells, a protein-protein interaction based mechanism becomes likely47. However, the C-
terminus is described to loop back to the active center of Vav thereby forming an additional 
inhibitory loop158. Hence, a putative regulatory function of the CH domain cannot be excluded. 
Based on the data presented in this thesis and on findings from the literature, I speculate that 
the CH domain and the GEF-activity of Vav1 cooperate to achieve the full activation of the 
BCR-induced signaling cascade. To analyze whether the loss of GEF-activity was 
compensated by enhanced and prolonged recruitment of Vav1 to the Igα/Igβ complex, a 
construct was used in which the SH2 domain of Vav1 was replaced with the tandem SH2 
domains of Syk47. The resulting protein (Vav1Syk(SH2)2) is reported to be specifically recruited 
to the Igα and Igβ heterodimer47. Vav1-deficient DG75 B cells expressing Vav1Syk(SH2)2 
exhibited an enhanced and sustained BCR-induced Ca2+-kinetic47. The loss of GEF-activity 
was partly recovered by the Vav1Syk(SH2)2 construct after prolonged times of stimulation. 
Hence, the GEF-activity seemed to be critical especially for the Ca2+ signal immediately after 
stimulation of the BCR, but the loss of GEF-activity is compensated by prolonged recruitment 
in later stages of the stimulation process, one to four minutes after BCR activation. This 
compensation is most likely mediated by so far unknown function(s) of the CH domain. 
To further elucidate the involvement of Rho GTPases for proper BCR-induced Ca2+-signaling, 
putatively involved Rho family small G proteins were either genetically inactivated by our group 
or I pharmacologically inhibited these proteins47. DG75 B cells deficient for either Rac1 or Rac2 
showed a slight reduction in BCR-induced Ca2+-mobilization47. Unfortunately, Rac1 and Rac2 
double-deficient DG75 B cells and DG75 B cells deficient for RhoA could not be obtained47. 
However, pharmacological inhibition of Rac1 or RhoA in DG75 B cells with either E-Hop or 
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Rhosin resulted in reduced BCR-induced Ca2+-profiles comparable to the Ca2+-kinetics of 
Vav1-deficient DG75 B cells135–137. Treatment of Vav1-deficient DG75 B cells with E-Hop or 
Rhosin showed similar reductions but to lower extents. These reducing effects in Vav1-
deficient DG75 B cells might be caused by inhibition of small G proteins that are activated 
independently from Vav family members by other GEFs for Rho GTPases such as Tiam1, 
LARG or Dbl101. Furthermore, both inhibitors might also act on other Rho GTPases beyond the 
reported ones, Rac1 and Rac3 for E-Hop and RhoA and RhoC for Rhosin135–137. The specificity 
of E-Hop e.g. was determined in cells deficient for expression of Rac2, but the molecule also 
inhibited the close homolog Cdc42 at higher concentrations135. Rac2 in contrast is structurally 
closer related to Rac1 and Rac3 than Cdc42105. Hence, Rac2 might be inhibited by E-Hop as 
well, even at lower concentrations, which yet remains to be evaluated. One way to specifically 
determine which small G proteins are involved in the Ca2+-influx after BCR-stimulation would 
be to perform further GEF-activity assays with all Rho GTPases. Nevertheless, the presented 
results support the hypothesis that the GEF-activity of Vav proteins - most likely towards RhoA 
and Rac2 - is critical for full BCR-induced Ca2+-mobilization.  
5.2. The role of the acidic region of Vav2 
Vav2 did not support Ca2+-mobilization after BCR stimulation in Vav1-defcient DG75 B cells 
and Jurkat T cell47,77. This inability was not due to a general loss-of-function in Vav2 since the 
protein efficiently supported BCR-induced actin remodeling and activation of Akt upon 
reconstitution in Vav1-deficient DG75 B cells. In mice, a double-deficiency for either Vav1 and 
Vav2 or Vav1 and Vav3 was required to measure defects in B and T cell development and 
antigen receptor-induced signaling68,69. Not surprisingly, these negative effects were more 
pronounced upon deficiency for all three Vav isoforms in mice68. Additionally, murine Vav2 was 
shown to efficiently support BCR-induced Ca2+-mobilization in a murine B cell line159. This 
discrepancy between the model systems in mice and human cell line models might originate 
from species related differences or might be due to the respective cellular system47,68,69,77. 
Potentially, phosphorylation of Vav2 is not possible in DG75 B and Jurkat T cells because they 
might lack the kinase responsible for this process. In resting cells, the enzymatic GEF-activity 
of Vav proteins is inhibited by formation of an inhibitory loop of the acidic region78. Mediated 
by interactions between the DH domain, the adjacent PH domain and the C-SH3 domain, a 
“closed” conformation further supports this inhibition72,91. Since Vav2 did not promote BCR-
induced Ca2+-signaling in DG75 B cells, the molecule appeared to be an interesting Vav family 
member for investigations on the proposed inhibitory function of the acidic region. 
Consequently, the acidic region of Vav2 was deleted in one approach and the critical tyrosine 
residues at positions 142, 159 and 172 were each substituted with aspartate in another 
approach. Both resulting constructs enhanced BCR-induced Ca2+-mobilization in DG75 B cells 
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in a sustained manner, albeit to different extents. Interestingly, this effect was observed even 
though both proteins were expressed approx. ten times and five times less efficiently compared 
to wild-type Vav2. This low expression levels could result from a putative hyperactivity of this 
variant. It is tempting to speculate that a constitutively activated protein might be harmful to 
the cells and thus, only cells with low expression of the artificial Vav2 constructs might have 
survived the transduction procedure. 
Unfortunately, despite many optimization steps of the expression and purification procedures, 
none of the generated constructs of Vav2 could be purified in amounts sufficient for GEF-
activity measurements. However, GEF-activity measurements were performed with a 
commercially available recombinant DH domain of Vav2. Although it is reported that the whole 
DH-PH-ZF core unit of Vav proteins is required in vivo to mediate GEF-activity, using the 
purified DH domain for GEF-activity measurements gave at least some insights into substrate 
preferences of Vav2 in vitro72,160. The commercially available, recombinant DH domain 
consisted of amino acids 189 to 374 of Vav2. Of note, the obtained results in the following 
have to be interpreted carefully, since three essential domains - acidic region, PH domain and 
ZF domain - for GEF-activity mediated by Vav proteins were missing. In contrast to a previous 
report which claimed that Vav2 is an activator of Rac1, RhoA and Cdc42, the recombinant DH 
domain of Vav2 exhibited moderate GEF-activity towards Rac1 and Cdc42, but almost no 
detectable GEF-activity towards RhoA88. Intriguingly, the fact that the isolated DH domain of 
Vav2 was not able to mediate GEF-activity towards RhoA further supported my assumption 
that RhoA - and most likely its close relatives RhoB and RhoC as well as Rac2 - have a critical 
role in BCR-induced Ca2+-mobilization. In this work I demonstrated that the loss of GEF-activity 
towards Rho family members in mutant variants of Vav1 and Vav3 led to attenuated BCR-
induced Ca2+-mobilizations. Since the reduction of this signaling pathway for mutant variants 
was manifested by half, there has to be another mechanism by which Vav proteins support 
Ca2+-influx upon stimulation of the BCR. Loss of the CH-domain in Vav1 had even more severe 
effects for BCR and TCR-induced Ca2+-mobilization compared to the loss of GEF-activity47,94. 
Together, this allows the hypothesis that the GEF-activity and the CH domain of Vav proteins 
individually support Ca2+-mobilization upon stimulation of the BCR while both have to act in 
concert for full BCR-induced signaling. For Vav1, I demonstrated that enhanced and prolonged 
recruitment to the BCR seemed to compensate for the loss of GEF-activity towards Rho family 
members, which is most likely mediated by so far unknown functions of the CH domain. The 
generated artificial variants of Vav2 might possibly support BCR-induced Ca2+-signaling in a 
similar way, since no detectable GEF-activity towards RhoA of the isolated DH domain of Vav2 
was measured, but Vav2 was recruited more efficiently to the BCR compared to Vav1. In 
addition, experiments with variants of Vav2 might have revealed a newly identified regulatory 
role of the acidic region of Vav proteins78,95. The structural relief upon phosphorylation of 
 - 95 - 
several domains within Vav family members does not only enhance the GEF-activity of the 
proteins but might also allow the unknown functions mediated by the CH domain. Furthermore, 
acquisition of BCR stimulation-dependent recruitment kinetics revealed that Vav family 
members do not need to be recruited to specific phosphorylated docking sites but rather 
interact with phosphorylated tyrosine residues dependent on their availability. 
5.3. The PIP5Ks as potential downstream molecules of activated Rho 
GTPases 
So far, the results of this work strongly imply that proper BCR-induced Ca2+-mobilization 
depend on the GEF-activity towards RhoA. Thus, I investigated which components 
downstream of RhoA might be activated and involved in BCR-induced Ca2+-mobilization. 
Among other proteins, PIP5Ks are reportedly recruited to the activated BCR, eventually 
providing locally increased levels of the substrate PIP2 for PLCγ2 and PI3K at the plasma 
membrane122,123. Furthermore, PIP5Ks are described to be activated by small G proteins of the 
Rho family117,118,151. This activation of PIP5Ks is further enhanced through phosphorylation by 
Src family kinases119. In addition, two reports describe a role of PIP5Ks in activation and the 
formation of the immunological synapse, at least in T cells120,121. 
Either PIP5Kα or PIP5Kγ were able to partially re-establish the BCR-induced Ca2+-influx into 
the cytosol in DG75 B cells deficient for Vav1 after prolonged stimulation periods. Expression 
of PIP5Kβ did not affect the BCR-induced Ca2+-mobilization in Vav1-deficient DG75 B cells. 
However, the generated DG75 B cells deficient for all three PIP5K family members showed 
inconsistent BCR-induced Ca2+-phenotypes. These results challenge the previous postulated 
hypothesis that PIP5Ks provide locally increased levels of PIP2 upon BCR stimulation122,123,151. 
Perhaps, PIP4Ks compensate for the loss of PIP5Ks in the triple-deficient DG75 sub-clones, 
but since the cellular amount of PI5P is ten times lower than the quantity of PI4P, this 
compensation seemed to be rather unlikely. Additionally, this unlikely compensation would not 
explain the inconsistent Ca2+-phenotypes of DG75 B cells lacking either isoform of PIP5Ks. 
Possibly, the amounts of PIP2 in the plasma membrane are sufficient for BCR-induced 
signaling and PIP5Ks are recruited to restore the amount of PIP2. Parental DG75 B cells 
constitute a heterogenous cell line since they never have been sub-cloned. Thus, this cell line 
contains single B cells with either higher or lower capacity to mobilize Ca2+ upon stimulation of 
the BCR. The mean of hundreds of B cells is depicted as one data point for Ca2+-graphs. 
Possibly, differences in BCR-induced Ca2+-mobilization derive from the ability to mobilize Ca2+ 
after BCR stimulation of the respective single cell clones. Nevertheless, these experiments 
exclude involvement of PIP5Ks in Ca2+-mobilization upon stimulation of the BCR in DG75 B 
cells and thereby support the hypothesis that the GEF-activity towards RhoA and possibly 
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Rac2 of Vav family members enhances the activity of PLCγ2, which further promotes the BCR-
induced Ca2+-mobilization151,153,154,161. 
5.4. Vav family members constitute branching points for distinct BCR 
signaling pathways 
In this thesis I identified a critical role of Vav family members and their GEF-activity in DG75 B 
cells regarding BCR-induced Ca2+-mobilization. As a consequence, further signaling pathways 
of the BCR signaling cascade, such as antigen receptor-induced actin remodeling, were 
tested. The loss of GEF-activity towards Rho GTPases significantly diminished actin 
remodeling after BCR stimulation. The observed reduction in BCR-induced actin remodeling 
most likely depends on the reported link between activated Rac1 and cytoskeletal 
rearrangements139. Moreover, the reduction was comparable to the observed Ca2+-phenotypes 
and in line with the hypothesis that Vav family act at least in two manners upon recruitment to 
the stimulated BCR and its signaling molecules since the loss of GEF-activity did not fully 
abolish BCR-induced actin remodeling to the level of Vav1-deficient cells. Here, the differences 
between the Vav3 constructs were the least pronounced. Since Vav3 barely exhibited any 
GEF-activity towards Rac1, Vav3 most likely acts in this axis rather through its CH domain 
than through its GEF-activity. Vav2 and its enhanced variants were able to mediate BCR-
induced actin remodeling, even though to a different extent. The capacity of Vav2 to support 
this process most likely originates from its GEF-activity towards Rac1139. Both gain-of-function 
variants of Vav2 showed enhanced abilities in BCR-induced actin remodeling. These positive 
effects might result from an enhanced GEF-activity towards Rac1 and enhanced CH domain-
mediated functions. BCR internalization upon its stimulation, a process that requires actin 
remodeling, was also significantly reduced with the loss of GEF-activity in the Vav1 E201A 
variant98. However, as for BCR-induced Ca2+-mobilization, I proposed that actin remodeling 
depends on the GEF-activity and CH domain mediated functions of Vav family members. Here, 
in contrast to BCR-induced Ca2+-mobilization, the GEF-activity towards Rac1 might be of high 
importance. 
Activation of MAPK within the BCR signaling cascade is reportedly induced by Vav 
proteins66,99. Vav1-deficient DG75 B cells showed a reduced BCR-induced phosphorylation of 
the MAPK Erk similar to those cells reconstituted with the barely expressed Vav1 L213Q 
variant while Vav1-deficient DG75 B cells that were reconstituted with Vav1 E201A showed no 
differences in comparison to cells reconstituted with wild-type Vav1. Hence, these data 
implicated that the GEF-activity is dispensable for BCR-induced activation of Erk. I proposed 
that phosphorylation of Erk rather depends on the interaction of Vav1 with Grb282. This protein 
was lately identified to control activation of Erk upon stimulation of the BCR58. Since Vav1 
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L213Q was expressed ten-fold less efficiently, is probably folded incorrectly and degraded in 
the proteasome, this variant is likely unable to mediate any interaction with Grb2. In addition 
to Erk, the BCR-induced activation of p38 was tested. DG75 B cells with Vav1 deficiency 
showed a severely reduced capacity to BCR-dependently phosphorylate p38. Experiments to 
validate these data obtained by western blot analysis and for statistical analysis were 
conducted. Unfortunately, the phospho-specific antibodies used for detection of p38 produced 
a strong background staining, complicating a reliable evaluation of the acquired data by flow 
cytometry. The underlying mechanism whether the GEF-activity or so far unknown functions 
of the CH domain mediate the BCR-induced activation of p38 remain to be elucidated since 
these experiments were not conducted with any variant that lack GEF-activity towards Rac1, 
RhoA and Cdc42. 
In chicken DT40 B cells, a cellular model system that was frequently used in the past to 
investigate BCR signaling, activation of Akt has been reported to be dependent on Vav3140. In 
contrast, other studies suggested that Vav family members are dispensable for this process in 
primary murine B cells144. To shed light on the question of BCR-induced activation of Akt, I 
investigated whether stimulation of the BCR in Vav1-deficient DG75 B cells resulted in 
phosphorylation of Akt. BCR-induced activation of Akt was significantly enhanced in Vav1-
proficient DG75 B cells. Interestingly, similar to BCR-induced Ca2+-mobilization and actin 
remodeling, all variants of Vav1 and Vav3 lacking GEF-activity towards Rac1, RhoA and 
Cdc42 showed once again a reduction by half in phosphorylation of Akt compared to their wild-
type counterparts. Therefore, I proposed that the GEF-activity and the CH domain of Vav 
proteins collaborate to achieve the full potential in BCR signaling of these proteins since the 
loss of Vav1 had more severe effects than the loss of GEF-activity in Vav family members. 
Similar to BCR-induced actin remodeling, Vav2 was also able to support the BCR-induced 
activation of Akt, thus Rac1 potentially might be the critical Rho GTPases involved in this 
signaling axis. Discrepancies between avian and human model B cell lines compared to 
primary murine B cell possibly originate from species differences or differences between 
primary cells versus malignant transformed cells140,144. Collectively, the results of this thesis 
demonstrated that BCR-induced Ca2+-mobilization, actin remodeling and activation of Akt and 
MAPK such as Erk and p38 are supported by the presence of Vav family members (Figure 
5.1). Furthermore, at least BCR-induced Ca2+-mobilization, actin remodeling and 
phosphorylation of Akt depend on the GEF-activity of Vav proteins. From the results of this 
thesis and with published data I concluded that BCR-induced Ca2+-mobilization was regulated 
by the GEF-activity of Vav proteins towards RhoA and most likely Rac2. In contrast, I 
concluded that actin remodeling and phosphorylation of Akt might be dependent on activation 
of Rac1. 
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Figure 5.1 Schematic overview of the BCR-induced signaling cascade. The BCR signaling cascade is triggered 
by binding of the cognate antigen (Ag) to the BCR, mediating activation. Tyrosine residues inside and outside of 
ITAMs in Igα and Igβ are phosphorylated by Src family kinases like Lyn. Consequently, Syk and SLP-65 are 
recruited. Due to generation of binding sites for SH2 containing proteins by phosphorylation of SLP-65 through Syk, 
the Ca2+ initiation complex is formed consisting of Btk, PLCγ2, CIN85 and Vav1. As a result, Ca2+ is mobilized into 
the cytosol, mediating the nuclear translocation of the transcription factor NFAT. Additionally, the translocation of 
the transcription factor NF-κB into the nucleus is induced and MAPK like Erk, JNK and p38 are activated. Survival 
and proliferation are promoted via the PI3K/Akt pathway. Red arrows indicate phosphorylation processes, solid 
arrows indicate translocation processes and dashed arrows indicate multistep activation processes. Ca2+ is 
indicated as black dots. Kinases are colored in green, adaptor proteins in yellow, PLCγ2 in red, Vav1 in blue, Rho 
GTPases in purple, transcription factors in orange, Ca2+-channels in light brown, phosphatidylinositols and relatives 
in dark grey, actin in light grey, the BCR complex with Igα and Igβ in dark blue and the antigen in dark red. 
All of the before mentioned pathways that were controlled or enhanced by Vav proteins and 
their GEF-activity play an indispensable role in various developmental stages of a B cell. For 
example, proper BCR-induced Ca2+-mobilization along with activation of the transcription 
factors NFAT and NF-κB is already critical in B cell development during testing of functionality 
of the BCR after somatic recombination of the heavy and the light chain14,22. Most likely, B and 
T cells in either Vav1 and Vav2 double-deficient, Vav1 and Vav3 double-deficient or Vav1, 
Vav2 and Vav3 triple-deficient mice are unable to develop because they are not able to pass 
these checkpoints and most of the cells die by apoptosis due to insufficient BCR-induced 
signaling14,68,69. Similar to B cell development, the capacity of BCR-induced signaling is pivotal 
for the quality of the immune response upon activation of B cells21,49. Furthermore, proliferation 
and metabolic changes have to be induced through the PI3K/Akt pathway for clonal 
expansion60,61. Rearrangement of the cytoskeleton is reportedly critical for migration and BCR 
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internalization97,98,141,142. Activation of MAPK like Erk and p38 support cell proliferation and 
survival, gene transcription and stability of messenger RNA (mRNA)162. The generated data of 
this thesis strongly imply involvement of Vav proteins and their GEF-activity in all of the 
mentioned processes thereby highlighting the central role of this protein family for B cells. 
Lastly, the presented results gave rise to the question whether BCR-induced Ca2+-mobilization, 
actin remodeling and phosphorylation of Akt are dependent or independent of each other. 
From the generated data, I assumed that Vav family members are central coordinators of 
signaling pathways downstream of the stimulated BCR. Previous reports suggest that BCR-
induced Ca2+-mobilization depends on actin remodeling and that treatment of B cells with the 
actin polymerization inhibitor Latrunculin A (LatA) induces a Ca2+-influx into the cytosol without 
BCR stimulation141,142. Later it was demonstrated that this initiation of Ca2+-mobilization in the 
absence of BCR stimulation relies on co-expression of membrane-bound IgD, the co-receptor 
CD19 and the chemokine receptor CXCR4145. Therefore, the intracellular Ca2+-concentration 
was monitored for the 5 min of LatA treatment before BCR stimulation. In comparison to DG75 
B cells treated with the vehicle control DMSO, a slight increase in the intracellular Ca2+-
concentration was observed during treatment with LatA. However, this did not affect the 
capacity for BCR-induced Ca2+-mobilization. Hence, in DG75 B cells, the BCR-induced Ca2+-
mobilization did not depend on BCR-induced actin remodeling. An opposite dependency, that 
BCR-induced Ca2+-mobilization is required for actin remodeling, had already been excluded 
with the experiments that were conducted with Vav1-deficient DG75 B cells expressing wild-
type Vav2. Thus, I concluded that Ca2+-mobilization and actin remodeling most likely work 
independently of each other in BCR stimulated DG75 B cells. Additionally, the effect of LatA 
treatment on BCR-induced phosphorylation of Akt was tested. While inhibition of the actin 
polymerization appeared to have no significant effects on BCR-induced phosphorylation of Akt 
compared to DMSO treated DG75 B cells, treatment of these cells with LatA induced a dose-
dependent, significant phosphorylation of Akt in resting cells. To date, only the reversed 
process, that Akt induces cytoskeletal rearrangements promoting motility of the cells, has been 
described163. However, these results demonstrated that the BCR-induced activation of Akt 
takes place independently from actin remodeling. In the following, possible dependencies 
between BCR-induced Ca2+-mobilization and activation of Akt were examined. PLCγ1 and 
PLCγ2 double-deficient DG75 B cells were used based on their lack of Ca2+-mobilization upon 
stimulation of the BCR58. These cells were however still able to mediate BCR-induced 
activation of Akt, even to significantly higher extents than parental DG75 B cells. As for BCR-
induced actin remodeling, experiments with Vav1-deficient cells reconstituted with wild-type 
Vav2 supported these findings. Therefore, I concluded that BCR-induced activation of Akt is 
independent from Ca2+-mobilization. Both, BCR-induced Ca2+-mobilization and actin 
remodeling were at the highest 30 sec after BCR stimulation. However, after 1 min of 
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stimulation barely any phosphorylation of Akt was detected in DG75 B cells. Based on those 
findings, I assumed that these two early events in BCR signaling do not depend on the 
phosphorylation of Akt since full activation of Akt was observed later in the stimulation process, 
3 min after BCR stimulation. 
 
Figure 5.2 Schematic overview of processes within BCR signaling that are independently regulated by Vav 
family members. “actin” refers to BCR-induced actin remodeling, “Ca2+” refers to BCR-induced Ca2+-mobilization, 
“pAkt” refers to BCR-induced phosphorylation of Akt, “Vav” refers to Vav family members. 
The results of this last chapter of my thesis revealed that Vav-dependent pathways within BCR 
signaling work independently from each other leading to the hypothesis that Vav family 
members constitute a central branching point in this signaling cascade (Figure 5.2).
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6. Conclusion and Outlook 
The results of this thesis unraveled a new concept for the possible role of Vav family members 
within the BCR signaling cascade. Direct recruitment to the stimulated BCR and its associated 
signaling components is a prerequisite for Vav proteins to exert their functions. The GEF-
activity of Vav1 and Vav3 proteins towards RhoA and probably Rac2 was required for full BCR-
induced Ca2+-mobilization in DG75 B cells. Activated RhoA and Rac2 most likely support this 
signaling pathway within BCR signaling by full activation of PLCγ2. In contrast, the catalytic 
activity on Rac1 seems to be critical for Vav1 and Vav2 in BCR-induced actin remodeling and 
phosphorylation of Akt. Yet, the enzymatic GEF-activity was not the only mechanism by which 
Vav family members support BCR signaling. Another mechanism for full BCR signaling is 
possibly mediated by an unknown role of the CH domain, since the loss of this domain in Vav1 
reportedly led to severely reduced antigen receptor-induced Ca2+-kinetics. Furthermore, this 
work demonstrated that BCR-induced Ca2+-mobilization, actin remodeling and phosphorylation 
of Akt were independent processes within BCR signaling. I hence concluded that Vav family 
members and their GEF-activity are central coordinators of the BCR signaling cascade. Thus, 
a new class of proteins with enzymatic GEF-activity, besides the already known protein classes 
such as kinases, adaptor molecules and lipases, should be included in the literature into the 
protein classes of relevance for BCR proximal signaling. 
Despite intensive and successful research on Vav proteins and their detailed role in BCR-
induced signaling, several questions remain to be elucidated. Most importantly, the question 
of the role of the CH domain of Vav family members should be addressed. Using affinity 
purification experiments interaction partners could be determined in comparison of stimulated 
and unstimulated B cells. Putatively relevant proteins should be filtered and further 
investigated. In addition, GEF-activity assays for Vav family members and the respective 
mutant variants should be performed for the other Rho GTPases that haven’t been tested in 
this study. Here, special focus should be placed on Rac2, Rac3, RhoB and RhoC, the closest 
relatives of Rac1 and RhoA, respectively. Moreover, the influence of the GEF-activity of Vav 
family members regarding BCR-induced phosphorylation of p38 could be elucidated. Lastly, 
all the so far obtained results were obtained based on cancerous cells. To exclude any effects 
driven by malignant transformation and to confirm putative species differences between human 
and mice, the generation of primary human knockout B cells is considered.
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8. Appendix 
8.1. Abbreviations 
α   anti 
aa   amino acid 
Ag   antigen 
approx.  approximately 
AR   acidic region 
BCR   B cell antigen receptor 
BLNK   B cell linker protein 
bp   base pair 
BSA   bovine serum albumin 
Btk   Bruton’s tyrosine kinase 
° C   degree Celsius 
Cas9   CRISPR associated protein 9 
Cbl   Casitas B-lineage lymphoma 
CCL   cleared cellular lysate 
CD   Cluster of Differentiation 
Cdc42   Cell division control protein 42 
cDNA   complementary DNA 
CH   Calponin-homology 
CIN85   Cbl-interacting protein of 85 kDa 
CIP   calf intestine phosphatase 
Cit   Citrine 
CRISPR  Cluster Regulatory Interspaced Short Palindromic Repeats 
C-terminal  carboxy-terminal 
DAG   diacylglycerol 
dATPs   deoxyribose adenine triphosphate 
DH   Dbl-homology 
DMSO   dimethylsulfoxide 
DNA   deoxyribonucleic acid 
DSMZ   Deutsche Sammlung für Mikroorganismen und Zellkulturen 
EB   EcoBlast (Ecotropic receptor, Blasticidine as selection marker) 
ECL   enhanced chemiluminescence 
E. coli   Escherichia coli 
e.g.   exempli gratia 
eGFP   enhanced green fluorescent protein 
env   envelope, gene encoding glycoprotein 160 
ER   endoplasmic reticulum 
Erk   extracellular regulated kinase 
F(ab’)2   bivalent antigen binding fragment 
FACS   fluorescent activated cell sorter 
Fc region  fragment crystallizable region 
FCS   fetal calf serum 
g   gram 
gag   group specific antigen, gene encoding p55 (core protein) 
GC   germinal center 
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GDI   guanine-nucleotide dissociation inhibitor 
GDP   guanosine diphosphate 
GEF   guanine-nucleotide exchange factor 
Grb2   growth factor receptor-bound protein 2 
GTP   guanosine triphosphate 
h   hours 
HEK   human embryonic kidney 
HEPES  N-2-Hydroxyethyl piperazine-N'-2-ethane sulphonic acid 
HRPO   horseradish peroxidase 
i.e.   id est 
Ig   immunoglobulin 
Indo-1 AM  1H-Indole-6-carboxylic acid, 2-[4-[bis[2-[(acetyloxy)methoxy]-2-
oxoethyl]amino]-3-[2-[2-[bis[2-[(acetyloxy)methoxy]-2-oxoethyl]amino]-
5-methylphenoxy]ethoxy]phenyl]-, (acetyloxy)methyl ester 
IP3 inositol-1,4,5-trisphosphate 
IP3R IP3 receptor 
IPTG  Isopropyl-β-D-thiogalacto-pyranoside 
IRES  internal ribosome entry site 
ITAM  immunoreceptor tyrosine-based activation motif 
JNK c-Jun N-terminal kinase 
l liter 
LB  Lysogeny broth 
Lyn Lck/yes-related protein kinase 
kDa kilo Dalton 
M mole 
mA   milliampere 
MAPK   mitogen activated protein kinases 
µg   microgram 
mg   milligram 
MHC   major histocompatibility complex 
min   minutes 
µl   microliter 
ml   milliliter 
µM   micromole 
mM   millimole 
MMLV   Moloney murine leukemia virus 
mRNA   messenger RNA 
NFAT   nuclear factor of activated T cell 
NF-κB   nuclear factor ‘kappa-light-chain-enhancer’ of activated B cells 
nM   nanomole 
NP-40   Nonidet P40 
N-terminal  amino-terminal 
OD   optical density 
ORF   open reading frame 
PAGE   polyacrylamide gel electrophoresis 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PH   Pleckstrin-homology 
PI3K   Phosphoinositide 3’-kinase 
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PI4P   phosphatidylinositol-4-phosphate 
PI5P   phosphatidylinositol-5-phosphate 
PIP2   phosphatidyl-inositol-4,5-bisphosphate 
PIP3   phosphatidyl-inositol-3,4,5-trisphosphate 
PIP5K   phosphatidyl-inositol-4-phosphate 5-kinase 
PKB   protein kinase B 
PKC   protein kinase C 
PlatE   Platinum E 
PR   proline rich 
PRR   pattern recognition receptors 
Rac   Ras-related C3 botulinum toxin substrate 
Ras   Rat sarcoma 
Rho   Ras homolog 
RNA   ribonucleic acid 
RPMI   Roswell Park Memorial Institute medium 
RT   room temperature 
s   seconds 
S1P   sphingosine-1-phosphate 
SDS   sodium dodecyl sulfate 
SH2   Src-homology 2 domain 
SH3   Src-homology 3 domain 
SLP-65  SH2-domain-containing leukocyte adaptor protein of 65 kDa 
SOC   Store-operated Ca2+-channels 
Src   sarcoma 
STED   stimulated emission depletion 
STIM   Stromal interaction molecule 
Syk   Spleen tyrosine kinase 
TAE buffer  Tris Acetate EDTA buffer 
TALEN  Transcription activator-like effector nuclease 
TB   terrific broth 
TBS   Tris buffered saline 
TCR   T cell antigen receptor 
Tris   Tris-(hydroxymethyl)-amino methane 
Triton-X-100  4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol ether 
UV   ultraviolet 
V   volt 
v/v   volume/volume 
w/v   weight/volume 
X-Gal   5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside 
ZF   zinc finger 
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